

(2001. 1. 2001. 12.)

Annual Report of the Korea Central Cancer Registry

(Based on Registered Data from 134 Hospitals)

2003. 2.

**Korea Central Cancer Registry
Ministry of Health and Welfare
Republic of Korea**

2003. 2.

, , ,
, ,

.....	3
.....	4
.....	7
.....	10
1. Foreword	19
2. Background of Cancer Registries in Korea	20
3. Data Processing	22
4. Results	23
1-1. (T-Code) ,	30
1-2. (T-Code) ,	50
2-1. , (/)	62
2-2. , ()	68
3. ,	70
4. ,	80
5.	82
6.	83
7.	100
8. ,	102
9. ‘ , ‘ , ‘	112
.....	116
1.	116
2.	120
3.	122
1.	123
.....	123

Tables

Table 1-1. Marginal frequency of malignant cases by age, sex and topography(T-code) -----	30
Table 1-2. Marginal frequency of in situ cases by age, sex and topography(T-code) -----	50
Table 2-1. Distribution of malignant cases by age, sex and place of residence (Province) -----	62
Table 2-2. Distribution of malignant cases by age, sex and place of residence (Region) -----	68
Table 3. Distribution of malignant cases by age, sex, place of residence and topography -----	70
Table 4. Distribution of malignant cases by age, sex and basis of diagnosis -----	80
Table 5. Distribution of malignant cases by sex, place of residence and basis of diagnosis -----	82
Table 6. Marginal frequency of topography and morphology in primary cancer sites -----	83
Table 7. Marginal frequency of morphology(M-code) in malignant cases -----	100
Table 8. Distribution of childhood malignancies by age, sex and diagnostic groups -----	102
Table 9. Marginal frequency of the microscopically unconfirmed and the clinical investigation only by topography -----	112

Incidence in Five Continents 7

가

가

20

22

80%

가

1993

, 2001

, 2002 8

(International Agency for Research on Cancer (IARC))

, 2002 12 8

, 1980

(Completeness)

, 1997 가

Cancer

6

1.

1978 (WHO) 1980 2002 가 .

“ ” , 1980 47 가 . 1 .

1989 6 28-29 “ ” 가 1990 6 15 “ ” . 1992 1 “ ” 1992 13 1 12 . 1993 14 가 . 1995 , 12 20 “ ” , 1996 (WHO) “ ” (International Classification of Diseases for Oncology, second edition; ICD-O II) 16 .

1998 1999 2 , “ ” 1 , 2 , 3 , 4 , 5 , “ ” . 2000 9 가 , 2000 10 2001 12 “ ” “ ” 가

. , 2001 12

SEER Summary Staging System

TNM stage

, WHO 2000

ICD-0-3

2003

ICD-0-3 , “ ”

2003

2002 8 30 9 13

. 2001 6

“ ” , 2002 12 IARC “

(CanReg 4) ”

2.

2000 9

(,), (.), 2 , 5 ,
6 11 .

3.

1996 7 10 ,
. 가

4.

가 , 가 . 1991

. 2002 7

가

1999 9

가, 2000 9

가

5.

1.

2001 1 1 2001 12 31 1
 134 , 180 (
 188 2002 8)
 가 46
 21 3 가 .
 가 2001 9
 30 , 2002 3 31 .

2.

(T-code: Topography), (M-code: Morphology)
 , IARC check 가
 2002 10 , 2002 11 2003
 1 가
 ,
 ,
 ,
 , 4 .

3.

15

(M-8000)

111,816 2000 94,474 18.4%

가 10,106 (9.0%)

'95~2000 6,022

146 (83 , 63) 95,542

101,710 2000

86,739 17.3% 가 '98 1.6%, '99 6.9%, 2000 1.4% 가

가

가 . 2000 19

(Morphology-code) 가 2 , 22

3,598 (3.8%) . , 2001

가 , 2001

2001 , 가

95,542 . 91,944 .

4.

1 15

가 가 , 1990 ICD-O II (international Classification of Diseases for
Oncology, second edition)가 16 . 17

1996 OECD 가

1 4 % , % . 5
% , % . 8
% .
6 .

5.

, 2001
.
.
,
,
.
,
가 . , 2001
가
, 2001 A 가 2001 B
, B , 2001
.
.
, 22 ,
가 .
2001
, 가
가 .

1. , (1-1, 1-2)

1) 2001 1 1 2001 12 31 () 91,944
 51,753 (56.3%), 40,191 (43.7%) 1.29 .

2) 5 60 64 (15.0%), 65 69 (13.8%), 55 59 (12.4%),
 70 74 (10.3%), 50 54 (10.0%), 45 49 (8.9%) . 44
 0.1 7.6% 75 10.3% .

3) (C16: 20.3%), (C34: 11.9%),
 (C22: 11.8%), (, C18-C20: 10.5%), (C50: 7.1%), (C53:
 4.4%), (C73: 4.2%), (C42: 2.7%), (C67: 2.3%), (C25:
 2.2%), (C15: 1.7%), (C56: 1.6%), (C64: 1.6%), (C61: 1.6%), (C24:
 1.5%), 가 (C80: 1.5%), (C44: 1.4%), (C23: 1.3%), (C77:
 1.1%), (C71: 1.1%) .

4) 10 (C16: 24.1%), (C34:
 16.0%), (C22: 16.0%), (, C18-C20: 10.5%), (C67: 3.4%),
 (C61: 2.8%), (C15: 2.7%), (C42: 2.7%), (C25: 2.3%),
 (C64: 2.0%) . (C50: 16.1%), (C16: 15.3%), (C
 , C18-C20: 10.5%), (C53: 10.1%), (C73: 8.3%), (C34:
 6.6%), (C22: 6.5%), (C56: 3.8%), (C42: 2.7%), (C25:
 2.1%) .


5) 3,598 122 (3.4%), 3,476 (96.6%) .
 , , (C53) 2,898 (83.4%),
 (C50) 473 (13.6%) . 41.6%,
 6.8% .

10

(%)

Ten Leading Primary Cancer Sites (2001.1. – 2001. 12.)

< , Total >




10


(%)

Ten Leading Primary Cancer Sites (2001.1. – 2001. 12.)

< , Male >



< , Female >



· () · () 65 69 가 . 7
· () 65 69 가 , · ()
60 64 가 . 가 7 · ()
65 69 가 · () 60 64 가 .
7 · () 60 64 16.1%, 16.5% 가 ,
· () 65 69 20.4% 가 . 7
· () 60 64 15.2%, 16.6% , · ()
65 69 가 . 가
, , · ()
2) , , , ,
, 7 · () 가,
· () .

4. , (4)

1) ,
60 64 15.5%, 17.6%, 14.9% 가 ,
70 74 13.9% 가 ,
55 59 16.4% 가 .
2) , 60 64
16.7%, 19.3%, 17.8% 가 , 65 69 15.3% 가
, 55 59 16.5% 가
. 60 64 15.7%,
11.5% 가 , 75 79 13.8% 가 , 70 74
15.7%, 55 59 16.2% 가 .

5. (5)

1) 가 , 가 83.6% 가
, 14.4%, 1.5%, 0.4%,

가 16.4%

2) 7 (), () 83.4%, 84.3%, 82.5%

3.6 7.2%

CT MRI

6. (6)

10 , 18,648 (C16)

6,273 (33.6%), 4,523 (24.3%), 2,536 (13.6%) ,

9,559 (51.3%), 4,120 (22.1%), 2,914 (15.6%)

10,922 3,310 (30.3%), 2,365 (21.7%),

449 (4.1%) , 3,615 (33.1%), 2,894 (26.5%),

1,446 (13.2%) .

10,856 8,967 (82.6%),

1,889 (17.4%) , 7,947 (73.2%), 631 (5.3%),

265 (2.4%) .

6,505 2,301 (35.4%),

843 (13.0%), 753 (11.6%), 374 (5.7%) 5,369 (82.5%),

223 (3.4%), 146 (2.2%), 116 (1.8%) .

4,899 4,351 (88.8%), S

548 (11.2%) , 3,023 (61.7%), 1,155 (23.6%),

139 (2.8%) , 4,796 S

1,820 (37.9%), 1,011 (21.1%), 368 (7.7%) 2,879 (60.0%),

990 (20.6%), 312 (6.5%) .

4,061 3,162 (77.9%),

351 (8.6%), 100 (2.5%) . 3,872

2,979 (76.9%), 254 (6.6%), 167 (4.3%) .

C42 가 2,450 (97.7%) 가 ,
 1,129 (45.0%), 479 (19.1%), 441 (17.6%) . 2,150
 1,236 (57.5%), 656 (30.5%),
 28 (1.3%) . 942 (46.2%), 269 (13.2%),
 176 (8.6%) , 584 (28.6%), 68 (3.3%),
 43 (2.1%) .

7. (7)

91,944 (M-code) (814 838) 41,984 (45.7%),
 (805 808) 14,182 (15.4%), , (850 854) 5,964 (6.5%),
 , (844 849) 5,074 (5.5%), (801 804) 3,338 (3.6%),
 (812 813) 2,317 (2.5%), (959 970) 1,969 (2.1%)
 (980 994) 1,173 (1.9%) , M-8000 10.9%
 9,992 .

8. , (8)

15 1.2% 1,136 . 661 , 475
 1.4 .
 1) , 0 4 537 (47.3%), 5 9 312 (27.5%), 10 14
 287 (25.3%) 0 4 가 , , 100%, 100%,
 94.1%, 85.5%, 84.2% . 5 67.4%,
 59.1% , , 10 14 가 .
 2) 384 (33.8%) 가 , 1.5 가
 , 239 (62.2%), 109 (28.4%),
 19 (5.0%) .
 3) 172 (15.1%) 1.4 .
 59 (34.3%), 51 (29.7%), 32 (18.6%),

17 (9.9%) .

4) 89 (7.8%), 84 (7.4%), 83 (7.3%),
66 (5.8%), 60 (5.3%), 59 (5.2%), 50 (4.4%),
42 (3.7%), 26 (2.3%), 21 (1.8%) .

9. (9)

1) M-8000
. M-8000 9,963 (10.8%) 2000
10,420 (12.4%) .

2) (M-8000/3) 9,963 ,
1,817 (18.2%), 1,532 (15.4%), 1,205 (12.1%), 916 (9.2%) .
59.0% 가 , 53.6%, 45.0%,
40.9%, 가 32.2% .

3) (Sonography, CT , MRI, UGI) 13,246 (14.4%) .
, 67.7% 가 ,
50.9%, 39.5%, 35.4%, 26.1% .

10. (1)

2001 1 1 2001 12 31 1 134
111,816 . 10,106 (9.0%) .
2,000 8,746 (7.8%),
7,168 (6.4%), 5,521 (4.9%), 5,294 (4.7%),
4,968 (4.4%), 3,862 (3.5%) 3,839 (3.4%),
2,257 (2.0%), 2,225 (2.0%),
2,218 (2.0%), 2,189 (2.0%), 가 2,067 (1.9%),
2,065 (1.9%), 2,027(1.8%) .

11. (2)

, 가 9,040 (48.5%),

4,744 (25.4%), 2,930 (15.7%),

1,308 (7.0%), 가 4,472 (40.9%)

가 , 2,712 (24.8%), 1,523 (13.9%), 926 (8.5%) .

가 5,764 (53.1%), 3,209 (29.6%),

1,034 (9.5%) . 3,143 (48.3%),

2,189 (33.7%), 357 (5.5%), 가 287 (4.4%) .

2,380 (48.6%), 991 (20.2%),

699 (14.3%), , 326 (6.7%) , 2,470 (51.5%),

1,261 (26.3%), 762 (15.9%), 206 (4.3%) .

1,649(40.6%), 683 (16.8%),

444 (10.9%), 387 (9.5%) . 3,004 (77.6%),

479 (12.4%), 218 (5.6%) .

1,347 (53.7%) 가 , 782 (31.2%)

122 (4.9%) . 1,596 (74.2%),

231 (10.7%), 203 (9.4%), 37 (1.7%) ,

1,192 (58.4%), 338 (16.6%), 274 (13.4%) ,

538 (34.9%), 360 (23.4%), 191 (12.4%),

183 (11.9%) .

가

. 4 ,

FOREWORD

This 22nd annual report contains information on the relative frequencies of various cancers in the Republic of Korea, derived from the database of the nation-wide, hospital-based cancer registry program from January 1, 2001 to December 31, 2001. The cancer registry program of the Republic of Korea is managed by the Ministry of Health and Welfare to accurately measure the national cancer incidence and to construct a useful database for basic cancer research and treatment plans. The numbers of registered and data-sending hospitals at Dec. 31, 2001 were 180 and 134, respectively. It was estimated that about 80% of malignancies were registered and analyzed by this registry program. Many of the variations demonstrated in this monograph provide a challenge to population-based cancer registries, and thereby necessitate further investigations on malignancies in Korea.

Information on cancer incidence and mortality, and their changing trends over time, is an essential components in the planning and monitoring of the programs for cancer prevention, early detection and treatment. Population-based, regional cancer registry programs are ongoing in connection with this Central Cancer Registry Program in 8 large cities in 2002: Seoul, Busan, Daegu, Incheon, Gwangju, Daejeon, Ulsan and Jeju. This hospital-based cancer registry report, however, continues to hold the most important position until nationwide, population-based data are constructed on the basis of the international standard.

The office of Korea Central Cancer Registry moved to the National Cancer Center in September 2000, this is the third report in the National Cancer Center. We wish to give cordial thanks for the painstaking efforts of the medical record administrators in all participating hospitals and advisory senior cancer specialists.

BACKGROUND OF CANCER REGISTRIES IN KOREA

The Korea Central Cancer Registry (KCCR) was started as one of the ambitious projects of the Ministry of Health and Welfare in 1980. After "The Korea Cancer Control Workshop", held in 1978 with the aid of WHO, various individual cancer registry programs were merged into a nation-wide, hospital-based program managed by the ministry. In the beginning, 47 resident-training general hospitals over the nation participated in this program. The number of participating hospitals and registered malignancies increased year by year, and 134 hospitals submitted their data diskettes last year. Twenty one annual reports of KCCR from 1980 to 1999, and two 5-year reports (July, 1982 – June, 1987; July, 1988 – June, 1992) have been published.

In June, 1989, "The Workshop for Cancer Registry" was held in Seoul with the support of WHO, the Korean Academy of Medical Science, and the Korean Medical Association. Lots of advice and opinions were raised regarding the registry program at the time. On the 15th of June 1990, "The Workshop on Cancer Registry for Medical Recorders" was held at the National Medical Center. From 106 hospitals, 140 recorders attended the meeting. In the same year, many of the intern-training hospitals also participated in the registry program. In 1992, the Korean cancer registry form was revised to include items of occupation and treatment modalities. From 1992, the annual reports have shown results of the data analysis from January to December of the preceding year for easy comparison between the years. From 1993, all the data have been statistically analyzed by PC program constructed by the central cancer registry committee. In 1995, a PC software program for cancer registry was developed and distributed to all participating hospitals after job training for medical record administrators. The participating hospitals have sent their data in the form of diskette from 1996. In 1996, the second edition of International Classification of Diseases for Oncology (ICD-O, 2nd edition) was translated into Korean and distributed to all the participating hospitals. Topography and Morphology codes of the ICD-O, 2nd edition were used from the 16th annual report. On the 6th of May 1998, "In-service Training Workshop for Cancer Registry" was held for the efficient conduct of the cancer registry.

Since being transferred to the National Cancer Center in September 2000, the Korea Central Cancer Registry has been continuously performing the Korea Central Cancer Registry Program and also making every effort to collect more complete and accurate registry data by holding the "Symposium on Cancer Registration and Biostatistics" in October 2000 and the "Academic Symposium on Cancer Registry Program" in December 2001. Especially, the registration index was revised to use the SEER Summary Staging System and to complementarily register TNM stage for the staging classification instead of deleting the item of birth

origin in the symposium of December 2001, and the ICD-O-3 classification system that was newly revised by WHO in 2000 will be applied to the cases registered from 2003. To achieve this, International Classification of Diseases for Oncology was translated into Korean, compiled as ICD-O-3, and distributed to associated organizations for application from 2003. Meanwhile, workshops on August 30 and September 13, 2002 were opened for working-level associates capable of applying the revised classification system for oncology. The office of the KCCR is maintaining its efforts; it held the International Training Workshop for Cancer Registrars in cooperation with the American National Cancer Institute (NCI) in June 2001 and performed an educational workshop of a cancer registration biostatistics program, "IARC workshop on CanReg 4 and ICD-O-3" together with IARC (Unit of descriptive epidemiology) in December 2002 to standardize and qualitatively improve cancer registry data. The organization of the KCCR is composed of a chief, executive secretary, medical record administrator, statistician, and 11 advisory members.

DATA PROCESSING

Among 180 registered hospitals, 134 participated in the KCCR program in 2001. All cancer registry data, submitted from the participating hospitals on diskettes during the year, were reviewed and sorted out by the committee members who were all board-qualified clinical oncologists and pathologists. After correction of erroneous coding of topography and morphology in ICD-O, 2nd edition, data underwent computer analysis. To avoid duplication, the computer compared the resident registration number of all subjects. Much emphasis was placed on the item of the basis of diagnosis during this selection procedure. Cases diagnosed by histological examination were preferentially chosen. Of 111,816 malignancies registered, 10,106 (9.0%) duplicated malignancies were excluded. Among the remaining 95,542 malignancies, 3,598 (3.8%) carcinoma in situ (Morphology code /2) were separated. Finally, 91,944 malignancies were analyzed. The advisory committee reevaluated the analysis results. The report of KCCR is pressed and released annually by the Ministry of Health and Welfare.

RESULTS

1. Marginal frequency of malignant neoplasm and carcinoma in situ by age, sex, and topography (Table 1-1, 1-2)

1) Of the total of 91,944 malignancies registered, 51,753 (56.3%) cases were male and 40,191 (43.7%) cases were female; a sex ratio of 1.29:1.

2) The leading age groups in order of relative frequency were 60-64 years of age (15.0%), followed by 65-69 (13.8%), 55-59 (12.4%), 70-74 (10.3%), 50-54 (10.0%), and 45-49 (8.9%). The relative frequencies of age groups below 45 and above 75 were 0.1% and 10.3%, respectively.

3) The leading primary cancer sites in order of relative frequency were stomach (20.3%), followed by bronchus & lung (11.9%), liver & intrahepatic bile ducts (11.8%), colorectum (10.5%), breast (7.1%), uterine cervix (4.4%), thyroid (4.2%), hematopoietic & reticuloendothelial systems (2.7%), urinary bladder (2.3%), and pancreas (2.2%).

4) In males, the leading primary cancer sites were stomach (24.1%), followed by bronchus & lung (16.0%), liver & intrahepatic bile ducts (16.0%), colorectum (10.5%), urinary bladder (3.4%), prostate (2.8%), esophagus (2.7%), hematopoietic & reticuloendothelial systems (2.7%), pancreas (2.3%), and kidney (2.0%). In females, breast (16.1%) was the most common site, followed by stomach (15.3%), colorectum (10.5%), uterine cervix (10.1%), thyroid (8.3%), bronchus & lung (6.6%), liver & intrahepatic bile ducts (6.5%), ovary (3.8%), hematopoietic & reticuloendothelial systems (2.7%), and pancreas (2.1%).

5) Of the total 3,598 cases of carcinoma in situ, 122 (3.4%) were male and 3,476 (96.6%) were female. In females, the major sites were uterine cervix [2,898 cases (83.4%)] and breast [473 cases (13.6%)], which occupied 41.6% of registered uterine cervix cases and 6.8% of registered female breast cases.

2. Distribution of malignant neoplasm by age, sex, and place of residence (Table 2-1, 2-2)

1) The leading place of residence in the order of relative frequency of registered malignancies was Seoul (23.5%), followed by Gyeonggido (18.4%), Busan (8.2%), Gyeongsangbugdo (7.1%), Gyeongsangnamdo

(6.3%), Daegu (5.5%), Incheon (4.6%), Jeonlanamdo (4.4%), Chungcheongnamdo (4.2%), Jeonlabugdo (3.9%), Gangweondo (3.7%), Chungcheongbugdo (2.9%), Daejeon (2.6%), Gwangju (2.3%), Ulsan (1.4%), and Jejudo (0.9%); the residential area was unknown for 55 cases of the total 91,944.

2) In all the places of residence, the relative frequencies of the males (52.3–63.7%) were higher than those of the females.

3) The leading age group in the order of relative frequency in 7 metropolitan cities, small- and medium-sized cities and country-sized regions was in 55–69.

3. Distribution of malignant neoplasms by age, sex, place of residence and topography (Table 3)

1) The leading age group differed according to the places of residence. In cancers of the stomach and colorectum the leading age group of country-sized regions was higher than that of metropolitan and small to medium-sized city regions.

2) The age of the leading age groups of malignancies was the same or higher in females through all places of residence in malignancies of stomach, liver, colorectum, bladder, and pancreas.

4. Distribution of malignant neoplasms by age, sex, and basis of diagnosis (Table 4)

1) The age group 60–64 was the leading age group in the order of relative frequency for diagnostic methods of clinical investigation (15.5%), exploratory surgery (17.6%), and microscopic examination (14.9%). For specific biochemical/immunological tests, the leading age group was 55–59 (16.4%), but was 70–74 for clinical findings only (13.9%).

2) In males, 60–64 was the leading age group for clinical investigation (16.7%), microscopic examination (17.8%), and exploratory surgery (19.3%), while 65–69 was for clinical findings only (15.3%), and 55–59 was for specific biochemical/immunologic tests (16.5%). In females, 60–64 was the leading age group for exploratory surgery (15.7%), and microscopic examination (11.5%), while 70–74 was for clinical investigation (15.7%), and 55–59 was for specific biochemical/immunological tests (16.2%).

5. Distribution of malignant neoplasms by sex, place of residence, and basis of diagnosis (Table 5)

1) In general, microscopic examination (83.6%) was the leading method of diagnosis, followed by clinical investigation (14.4%), clinical findings only (1.5%), specific biochemical/immunologic tests (0.4%), and exploratory surgery, among the subject whose address was identified. About 16% of cancers were diagnosed only by clinical judgment without microscopic examination.

2) The relative frequencies of malignancies diagnosed by microscopic examination for 7 metropolitan cities, small to medium-sized cities, and country-sized regions were 83.4%, 84.3%, and 82.5%, respectively. The relative frequency of microscopic examination of females was 3.6–7.2% higher than that of males throughout three categories of residence, showing a trend similar to the preceding years.

6. Marginal frequency of topography and morphology in primary cancer sites (Table 6)

The marginal frequencies of topography and morphology in the leading malignancies are shown in table 6.

7. Marginal frequency of morphology in malignant neoplasms (Table 7)

The leading morphology (M-code) of malignancies in the order of marginal frequency was adenocarcinomas (814–838) [41,984(45.7%)], followed by papillary & squamous cell neoplasms (805–808) [14,182(15.4%)], ductal, lobular & medullary neoplasms (850–854) [5,964(6.5%)], cystic, mucinous & serous neoplasms (844–849) [5,074(5.5%)], epithelial neoplasms, NOS (801–804) [3,338(3.6%)], transitional cell carcinomas (812–813) [2,317(2.5%)], Hodgkin's & non-Hodgkin's lymphoma (959–970) [1,969(2.1%)], and leukemias (980–994) [1,173(1.9%)]. There were 9,992 cases (10.9%) of malignancies not diagnosed morphologically (M-8000).

8. Distribution of childhood malignancies by age, sex and diagnostic groups (Table 8)

Childhood malignancies, defined as malignancies occurring under the age of fifteen, occurred in 1,136 cases (1.2%). There were 661 male cases and 475 female cases, with a sex ratio of 1.4:1.

1) The age groups in the order of relative frequency were 0–4 (47.3%), 5–9 (27.5%) and 10–14 (25.3%). The 0–4 age group comprised 100% of the other and unspecified non-gonadal germ cell tumors and retinoblastoma, 94.1% of the ependymoma, 85.5% of the neuroblastoma and 84.2% of the hepatoblastoma.

These cancers had the highest incidence in this age group. Malignant bone tumors and carcinoma / epithelial neoplasms were the most common in the 10 - 14 age group.

2) Leukemia (33.8%) was the most common malignancy, with a sex ratio of 1.5:1, of which subtypes in the order of frequency were lymphoid leukemia (62.2%), acute non-lymphocytic leukemia (28.4%), and CML (5.0%).

3) CNS tumor (15.1%) was the next in frequency, followed by lymphoma (7.8%), tumor of the sympathetic nervous system (7.4%), gonadal and germ cell tumor (7.3%), soft tissue sarcoma (5.8%), malignant bone tumor (5.3%), carcinoma and epithelial neoplasm (4.4%), renal tumors (3.7%), hepatic tumor (2.3%), and retinoblastoma (1.8%).

9. Marginal frequency of the microscopically unconfirmed and the clinical investigation only by topography (Table 9)

1) To augment the substantiality of this registry program, the malignancies with M8000 should be minimized while those diagnosed by microscopic examination should be increased. The M-8000/3 cases were 9,963 (10.8%). The leading organ in the order of number of M-8000/3 was the liver & intrahepatic bile ducts (1,817; 18.2%), followed by bronchus & lung (1,532; 15.4%), pancreas (1,205; 12.1%), and stomach (916; 9.2%), The leading organ in the order of frequency of M-8000/3 was pancreas (59.0%), followed by placenta (53.6%), gallbladder (45.0%), and unspecified biliary tract (40.9%).

2) There were 13,246 cases (14.4%) of malignancies diagnosed by clinical investigation without microscopic examination. The liver and intrahepatic bile ducts (67.7%) was the most common organ, followed by pancreas (50.9%), gallbladder (39.5%), unspecified biliary tract (35.4%) and placenta (26.1%).

Tables

1-1.

		†	0	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
, %		Total	Year								
C00-C80		91944	128	409	312	287	502	766	1477	2647	4347
	%	100.0	0.1	0.4	0.3	0.3	0.5	0.8	1.6	2.9	4.7
		51753	75	237	189	160	256	298	500	869	1546
	%	56.3	0.1	0.5	0.4	0.3	0.5	0.6	1.0	1.7	3.0
	%	43.7	0.1	0.4	0.3	0.3	0.6	1.2	2.4	4.4	7.0
C00-C14		1829	1	2	6	5	15	35	28	52	90
	%	2.0	0.1	0.1	0.3	0.3	0.8	1.9	1.5	2.8	4.9
		1342	1	2	3	4	8	20	11	30	64
	%	2.6	0.1	0.1	0.2	0.3	0.6	1.5	0.8	2.2	4.8
	%	1.2	-	-	0.6	0.2	1.4	3.1	3.5	4.5	5.3
C00		31	-	-	-	-	-	-	-	-	1
	%	0.0	-	-	-	-	-	-	-	-	3.2
		17	-	-	-	-	-	-	-	-	1
	%	0.0	-	-	-	-	-	-	-	-	5.9
	%	0.0	-	-	-	-	-	-	-	-	-
C01		70	-	-	-	-	-	1	2	-	2
	%	0.1	-	-	-	-	-	1.4	2.9	-	2.9
		60	-	-	-	-	-	1	1	-	2
	%	0.1	-	-	-	-	-	1.7	1.7	-	3.3
	%	0.0	-	-	-	-	-	-	10.0	-	-
C02		228	-	-	1	-	-	5	6	8	20
	%	0.2	-	-	0.4	-	-	2.2	2.6	3.5	8.8
		154	-	-	1	-	-	3	4	5	13
	%	0.3	-	-	0.6	-	-	1.9	2.6	3.2	8.4
	%	0.2	-	-	-	-	-	2.7	2.7	4.1	9.5
C03		55	-	-	-	-	-	-	-	1	-
	%	0.1	-	-	-	-	-	-	-	1.8	-
		33	-	-	-	-	-	-	-	1	-
	%	0.1	-	-	-	-	-	-	-	3.0	-
	%	0.1	-	-	-	-	-	-	-	-	-
C04		65	-	-	-	-	-	-	-	-	2
	%	0.1	-	-	-	-	-	-	-	-	3.1
		59	-	-	-	-	-	-	-	-	2
	%	0.1	-	-	-	-	-	-	-	-	3.4
	%	0.0	-	-	-	-	-	-	-	-	-
C05		103	-	-	-	1	-	4	-	1	4
	%	0.1	-	-	-	1.0	-	3.9	-	1.0	3.9
		70	-	-	-	1	-	1	-	-	1
	%	0.1	-	-	-	1.4	-	1.4	-	-	1.4
	%	0.1	-	-	-	-	-	3	-	1	3

† Column %,

Row %

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
6976	8169	9187	11364	13767	12688	9437	6036	2482	963	-	T	Total malignant neoplasms
7.6	8.9	10.0	12.4	15.0	13.8	10.3	6.6	2.7	1.0	-	%	
2825	3962	5233	7101	9071	8167	5774	3583	1438	469	-	M	
5.5	7.7	10.1	13.7	17.5	15.8	11.2	6.9	2.8	0.9	-	%	
4151	4207	3954	4263	4696	4521	3663	2453	1044	494	-	F	
10.3	10.5	9.8	10.6	11.7	11.2	9.1	6.1	2.6	1.2	-	%	
144	173	167	245	313	266	151	84	38	14	-	T	Lip, oral cavity and pharynx
7.9	9.5	9.1	13.4	17.1	14.5	8.3	4.6	2.1	0.8	-	%	
100	128	122	195	246	203	110	58	26	11	-	M	
7.5	9.5	9.1	14.5	18.3	15.1	8.2	4.3	1.9	0.8	-	%	
44	45	45	50	67	63	41	26	12	3	-	F	
9.0	9.2	9.2	10.3	13.8	12.9	8.4	5.3	2.5	0.6	-	%	
1	2	-	3	8	10	2	2	1	1	-	T	Lip
3.2	6.5	-	9.7	25.8	32.3	6.5	6.5	3.2	3.2	-	%	
1	2	-	3	5	4	-	-	-	1	-	M	
5.9	11.8	-	17.6	29.4	23.5	-	-	-	5.9	-	%	
-	-	-	-	3	6	2	2	1	-	-	F	
-	-	-	-	21.4	42.9	14.3	14.3	7.1	-	-	%	
5	5	7	7	14	18	2	3	3	1	-	T	Base of tongue
7.1	7.1	10.0	10.0	20.0	25.7	2.9	4.3	4.3	1.4	-	%	
4	5	6	7	11	16	2	2	2	1	-	M	
6.7	8.3	10.0	11.7	18.3	26.7	3.3	3.3	3.3	1.7	-	%	
1	-	1	-	3	2	-	1	1	-	-	F	
10.0	-	10.0	-	30.0	20.0	-	10.0	10.0	-	-	%	
19	34	20	26	30	22	18	10	5	4	-	T	Other and unspecified parts of tongue
8.3	14.9	8.8	11.4	13.2	9.6	7.9	4.4	2.2	1.8	-	%	
13	27	15	17	21	12	11	6	3	3	-	M	
8.4	17.5	9.7	11.0	13.6	7.8	7.1	3.9	1.9	1.9	-	%	
6	7	5	9	9	10	7	4	2	1	-	F	
8.1	9.5	6.8	12.2	12.2	13.5	9.5	5.4	2.7	1.4	-	%	
2	3	7	5	14	7	8	4	3	1	-	T	Gum
3.6	5.5	12.7	9.1	25.5	12.7	14.5	7.3	5.5	1.8	-	%	
2	3	3	3	9	2	5	3	1	1	-	M	
6.1	9.1	9.1	9.1	27.3	6.1	15.2	9.1	3.0	3.0	-	%	
-	-	4	2	5	5	3	1	2	-	-	F	
-	-	18.2	9.1	22.7	22.7	13.6	4.5	9.1	-	-	%	
3	7	5	10	19	13	2	2	2	-	-	T	Floor of mouth
4.6	10.8	7.7	15.4	29.2	20.0	3.1	3.1	3.1	-	-	%	
1	7	5	10	18	10	2	2	2	-	-	M	
1.7	11.9	8.5	16.9	30.5	16.9	3.4	3.4	3.4	-	-	%	
2	-	-	-	1	3	-	-	-	-	-	F	
33.3	-	-	-	16.7	50.0	-	-	-	-	-	%	
7	11	6	17	24	10	11	6	1	-	-	T	Palate
6.8	10.7	5.8	16.5	23.3	9.7	10.7	5.8	1.0	-	-	%	
4	7	5	13	19	8	6	4	1	-	-	M	
5.7	10.0	7.1	18.6	27.1	11.4	8.6	5.7	1.4	-	-	%	
3	4	1	4	5	2	5	2	-	-	-	F	
9.1	12.1	3.0	12.1	15.2	6.1	15.2	6.1	-	-	-	%	

1-1.

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C06		134	-	1	1	1	1	2	1	4	7
	%	0.1	-	0.7	0.7	0.7	0.7	1.5	0.7	3.0	5.2
		89	-	1	-	-	-	1	-	1	5
	%	0.2	-	1.1	-	-	-	1.1	-	1.1	5.6
		45	-	-	1	1	1	1	1	3	2
	%	0.1	-	-	2.2	2.2	2.2	2.2	2.2	6.7	4.4
C07		185	-	-	3	1	5	7	9	10	16
	%	0.2	-	-	1.6	0.5	2.7	3.8	4.9	5.4	8.6
		105	-	-	1	1	4	3	1	5	11
	%	0.2	-	-	1.0	1.0	3.8	2.9	1.0	4.8	10.5
		80	-	-	2	-	1	4	8	5	5
	%	0.2	-	-	2.5	-	1.3	5.0	10.0	6.3	6.3
C08		75	-	-	-	-	3	3	2	3	4
	%	0.1	-	-	-	-	4.0	4.0	2.7	4.0	5.3
		40	-	-	-	-	1	1	-	2	3
	%	0.1	-	-	-	-	2.5	2.5	-	5.0	7.5
		35	-	-	-	-	2	2	2	1	1
	%	0.1	-	-	-	-	5.7	5.7	5.7	2.9	2.9
C09		202	-	-	1	-	-	3	1	7	9
	%	0.2	-	-	0.5	-	-	1.5	0.5	3.5	4.5
		156	-	-	1	-	-	2	-	2	6
	%	0.3	-	-	0.6	-	-	1.3	-	1.3	3.8
		46	-	-	-	-	-	1	1	5	3
	%	0.1	-	-	-	-	-	2.2	2.2	10.9	6.5
C10		61	-	-	-	-	-	-	-	1	1
	%	0.1	-	-	-	-	-	-	-	1.6	1.6
		51	-	-	-	-	-	-	-	1	1
	%	0.1	-	-	-	-	-	-	-	2.0	2.0
		10	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
C11		325	1	-	-	2	6	10	7	16	22
	%	0.4	0.3	-	-	0.6	1.8	3.1	2.2	4.9	6.8
		231	1	-	-	2	3	8	5	12	17
	%	0.4	0.4	-	-	0.9	1.3	3.5	2.2	5.2	7.4
		94	-	-	-	-	3	2	2	4	5
	%	0.2	-	-	-	-	3.2	2.1	2.1	4.3	5.3
C12		80	-	-	-	-	-	-	-	-	1
	%	0.1	-	-	-	-	-	-	-	-	1.3
		78	-	-	-	-	-	-	-	-	1
	%	0.2	-	-	-	-	-	-	-	-	1.3
		2	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
C13		178	-	-	-	-	-	-	-	-	-
	%	0.2	-	-	-	-	-	-	-	-	-
		166	-	-	-	-	-	-	-	-	-
	%	0.3	-	-	-	-	-	-	-	-	-
		12	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %
6	12	7	21	25	21	10	8	3	3	-	T Other and unspecified parts of mouth
4.5	9.0	5.2	15.7	18.7	15.7	7.5	6.0	2.2	2.2	-	%
3	7	7	14	19	17	6	3	3	2	-	M
3.4	7.9	7.9	15.7	21.3	19.1	6.7	3.4	3.4	2.2	-	%
3	5	-	7	6	4	4	5	-	1	-	F
6.7	11.1	-	15.6	13.3	8.9	8.9	11.1	-	2.2	-	%
16	19	15	23	17	19	10	9	5	1	-	T Parotid gland
8.6	10.3	8.1	12.4	9.2	10.3	5.4	4.9	2.7	0.5	-	%
9	9	8	17	10	10	7	5	3	1	-	M
8.6	8.6	7.6	16.2	9.5	9.5	6.7	4.8	2.9	1.0	-	%
7	10	7	6	7	9	3	4	2	-	-	F
8.8	12.5	8.8	7.5	8.8	11.3	3.8	5.0	2.5	-	-	%
7	11	10	6	10	8	6	1	1	-	-	T Other and unspecified major salivary glands
9.3	14.7	13.3	8.0	13.3	10.7	8.0	1.3	1.3	-	-	%
3	8	2	2	5	6	5	1	1	-	-	M
7.5	20.0	5.0	5.0	12.5	15.0	12.5	2.5	2.5	-	-	%
4	3	8	4	5	2	1	-	-	-	-	F
11.4	8.6	22.9	11.4	14.3	5.7	2.9	-	-	-	-	%
16	21	21	32	28	29	20	9	4	1	-	T Tonsil
7.9	10.4	10.4	15.8	13.9	14.4	9.9	4.5	2.0	0.5	-	%
14	18	16	27	24	22	15	6	3	-	-	M
9.0	11.5	10.3	17.3	15.4	14.1	9.6	3.8	1.9	-	-	%
2	3	5	5	4	7	5	3	1	1	-	F
4.3	6.5	10.9	10.9	8.7	15.2	10.9	6.5	2.2	2.2	-	%
5	1	7	8	15	14	6	3	-	-	-	T Oropharynx
8.2	1.6	11.5	13.1	24.6	23.0	9.8	4.9	-	-	-	%
5	-	5	8	12	13	3	3	-	-	-	M
9.8	-	9.8	15.7	23.5	25.5	5.9	5.9	-	-	-	%
-	1	2	-	3	1	3	-	-	-	-	F
-	10.0	20.0	-	30.0	10.0	30.0	-	-	-	-	%
48	30	35	39	41	33	24	9	2	-	-	T Nasopharynx
14.8	9.2	10.8	12.0	12.6	10.2	7.4	2.8	0.6	-	-	%
34	18	25	29	26	24	18	7	2	-	-	M
14.7	7.8	10.8	12.6	11.3	10.4	7.8	3.0	0.9	-	-	%
14	12	10	10	15	9	6	2	-	-	-	F
14.9	12.8	10.6	10.6	16.0	9.6	6.4	2.1	-	-	-	%
3	4	13	12	18	11	8	8	1	1	-	T Pyriform sinus
3.8	5.0	16.3	15.0	22.5	13.8	10.0	10.0	1.3	1.3	-	%
3	4	13	12	17	11	8	7	1	1	-	M
3.8	5.1	16.7	15.4	21.8	14.1	10.3	9.0	1.3	1.3	-	%
-	-	-	-	1	-	-	1	-	-	-	F
-	-	-	-	50.0	-	-	50.0	-	-	-	%
5	9	11	32	44	44	19	7	7	-	-	T Hypopharynx
2.8	5.1	6.2	18.0	24.7	24.7	10.7	3.9	3.9	-	-	%
3	9	9	31	44	42	18	6	4	-	-	M
1.8	5.4	5.4	18.7	26.5	25.3	10.8	3.6	2.4	-	-	%
2	-	2	1	-	2	1	1	3	-	-	F
16.7	-	16.7	8.3	-	16.7	8.3	8.3	25.0	-	-	%

1-1.

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C14		37	-	1	-	-	-	-	-	1	1
	%	0.0	-	2.7	-	-	-	-	-	2.7	2.7
		33	-	1	-	-	-	-	-	1	1
	%	0.1	-	3.0	-	-	-	-	-	3.0	3.0
		4	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
C15-C26		46001	11	14	6	19	37	91	331	784	1561
	%	50.0	0.0	0.0	0.0	0.0	0.1	0.2	0.7	1.7	3.4
		30542	4	12	1	9	23	43	169	437	952
	%	59.0	0.0	0.0	0.0	0.0	0.1	0.1	0.6	1.4	3.1
		15459	7	2	5	10	14	48	162	347	609
	%	38.5	0.0	0.0	0.0	0.1	0.1	0.3	1.0	2.2	3.9
C15		1540	-	-	-	-	-	-	-	-	5
	%	1.7	-	-	-	-	-	-	-	-	0.3
		1419	-	-	-	-	-	-	-	-	4
	%	2.7	-	-	-	-	-	-	-	-	0.3
		121	-	-	-	-	-	-	-	-	1
	%	0.3	-	-	-	-	-	-	-	-	0.8
C16		18648	-	-	-	6	13	45	196	465	831
	%	20.3	-	-	-	0.0	0.1	0.2	1.1	2.5	4.5
		12481	-	-	-	2	6	15	88	235	449
	%	24.1	-	-	-	0.0	0.0	0.1	0.7	1.9	3.6
		6167	-	-	-	4	7	30	108	230	382
	%	15.3	-	-	-	0.1	0.1	0.5	1.8	3.7	6.2
C17		415	1	-	-	2	3	4	7	16	19
	%	0.5	0.2	-	-	0.5	0.7	1.0	1.7	3.9	4.6
		250	1	-	-	2	2	2	2	11	13
	%	0.5	0.4	-	-	0.8	0.8	0.8	0.8	4.4	5.2
		165	-	-	-	-	1	2	5	5	6
	%	0.4	-	-	-	-	0.6	1.2	3.0	3.0	3.6
C18		4796	1	-	3	3	9	14	35	82	148
	%	5.2	0.0	-	0.1	0.1	0.2	0.3	0.7	1.7	3.1
		2657	-	-	1	1	6	5	20	46	82
	%	5.1	-	-	0.0	0.0	0.2	0.2	0.8	1.7	3.1
		2139	1	-	2	2	3	9	15	36	66
	%	5.3	0.0	-	0.1	0.1	0.1	0.4	0.7	1.7	3.1
C19	S	548	-	-	-	1	1	1	-	5	17
	%	0.6	-	-	-	0.2	0.2	0.2	-	0.9	3.1
		316	-	-	-	1	-	1	-	2	9
	%	0.6	-	-	-	0.3	-	0.3	-	0.6	2.8
		232	-	-	-	-	1	-	-	3	8
	%	0.6	-	-	-	-	0.4	-	-	1.3	3.4
C20		4351	-	-	-	-	2	10	31	67	130
	%	4.7	-	-	-	-	0.0	0.2	0.7	1.5	3.0
		2501	-	-	-	-	2	8	13	29	76
	%	4.8	-	-	-	-	0.1	0.3	0.5	1.2	3.0
		1850	-	-	-	-	-	2	18	38	54
	%	4.6	-	-	-	-	-	0.1	1.0	2.1	2.9

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
1	4	3	4	6	7	5	3	-	1	-	T	Other and ill-defined sites in lip, oral cavity and pharynx
2.7	10.8	8.1	10.8	16.2	18.9	13.5	8.1	-	2.7	-	%	
1	4	3	2	6	6	4	3	-	1	-	M	
3.0	12.1	9.1	6.1	18.2	18.2	12.1	9.1	-	3.0	-	%	
-	-	-	2	-	1	1	-	-	-	-	F	
-	-	-	50.0	-	25.0	25.0	-	-	-	-	%	
2823	3764	5000	6457	7864	7109	5125	3211	1286	508	-	T	Digestive organs
6.1	8.2	10.9	14.0	17.1	15.5	11.1	7.0	2.8	1.1	-	%	
1883	2685	3624	4660	5592	4667	3054	1804	699	224	-	M	
6.2	8.8	11.9	15.3	18.3	15.3	10.0	5.9	2.3	0.7	-	%	
940	1079	1376	1797	2272	2442	2071	1407	587	284	-	F	
6.1	7.0	8.9	11.6	14.7	15.8	13.4	9.1	3.8	1.8	-	%	
23	58	139	239	347	338	220	118	41	12	-	T	Esophagus
1.5	3.8	9.0	15.5	22.5	21.9	14.3	7.7	2.7	0.8	-	%	
20	57	129	229	323	314	202	100	33	8	-	M	
1.4	4.0	9.1	16.1	22.8	22.1	14.2	7.0	2.3	0.6	-	%	
3	1	10	10	24	24	18	18	8	4	-	F	
2.5	0.8	8.3	8.3	19.8	19.8	14.9	14.9	6.6	3.3	-	%	
1271	1479	1863	2510	3139	2919	2069	1212	466	164	-	T	Stomach
6.8	7.9	10.0	13.5	16.8	15.7	11.1	6.5	2.5	0.9	-	%	
804	1022	1329	1825	2318	2016	1303	727	257	85	-	M	
6.4	8.2	10.6	14.6	18.6	16.2	10.4	5.8	2.1	0.7	-	%	
467	457	534	685	821	903	766	485	209	79	-	F	
7.6	7.4	8.7	11.1	13.3	14.6	12.4	7.9	3.4	1.3	-	%	
30	39	43	55	57	47	44	31	12	5	-	T	Small intestine
7.2	9.4	10.4	13.3	13.7	11.3	10.6	7.5	2.9	1.2	-	%	
16	24	29	30	41	30	24	19	3	1	-	M	
6.4	9.6	11.6	12.0	16.4	12.0	9.6	7.6	1.2	0.4	-	%	
14	15	14	25	16	17	20	12	9	4	-	F	
8.5	9.1	8.5	15.2	9.7	10.3	12.1	7.3	5.5	2.4	-	%	
277	344	466	583	782	763	590	438	184	74	-	T	Colon
5.8	7.2	9.7	12.2	16.3	15.9	12.3	9.1	3.8	1.5	-	%	
154	202	291	350	465	413	283	226	88	24	-	M	
5.8	7.6	11.0	13.2	17.5	15.5	10.7	8.5	3.3	0.9	-	%	
123	142	175	233	317	350	307	212	96	50	-	F	
5.8	6.6	8.2	10.9	14.8	16.4	14.4	9.9	4.5	2.3	-	%	
25	30	52	78	91	91	68	48	28	12	-	T	Rectosigmoid junction
4.6	5.5	9.5	14.2	16.6	16.6	12.4	8.8	5.1	2.2	-	%	
11	12	27	51	56	64	41	20	16	5	-	M	
3.5	3.8	8.5	16.1	17.7	20.3	13.0	6.3	5.1	1.6	-	%	
14	18	25	27	35	27	27	28	12	7	-	F	
6.0	7.8	10.8	11.6	15.1	11.6	11.6	12.1	5.2	3.0	-	%	
271	362	488	612	697	686	512	317	115	51	-	T	Rectum
6.2	8.3	11.2	14.1	16.0	15.8	11.8	7.3	2.6	1.2	-	%	
153	203	300	390	433	386	273	154	60	21	-	M	
6.1	8.1	12.0	15.6	17.3	15.4	10.9	6.2	2.4	0.8	-	%	
118	159	188	222	264	300	239	163	55	30	-	F	
6.4	8.6	10.2	12.0	14.3	16.2	12.9	8.8	3.0	1.6	-	%	

1-1.

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C21		122	-	-	-	-	-	-	2	1	1
	%	0.1	-	-	-	-	-	-	1.6	0.8	0.8
		60	-	-	-	-	-	-	1	-	1
	%	0.1	-	-	-	-	-	-	1.7	-	1.7
		62	-	-	-	-	-	-	1	1	-
	%	0.2	-	-	-	-	-	-	1.6	1.6	-
C22		10856	8	13	3	5	7	14	51	119	337
	%	11.8	0.1	0.1	0.0	0.0	0.1	0.1	0.5	1.1	3.1
		8261	2	11	-	3	6	11	39	98	274
	%	16.0	0.0	0.1	-	0.0	0.1	0.1	0.5	1.2	3.3
		2595	6	2	3	2	1	3	12	21	63
	%	6.5	0.2	0.1	0.1	0.1	0.0	0.1	0.5	0.8	2.4
C23		1208	-	-	-	1	-	-	1	7	19
	%	1.3	-	-	-	0.1	-	-	0.1	0.6	1.6
		526	-	-	-	-	-	-	1	3	9
	%	1.0	-	-	-	-	-	-	0.2	0.6	1.7
		682	-	-	-	1	-	-	-	4	10
	%	1.7	-	-	-	0.1	-	-	-	0.6	1.5
C24		1397	-	-	-	-	1	2	2	4	19
	%	1.5	-	-	-	-	0.1	0.1	0.1	0.3	1.4
		836	-	-	-	-	1	1	1	2	13
	%	1.6	-	-	-	-	0.1	0.1	0.1	0.2	1.6
		561	-	-	-	-	-	1	1	2	6
	%	1.4	-	-	-	-	-	0.2	0.2	0.4	1.1
C25		2041	1	1	-	-	1	1	5	16	33
	%	2.2	0.0	0.0	-	-	0.0	0.0	0.2	0.8	1.6
		1187	1	1	-	-	-	-	3	9	21
	%	2.3	0.1	0.1	-	-	-	-	0.3	0.8	1.8
		854	-	-	-	-	1	1	2	7	12
	%	2.1	-	-	-	-	0.1	0.1	0.2	0.8	1.4
C26		79	-	-	-	1	-	-	1	2	2
	%	0.1	-	-	-	1.3	-	-	1.3	2.5	2.5
		48	-	-	-	-	-	-	1	2	1
	%	0.1	-	-	-	-	-	-	2.1	4.2	2.1
		31	-	-	-	1	-	-	-	-	1
	%	0.1	-	-	-	3.2	-	-	-	-	3.2
C30-C39		12549	2	13	3	8	26	31	46	95	190
	%	13.6	0.0	0.1	0.0	0.1	0.2	0.2	0.4	0.8	1.5
		9613	-	7	3	7	15	20	27	49	122
	%	18.6	-	0.1	0.0	0.1	0.2	0.2	0.3	0.5	1.3
		2936	2	6	-	1	11	11	19	46	68
	%	7.3	0.1	0.2	-	0.0	0.4	0.4	0.6	1.6	2.3
C30		164	-	2	1	-	3	6	7	9	7
	%	0.2	-	1.2	0.6	-	1.8	3.7	4.3	5.5	4.3
		105	-	1	1	-	1	5	5	2	5
	%	0.2	-	1.0	1.0	-	1.0	4.8	4.8	1.9	4.8
		59	-	1	-	-	2	1	2	7	2
	%	0.1	-	1.7	-	-	3.4	1.7	3.4	11.9	3.4

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %
6	11	7	19	19	22	14	15	3	2	-	T Anus and anal canal
4.9	9.0	5.7	15.6	15.6	18.0	11.5	12.3	2.5	1.6	-	%
5	6	2	9	10	10	4	9	2	1	-	M
8.3	10.0	3.3	15.0	16.7	16.7	6.7	15.0	3.3	1.7	-	%
1	5	5	10	9	12	10	6	1	1	-	F
1.6	8.1	8.1	16.1	14.5	19.4	16.1	9.7	1.6	1.6	-	%
743	1206	1561	1781	1895	1417	892	527	198	79	-	T Liver and intrahepatic
6.8	11.1	14.4	16.4	17.5	13.1	8.2	4.9	1.8	0.7	-	% bile ducts
622	1027	1284	1422	1444	968	563	329	128	30	-	M
7.5	12.4	15.5	17.2	17.5	11.7	6.8	4.0	1.5	0.4	-	%
121	179	277	359	451	449	329	198	70	49	-	F
4.7	6.9	10.7	13.8	17.4	17.3	12.7	7.6	2.7	1.9	-	%
42	56	94	159	254	186	170	126	63	30	-	T Gallbladder
3.5	4.6	7.8	13.2	21.0	15.4	14.1	10.4	5.2	2.5	-	%
17	20	47	81	112	85	64	50	22	15	-	M
3.2	3.8	8.9	15.4	21.3	16.2	12.2	9.5	4.2	2.9	-	%
25	36	47	78	142	101	106	76	41	15	-	F
3.7	5.3	6.9	11.4	20.8	14.8	15.5	11.1	6.0	2.2	-	%
46	68	120	160	216	253	207	167	92	40	-	T Other and unspecified
3.3	4.9	8.6	11.5	15.5	18.1	14.8	12.0	6.6	2.9	-	% parts of biliary tract
27	33	75	100	147	171	115	81	53	16	-	M
3.2	3.9	9.0	12.0	17.6	20.5	13.8	9.7	6.3	1.9	-	%
19	35	45	60	69	82	92	86	39	24	-	F
3.4	6.2	8.0	10.7	12.3	14.6	16.4	15.3	7.0	4.3	-	%
85	102	160	253	356	372	327	210	79	39	-	T Pancreas
4.2	5.0	7.8	12.4	17.4	18.2	16.0	10.3	3.9	1.9	-	%
52	73	106	169	235	200	175	89	35	18	-	M
4.4	6.1	8.9	14.2	19.8	16.8	14.7	7.5	2.9	1.5	-	%
33	29	54	84	121	172	152	121	44	21	-	F
3.9	3.4	6.3	9.8	14.2	20.1	17.8	14.2	5.2	2.5	-	%
4	9	7	8	11	15	12	2	5	-	-	T Other and ill-defined
5.1	11.4	8.9	10.1	13.9	19.0	15.2	2.5	6.3	-	-	% digestive organs
2	6	5	4	8	10	7	-	2	-	-	M
4.2	12.5	10.4	8.3	16.7	20.8	14.6	-	4.2	-	-	%
2	3	2	4	3	5	5	2	3	-	-	F
6.5	9.7	6.5	12.9	9.7	16.1	16.1	6.5	9.7	-	-	%
357	587	947	1570	2305	2455	1987	1285	485	157	-	T Respiratory system
2.8	4.7	7.5	12.5	18.4	19.6	15.8	10.2	3.9	1.3	-	% and intrathoracic
208	422	750	1246	1856	1983	1525	958	326	89	-	M organs
2.2	4.4	7.8	13.0	19.3	20.6	15.9	10.0	3.4	0.9	-	%
149	165	197	324	449	472	462	327	159	68	-	F
5.1	5.6	6.7	11.0	15.3	16.1	15.7	11.1	5.4	2.3	-	%
9	15	18	20	21	21	14	8	2	1	-	T Nasal cavity and
5.5	9.1	11.0	12.2	12.8	12.8	8.5	4.9	1.2	0.6	-	% middle ear
3	12	12	15	16	14	8	4	1	-	-	M
2.9	11.4	11.4	14.3	15.2	13.3	7.6	3.8	1.0	-	-	%
6	3	6	5	5	7	6	4	1	1	-	F
10.2	5.1	10.2	8.5	8.5	11.9	10.2	6.8	1.7	1.7	-	%

1-1.

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C31		145	-	1	-	1	-	-	3	4	9
	%	0.2	-	0.7	-	0.7	-	-	2.1	2.8	6.2
		91	-	1	-	1	-	-	3	2	7
	%	0.2	-	1.1	-	1.1	-	-	3.3	2.2	7.7
		54	-	-	-	-	-	-	-	2	2
	%	0.1	-	-	-	-	-	-	-	3.7	3.7
C32		997	-	-	-	-	1	1	-	3	18
	%	1.1	-	-	-	-	0.1	0.1	-	0.3	1.8
		923	-	-	-	-	-	1	-	2	15
	%	1.8	-	-	-	-	-	0.1	-	0.2	1.6
		74	-	-	-	-	1	-	-	1	3
	%	0.2	-	-	-	-	1.4	-	-	1.4	4.1
C33		24	-	-	1	-	1	-	-	1	1
	%	0.0	-	-	4.2	-	4.2	-	-	4.2	4.2
		15	-	-	1	-	-	-	-	-	-
	%	0.0	-	-	6.7	-	-	-	-	-	-
		9	-	-	-	-	1	-	-	1	1
	%	0.0	-	-	-	-	11.1	-	-	11.1	11.1
C34		10922	-	1	-	4	10	12	23	62	135
	%	11.9	-	0.0	-	0.0	0.1	0.1	0.2	0.6	1.2
		8284	-	-	-	4	6	2	11	37	79
	%	16.0	-	-	-	0.0	0.1	0.0	0.1	0.4	1.0
		2638	-	1	-	-	4	10	12	25	56
	%	6.6	-	0.0	-	-	0.2	0.4	0.5	0.9	2.1
C37		120	-	-	-	-	3	3	5	8	8
	%	0.1	-	-	-	-	2.5	2.5	4.2	6.7	6.7
		70	-	-	-	-	3	3	4	3	6
	%	0.1	-	-	-	-	4.3	4.3	5.7	4.3	8.6
		50	-	-	-	-	-	-	1	5	2
	%	0.1	-	-	-	-	-	-	2.0	10.0	4.0
C38		175	2	9	1	3	8	9	8	8	12
	%	0.2	1.1	5.1	0.6	1.7	4.6	5.1	4.6	4.6	6.9
		123	-	5	1	2	5	9	4	3	10
	%	0.2	-	4.1	0.8	1.6	4.1	7.3	3.3	2.4	8.1
		52	2	4	-	1	3	-	4	5	2
	%	0.1	3.8	7.7	-	1.9	5.8	-	7.7	9.6	3.8
C39		2	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		2	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C40-C41		425	1	6	19	37	64	45	21	26	28
	%	0.5	0.2	1.4	4.5	8.7	15.1	10.6	4.9	6.1	6.6
		228	-	2	15	19	43	25	13	14	13
	%	0.4	-	0.9	6.6	8.3	18.9	11.0	5.7	6.1	5.7
		197	1	4	4	18	21	20	8	12	15
	%	0.5	0.5	2.0	2.0	9.1	10.7	10.2	4.1	6.1	7.6

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
14	18	10	17	15	13	19	11	5	5	-	T	Accessory sinuses
9.7	12.4	6.9	11.7	10.3	9.0	13.1	7.6	3.4	3.4	-	%	
12	13	5	10	12	8	13	2	1	1	-	M	
13.2	14.3	5.5	11.0	13.2	8.8	14.3	2.2	1.1	1.1	-	%	
2	5	5	7	3	5	6	9	4	4	-	F	
3.7	9.3	9.3	13.0	5.6	9.3	11.1	16.7	7.4	7.4	-	%	
20	52	108	151	221	192	130	64	28	8	-	T	Larynx
2.0	5.2	10.8	15.1	22.2	19.3	13.0	6.4	2.8	0.8	-	%	
19	45	102	146	211	176	117	57	27	5	-	M	
2.1	4.9	11.1	15.8	22.9	19.1	12.7	6.2	2.9	0.5	-	%	
1	7	6	5	10	16	13	7	1	3	-	F	
1.4	9.5	8.1	6.8	13.5	21.6	17.6	9.5	1.4	4.1	-	%	
-	5	3	2	1	3	4	2	-	-	-	T	Trachea
-	20.8	12.5	8.3	4.2	12.5	16.7	8.3	-	-	-	%	
-	3	2	1	1	2	3	2	-	-	-	M	
-	20.0	13.3	6.7	6.7	13.3	20.0	13.3	-	-	-	%	
-	2	1	1	-	1	1	-	-	-	-	F	
-	22.2	11.1	11.1	-	11.1	11.1	-	-	-	-	%	
299	470	786	1350	2013	2187	1802	1180	447	141	-	T	Bronchus and lung
2.7	4.3	7.2	12.4	18.4	20.0	16.5	10.8	4.1	1.3	-	%	
166	331	616	1054	1593	1757	1371	877	297	83	-	M	
2.0	4.0	7.4	12.7	19.2	21.2	16.5	10.6	3.6	1.0	-	%	
133	139	170	296	420	430	431	303	150	58	-	F	
5.0	5.3	6.4	11.2	15.9	16.3	16.3	11.5	5.7	2.2	-	%	
10	15	12	12	13	18	6	6	1	-	-	T	Thymus
8.3	12.5	10.0	10.0	10.8	15.0	5.0	5.0	0.8	-	-	%	
6	7	8	5	7	12	2	4	-	-	-	M	
8.6	10.0	11.4	7.1	10.0	17.1	2.9	5.7	-	-	-	%	
4	8	4	7	6	6	4	2	1	-	-	F	
8.0	16.0	8.0	14.0	12.0	12.0	8.0	4.0	2.0	-	-	%	
5	12	10	17	21	20	12	14	2	2	-	T	Heart, mediastinum, and pleura
2.9	6.9	5.7	9.7	12.0	11.4	6.9	8.0	1.1	1.1	-	%	
2	11	5	14	16	13	11	12	-	-	-	M	
1.6	8.9	4.1	11.4	13.0	10.6	8.9	9.8	-	-	-	%	
3	1	5	3	5	7	1	2	2	2	-	F	
5.8	1.9	9.6	5.8	9.6	13.5	1.9	3.8	3.8	3.8	-	%	
-	-	-	1	-	1	-	-	-	-	-	T	Other and ill-defined sites within respiratory system and intrathoracic organs
-	-	-	50.0	-	50.0	-	-	-	-	-	%	
-	-	-	1	-	1	-	-	-	-	-	M	
-	-	-	50.0	-	50.0	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
26	19	25	23	22	20	26	9	7	1	-	T	Bones, joints and articular cartilage
6.1	4.5	5.9	5.4	5.2	4.7	6.1	2.1	1.6	0.2	-	%	
18	8	17	7	11	8	6	5	4	-	-	M	
7.9	3.5	7.5	3.1	4.8	3.5	2.6	2.2	1.8	-	-	%	
8	11	8	16	11	12	20	4	3	1	-	F	
4.1	5.6	4.1	8.1	5.6	6.1	10.2	2.0	1.5	0.5	-	%	

1-1.

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C40	,	232	-	3	15	33	51	29	13	12	17
	%	0.3	-	1.3	6.5	14.2	22.0	12.5	5.6	5.2	7.3
		127	-	1	12	17	32	18	8	5	8
	%	0.2	-	0.8	9.4	13.4	25.2	14.2	6.3	3.9	6.3
		105	-	2	3	16	19	11	5	7	9
	%	0.3	-	1.9	2.9	15.2	18.1	10.5	4.8	6.7	8.6
C41	,	193	1	3	4	4	13	16	8	14	11
	%	0.2	0.5	1.6	2.1	2.1	6.7	8.3	4.1	7.3	5.7
		101	-	1	3	2	11	7	5	9	5
	%	0.2	-	1.0	3.0	2.0	10.9	6.9	5.0	8.9	5.0
		92	1	2	1	2	2	9	3	5	6
	%	0.2	1.1	2.2	1.1	2.2	2.2	9.8	3.3	5.4	6.5
C42		2507	29	141	140	92	111	100	118	140	138
	%	2.7	1.2	5.6	5.6	3.7	4.4	4.0	4.7	5.6	5.5
		1412	17	77	90	56	68	57	70	71	74
	%	2.7	1.2	5.5	6.4	4.0	4.8	4.0	5.0	5.0	5.2
		1095	12	64	50	36	43	43	48	69	64
	%	2.7	1.1	5.8	4.6	3.3	3.9	3.9	4.4	6.3	5.8
C44		1261	1	2	4	7	4	14	45	17	43
	%	1.4	0.1	0.2	0.3	0.6	0.3	1.1	3.6	1.3	3.4
		648	-	2	4	6	2	9	25	11	19
	%	1.3	-	0.3	0.6	0.9	0.3	1.4	3.9	1.7	2.9
		613	1	-	-	1	2	5	20	6	24
	%	1.5	0.2	-	-	0.2	0.3	0.8	3.3	1.0	3.9
C47		40	4	2	1	-	2	4	4	2	2
	%	0.0	10.0	5.0	2.5	-	5.0	10.0	10.0	5.0	5.0
		21	2	2	1	-	-	-	4	1	1
	%	0.0	9.5	9.5	4.8	-	-	-	19.0	4.8	4.8
		19	2	-	-	-	2	4	-	1	1
	%	0.0	10.5	-	-	-	10.5	21.1	-	5.3	5.3
C48		165	4	6	1	1	-	1	4	12	7
	%	0.2	2.4	3.6	0.6	0.6	-	0.6	2.4	7.3	4.2
		58	1	1	1	1	-	1	1	6	2
	%	0.1	1.7	1.7	1.7	1.7	-	1.7	1.7	10.3	3.4
		107	3	5	-	-	-	-	3	6	5
	%	0.3	2.8	4.7	-	-	-	-	2.8	5.6	4.7
C49	,	507	7	8	16	13	11	22	31	34	31
	%	0.6	1.4	1.6	3.2	2.6	2.2	4.3	6.1	6.7	6.1
		275	2	6	13	7	6	9	20	21	16
	%	0.5	0.7	2.2	4.7	2.5	2.2	3.3	7.3	7.6	5.8
		232	5	2	3	6	5	13	11	13	15
	%	0.6	2.2	0.9	1.3	2.6	2.2	5.6	4.7	5.6	6.5
C50		6505	-	-	-	-	5	24	148	434	819
	%	7.1	-	-	-	-	0.1	0.4	2.3	6.7	12.6
		36	-	-	-	-	-	-	-	-	3
	%	0.1	-	-	-	-	-	-	-	-	8.3
		6469	-	-	-	-	5	24	148	434	816
	%	16.1	-	-	-	-	0.1	0.4	2.3	6.7	12.6

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
14	5	6	6	6	7	10	1	4	-	-	T	Bones, joints and articular cartilage of limbs
6.0	2.2	2.6	2.6	2.6	3.0	4.3	0.4	1.7	-	-	%	
9	2	4	3	2	2	3	-	1	-	-	M	
7.1	1.6	3.1	2.4	1.6	1.6	2.4	-	0.8	-	-	%	
5	3	2	3	4	5	7	1	3	-	-	F	
4.8	2.9	1.9	2.9	3.8	4.8	6.7	1.0	2.9	-	-	%	
12	14	19	17	16	13	16	8	3	1	-	T	Bones, joints and articular cartilage of other and unspecified sites
6.1	7.3	9.8	8.8	8.3	6.7	8.3	4.1	1.6	0.5	-	%	
9	6	13	4	9	6	3	5	3	-	-	M	
8.9	5.9	12.9	4.0	8.9	5.9	3.0	5.0	3.0	-	-	%	
3	8	6	13	7	7	13	3	-	1	-	F	
3.3	8.7	6.5	14.1	7.6	7.6	14.1	3.3	-	1.1	-	%	
179	165	164	199	238	245	183	82	33	10	-	T	Hematopoietic and reticuloendothelial systems
7.1	6.6	6.5	7.9	9.5	9.8	7.3	3.3	1.3	0.4	-	%	
97	102	88	122	139	127	94	39	19	5	-	M	
6.9	7.2	6.2	8.6	9.8	9.0	6.7	2.8	1.3	0.4	-	%	
82	63	76	77	99	118	89	43	14	5	-	F	
7.5	5.8	6.9	7.0	9.0	10.8	8.1	3.9	1.3	0.5	-	%	
70	85	95	133	179	164	160	109	79	50	-	T	Skin
5.6	6.7	7.5	10.5	14.2	13.0	12.7	8.6	6.3	4.0	-	%	
39	53	52	72	100	84	74	41	38	17	-	M	
6.0	8.2	8.0	11.1	15.4	13.0	11.4	6.3	5.9	2.6	-	%	
31	32	43	61	79	80	86	68	41	33	-	F	
5.1	5.2	7.0	10.0	12.9	13.1	14.0	11.1	6.7	5.4	-	%	
3	-	1	4	3	3	4	1	-	-	-	T	Peripheral nerves and autonomic nervous system
7.5	-	2.5	10.0	7.5	7.5	10.0	2.5	-	-	-	%	
2	-	1	2	1	2	2	-	-	-	-	M	
9.5	-	4.8	9.5	4.8	9.5	9.5	-	-	-	-	%	
1	-	-	2	2	1	2	1	-	-	-	F	
5.3	-	-	10.5	10.5	5.3	10.5	5.3	-	-	-	%	
14	13	14	18	24	17	16	8	3	2	-	T	Retroperitoneum and peritoneum
8.5	7.9	8.5	10.9	14.5	10.3	9.7	4.8	1.8	1.2	-	%	
7	3	3	7	6	2	8	6	1	1	-	M	
12.1	5.2	5.2	12.1	10.3	3.4	13.8	10.3	1.7	1.7	-	%	
7	10	11	11	18	15	8	2	2	1	-	F	
6.5	9.3	10.3	10.3	16.8	14.0	7.5	1.9	1.9	0.9	-	%	
44	37	33	49	61	39	32	27	10	2	-	T	Connective, subcutaneous and other soft tissues
8.7	7.3	6.5	9.7	12.0	7.7	6.3	5.3	2.0	0.4	-	%	
25	22	15	30	31	19	15	11	6	1	-	M	
9.1	8.0	5.5	10.9	11.3	6.9	5.5	4.0	2.2	0.4	-	%	
19	15	18	19	30	20	17	16	4	1	-	F	
8.2	6.5	7.8	8.2	12.9	8.6	7.3	6.9	1.7	0.4	-	%	
1285	1271	870	639	445	293	157	69	33	13	-	T	Breast
19.8	19.5	13.4	9.8	6.8	4.5	2.4	1.1	0.5	0.2	-	%	
4	5	1	-	5	6	5	4	2	1	-	M	
11.1	13.9	2.8	-	13.9	16.7	13.9	11.1	5.6	2.8	-	%	
1281	1266	869	639	440	287	152	65	31	12	-	F	
19.8	19.6	13.4	9.9	6.8	4.4	2.3	1.0	0.5	0.2	-	%	

1-1.

		0	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
		Year								
, %	Total									
C51-C58	6579	-	2	9	14	67	92	193	407	677
%	7.2	-	0.0	0.1	0.2	1.0	1.4	2.9	6.2	10.3
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	6579	-	2	9	14	67	92	193	407	677
%	16.4	-	0.0	0.1	0.2	1.0	1.4	2.9	6.2	10.3
C51	68	-	-	-	-	1	-	1	3	2
%	0.1	-	-	-	-	1.5	-	1.5	4.4	2.9
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	68	-	-	-	-	1	-	1	3	2
%	0.2	-	-	-	-	1.5	-	1.5	4.4	2.9
C52	49	-	-	-	-	-	-	1	1	2
%	0.1	-	-	-	-	-	-	2.0	2.0	4.1
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	49	-	-	-	-	-	-	1	1	2
%	0.1	-	-	-	-	-	-	2.0	2.0	4.1
C53	4061	-	-	-	1	4	10	80	248	473
%	4.4	-	-	-	0.0	0.1	0.2	2.0	6.1	11.6
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	4061	-	-	-	1	4	10	80	248	473
%	10.1	-	-	-	0.0	0.1	0.2	2.0	6.1	11.6
C54	719	-	-	-	-	1	1	15	36	56
%	0.8	-	-	-	-	0.1	0.1	2.1	5.0	7.8
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	719	-	-	-	-	1	1	15	36	56
%	1.8	-	-	-	-	0.1	0.1	2.1	5.0	7.8
C55	62	-	-	-	-	-	-	4	2	8
%	0.1	-	-	-	-	-	-	6.5	3.2	12.9
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	62	-	-	-	-	-	-	4	2	8
%	0.2	-	-	-	-	-	-	6.5	3.2	12.9
C56	1517	-	2	9	13	56	73	79	101	124
%	1.6	-	0.1	0.6	0.9	3.7	4.8	5.2	6.7	8.2
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	1517	-	2	9	13	56	73	79	101	124
%	3.8	-	0.1	0.6	0.9	3.7	4.8	5.2	6.7	8.2
C57	34	-	-	-	-	-	-	-	3	3
%	0.0	-	-	-	-	-	-	-	8.8	8.8
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	34	-	-	-	-	-	-	-	3	3
%	0.1	-	-	-	-	-	-	-	8.8	8.8

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
931	924	756	714	643	491	347	209	71	32	-	T	Female genital organs
14.2	14.0	11.5	10.9	9.8	7.5	5.3	3.2	1.1	0.5	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
931	924	756	714	643	491	347	209	71	32	-	F	
14.2	14.0	11.5	10.9	9.8	7.5	5.3	3.2	1.1	0.5	-	%	
6	5	4	8	7	7	4	13	5	2	-	T	Vulva
8.8	7.4	5.9	11.8	10.3	10.3	5.9	19.1	7.4	2.9	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
6	5	4	8	7	7	4	13	5	2	-	F	
8.8	7.4	5.9	11.8	10.3	10.3	5.9	19.1	7.4	2.9	-	%	
3	4	7	6	7	6	7	4	1	-	-	T	Vagina
6.1	8.2	14.3	12.2	14.3	12.2	14.3	8.2	2.0	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
3	4	7	6	7	6	7	4	1	-	-	F	
6.1	8.2	14.3	12.2	14.3	12.2	14.3	8.2	2.0	-	-	%	
646	582	440	426	420	295	242	123	50	21	-	T	Cervix uteri
15.9	14.3	10.8	10.5	10.3	7.3	6.0	3.0	1.2	0.5	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
646	582	440	426	420	295	242	123	50	21	-	F	
15.9	14.3	10.8	10.5	10.3	7.3	6.0	3.0	1.2	0.5	-	%	
93	122	129	98	67	53	23	22	3	-	-	T	Corpus uteri
12.9	17.0	17.9	13.6	9.3	7.4	3.2	3.1	0.4	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
93	122	129	98	67	53	23	22	3	-	-	F	
12.9	17.0	17.9	13.6	9.3	7.4	3.2	3.1	0.4	-	-	%	
13	8	5	4	3	8	6	1	-	-	-	T	Uterus NOS
21.0	12.9	8.1	6.5	4.8	12.9	9.7	1.6	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
13	8	5	4	3	8	6	1	-	-	-	F	
21.0	12.9	8.1	6.5	4.8	12.9	9.7	1.6	-	-	-	%	
157	196	164	165	133	115	64	45	12	9	-	T	Ovary
10.3	12.9	10.8	10.9	8.8	7.6	4.2	3.0	0.8	0.6	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
157	196	164	165	133	115	64	45	12	9	-	F	
10.3	12.9	10.8	10.9	8.8	7.6	4.2	3.0	0.8	0.6	-	%	
1	3	4	5	6	7	1	1	-	-	-	T	Other and unspecified female genital organs
2.9	8.8	11.8	14.7	17.6	20.6	2.9	2.9	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
1	3	4	5	6	7	1	1	-	-	-	F	
2.9	8.8	11.8	14.7	17.6	20.6	2.9	2.9	-	-	-	%	

1-1.

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C58		69	-	-	-	-	5	8	13	13	9
	%	0.1	-	-	-	-	7.2	11.6	18.8	18.8	13.0
	%	-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
	%	69	-	-	-	-	5	8	13	13	9
	%	0.2	-	-	-	-	7.2	11.6	18.8	18.8	13.0
C60-C63		1692	10	15	1	4	6	15	26	30	15
	%	1.8	0.6	0.9	0.1	0.2	0.4	0.9	1.5	1.8	0.9
	%	1692	10	15	1	4	6	15	26	30	15
	%	3.3	0.6	0.9	0.1	0.2	0.4	0.9	1.5	1.8	0.9
	%	-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C60		44	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
	%	44	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C61		1467	-	-	-	1	-	-	-	4	1
	%	1.6	-	-	-	0.1	-	-	-	0.3	0.1
	%	1467	-	-	-	1	-	-	-	4	1
	%	2.8	-	-	-	0.1	-	-	-	0.3	0.1
	%	-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C62		147	10	15	1	3	6	14	23	25	14
	%	0.2	6.8	10.2	0.7	2.0	4.1	9.5	15.6	17.0	9.5
	%	147	10	15	1	3	6	14	23	25	14
	%	0.3	6.8	10.2	0.7	2.0	4.1	9.5	15.6	17.0	9.5
	%	-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C63		34	-	-	-	-	-	1	3	1	-
	%	0.0	-	-	-	-	-	2.9	8.8	2.9	-
	%	34	-	-	-	-	-	1	3	1	-
	%	0.1	-	-	-	-	-	2.9	8.8	2.9	-
	%	-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C64-C68		4012	10	27	9	-	5	10	35	59	128
	%	4.4	0.2	0.7	0.2	-	0.1	0.2	0.9	1.5	3.2
	%	3014	8	16	4	-	3	6	23	43	101
	%	5.8	0.3	0.5	0.1	-	0.1	0.2	0.8	1.4	3.4
	%	998	2	11	5	-	2	4	12	16	27
	%	2.5	0.2	1.1	0.5	-	0.2	0.4	1.2	1.6	2.7
C64		1478	9	25	8	-	4	4	24	34	82
	%	1.6	0.6	1.7	0.5	-	0.3	0.3	1.6	2.3	5.5
	%	1012	7	14	3	-	3	2	14	23	61
	%	2.0	0.7	1.4	0.3	-	0.3	0.2	1.4	2.3	6.0
	%	466	2	11	5	-	1	2	10	11	21
	%	1.2	0.4	2.4	1.1	-	0.2	0.4	2.1	2.4	4.5

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
12	4	3	2	-	-	-	-	-	-	-	T	Placenta
17.4	5.8	4.3	2.9	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
12	4	3	2	-	-	-	-	-	-	-	F	
17.4	5.8	4.3	2.9	-	-	-	-	-	-	-	%	
17	23	39	117	251	313	323	284	148	55	-	T	Male genital organs
1.0	1.4	2.3	6.9	14.8	18.5	19.1	16.8	8.7	3.3	-	%	
17	23	39	117	251	313	323	284	148	55	-	M	
1.0	1.4	2.3	6.9	14.8	18.5	19.1	16.8	8.7	3.3	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
3	4	3	5	4	8	5	8	4	-	-	T	Penis
6.8	9.1	6.8	11.4	9.1	18.2	11.4	18.2	9.1	-	-	%	
3	4	3	5	4	8	5	8	4	-	-	M	
6.8	9.1	6.8	11.4	9.1	18.2	11.4	18.2	9.1	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
3	12	29	105	233	297	313	273	141	55	-	T	Prostate gland
0.2	0.8	2.0	7.2	15.9	20.2	21.3	18.6	9.6	3.7	-	%	
3	12	29	105	233	297	313	273	141	55	-	M	
0.2	0.8	2.0	7.2	15.9	20.2	21.3	18.6	9.6	3.7	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
9	6	1	3	5	6	2	2	2	-	-	T	Testis
6.1	4.1	0.7	2.0	3.4	4.1	1.4	1.4	1.4	-	-	%	
9	6	1	3	5	6	2	2	2	-	-	M	
6.1	4.1	0.7	2.0	3.4	4.1	1.4	1.4	1.4	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
2	1	6	4	9	2	3	1	1	-	-	T	Other and unspecified male genital organs
5.9	2.9	17.6	11.8	26.5	5.9	8.8	2.9	2.9	-	-	%	
2	1	6	4	9	2	3	1	1	-	-	M	
5.9	2.9	17.6	11.8	26.5	5.9	8.8	2.9	2.9	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
237	315	364	456	659	619	479	385	151	64	-	T	Urinary tract
5.9	7.9	9.1	11.4	16.4	15.4	11.9	9.6	3.8	1.6	-	%	
184	256	283	348	504	466	351	270	101	47	-	M	
6.1	8.5	9.4	11.5	16.7	15.5	11.6	9.0	3.4	1.6	-	%	
53	59	81	108	155	153	128	115	50	17	-	F	
5.3	5.9	8.1	10.8	15.5	15.3	12.8	11.5	5.0	1.7	-	%	
142	172	181	180	230	187	108	66	10	12	-	T	Kidney
9.6	11.6	12.2	12.2	15.6	12.7	7.3	4.5	0.7	0.8	-	%	
106	135	127	122	146	125	64	45	7	8	-	M	
10.5	13.3	12.5	12.1	14.4	12.4	6.3	4.4	0.7	0.8	-	%	
36	37	54	58	84	62	44	21	3	4	-	F	
7.7	7.9	11.6	12.4	18.0	13.3	9.4	4.5	0.6	0.9	-	%	

1-1.

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C65		158	-	-	-	-	-	1	-	1	5
	%	0.2	-	-	-	-	-	0.6	-	0.6	3.2
		129	-	-	-	-	-	1	-	-	4
	%	0.2	-	-	-	-	-	0.8	-	-	3.1
		29	-	-	-	-	-	-	-	1	1
	%	0.1	-	-	-	-	-	-	-	3.4	3.4
C66		179	-	-	-	-	-	-	-	4	4
	%	0.2	-	-	-	-	-	-	-	2.2	2.2
		117	-	-	-	-	-	-	-	3	3
	%	0.2	-	-	-	-	-	-	-	2.6	2.6
		62	-	-	-	-	-	-	-	1	1
	%	0.2	-	-	-	-	-	-	-	1.6	1.6
C67		2150	1	2	1	-	1	5	11	19	37
	%	2.3	0.0	0.1	0.0	-	0.0	0.2	0.5	0.9	1.7
		1734	1	2	1	-	-	3	9	17	33
	%	3.4	0.1	0.1	0.1	-	-	0.2	0.5	1.0	1.9
		416	-	-	-	-	1	2	2	2	4
	%	1.0	-	-	-	-	0.2	0.5	0.5	0.5	1.0
C68		47	-	-	-	-	-	-	-	1	-
	%	0.1	-	-	-	-	-	-	-	2.1	-
		22	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		25	-	-	-	-	-	-	-	1	-
	%	0.1	-	-	-	-	-	-	-	4.0	-
C69-C72		1281	19	111	64	47	47	54	61	90	93
	%	1.4	1.5	8.7	5.0	3.7	3.7	4.2	4.8	7.0	7.3
		711	13	58	34	32	30	36	39	47	53
	%	1.4	1.8	8.2	4.8	4.5	4.2	5.1	5.5	6.6	7.5
		570	6	53	30	15	17	18	22	43	40
	%	1.4	1.1	9.3	5.3	2.6	3.0	3.2	3.9	7.5	7.0
C69		143	12	34	2	-	-	1	3	9	7
	%	0.2	8.4	23.8	1.4	-	-	0.7	2.1	6.3	4.9
		81	8	17	2	-	-	-	-	6	3
	%	0.2	9.9	21.0	2.5	-	-	-	-	7.4	3.7
		62	4	17	-	-	-	1	3	3	4
	%	0.2	6.5	27.4	-	-	-	1.6	4.8	4.8	6.5
C70		43	-	-	-	-	1	2	2	4	1
	%	0.0	-	-	-	-	2.3	4.7	4.7	9.3	2.3
		17	-	-	-	-	1	1	2	2	-
	%	0.0	-	-	-	-	5.9	5.9	11.8	11.8	-
		26	-	-	-	-	-	1	-	2	1
	%	0.1	-	-	-	-	-	3.8	-	7.7	3.8
C71		1028	5	75	58	45	43	48	55	71	81
	%	1.1	0.5	7.3	5.6	4.4	4.2	4.7	5.4	6.9	7.9
		577	4	40	29	32	27	33	36	34	48
	%	1.1	0.7	6.9	5.0	5.5	4.7	5.7	6.2	5.9	8.3
		451	1	35	29	13	16	15	19	37	33
	%	1.1	0.2	7.8	6.4	2.9	3.5	3.3	4.2	8.2	7.3

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %
6	8	13	21	28	33	20	13	8	1	-	T Renal pelvis
3.8	5.1	8.2	13.3	17.7	20.9	12.7	8.2	5.1	0.6	-	%
6	7	11	16	24	28	16	9	6	1	-	M
4.7	5.4	8.5	12.4	18.6	21.7	12.4	7.0	4.7	0.8	-	%
-	1	2	5	4	5	4	4	2	-	-	F
-	3.4	6.9	17.2	13.8	17.2	13.8	13.8	6.9	-	-	%
3	9	7	20	32	36	24	27	11	2	-	T Ureter
1.7	5.0	3.9	11.2	17.9	20.1	13.4	15.1	6.1	1.1	-	%
1	8	7	16	23	23	13	14	6	-	-	M
0.9	6.8	6.0	13.7	19.7	19.7	11.1	12.0	5.1	-	-	%
2	1	-	4	9	13	11	13	5	2	-	F
3.2	1.6	-	6.5	14.5	21.0	17.7	21.0	8.1	3.2	-	%
84	125	161	231	362	348	319	274	120	49	-	T Bladder
3.9	5.8	7.5	10.7	16.8	16.2	14.8	12.7	5.6	2.3	-	%
70	106	137	190	308	282	254	201	82	38	-	M
4.0	6.1	7.9	11.0	17.8	16.3	14.6	11.6	4.7	2.2	-	%
14	19	24	41	54	66	65	73	38	11	-	F
3.4	4.6	5.8	9.9	13.0	15.9	15.6	17.5	9.1	2.6	-	%
2	1	2	4	7	15	8	5	2	-	-	T Other and unspecified urinary organs
4.3	2.1	4.3	8.5	14.9	31.9	17.0	10.6	4.3	-	-	%
1	-	1	4	3	8	4	1	-	-	-	M
4.5	-	4.5	18.2	13.6	36.4	18.2	4.5	-	-	-	%
1	1	1	-	4	7	4	4	2	-	-	F
4.0	4.0	4.0	-	16.0	28.0	16.0	16.0	8.0	-	-	%
108	122	80	118	108	66	55	23	10	5	-	T Eye, brain and other parts of central nervous system
8.4	9.5	6.2	9.2	8.4	5.2	4.3	1.8	0.8	0.4	-	%
66	66	45	66	49	34	24	9	9	1	-	M
9.3	9.3	6.3	9.3	6.9	4.8	3.4	1.3	1.3	0.1	-	%
42	56	35	52	59	32	31	14	1	4	-	F
7.4	9.8	6.1	9.1	10.4	5.6	5.4	2.5	0.2	0.7	-	%
13	18	6	9	8	11	5	3	1	1	-	T Eye and adnexa
9.1	12.6	4.2	6.3	5.6	7.7	3.5	2.1	0.7	0.7	-	%
9	8	4	4	4	8	4	2	1	1	-	M
11.1	9.9	4.9	4.9	4.9	9.9	4.9	2.5	1.2	1.2	-	%
4	10	2	5	4	3	1	1	-	-	-	F
6.5	16.1	3.2	8.1	6.5	4.8	1.6	1.6	-	-	-	%
1	6	3	6	9	4	2	2	-	-	-	T Meninges
2.3	14.0	7.0	14.0	20.9	9.3	4.7	4.7	-	-	-	%
1	4	2	1	1	1	-	1	-	-	-	M
5.9	23.5	11.8	5.9	5.9	5.9	-	5.9	-	-	-	%
-	2	1	5	8	3	2	1	-	-	-	F
-	7.7	3.8	19.2	30.8	11.5	7.7	3.8	-	-	-	%
87	94	64	96	82	49	44	18	9	4	-	T Brain
8.5	9.1	6.2	9.3	8.0	4.8	4.3	1.8	0.9	0.4	-	%
52	52	36	58	40	24	18	6	8	-	-	M
9.0	9.0	6.2	10.1	6.9	4.2	3.1	1.0	1.4	-	-	%
35	42	28	38	42	25	26	12	1	4	-	F
7.8	9.3	6.2	8.4	9.3	5.5	5.8	2.7	0.2	0.9	-	%

1-1.

,

	, %	Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C72		67	2	2	4	2	3	3	1	6	4
	%	0.1	3.0	3.0	6.0	3.0	4.5	4.5	1.5	9.0	6.0
		36	1	1	3	-	2	2	1	5	2
	%	0.1	2.8	2.8	8.3	-	5.6	5.6	2.8	13.9	5.6
		31	1	1	1	2	1	1	-	1	2
	%	0.1	3.2	3.2	3.2	6.5	3.2	3.2	-	3.2	6.5
C73-C75		4063	21	37	19	24	62	175	320	371	430
	%	4.4	0.5	0.9	0.5	0.6	1.5	4.3	7.9	9.1	10.6
		678	13	23	10	5	21	31	34	55	61
	%	1.3	1.9	3.4	1.5	0.7	3.1	4.6	5.0	8.1	9.0
		3385	8	14	9	19	41	144	286	316	369
	%	8.4	0.2	0.4	0.3	0.6	1.2	4.3	8.4	9.3	10.9
C73		3872	-	1	4	16	50	165	315	362	420
	%	4.2	-	0.0	0.1	0.4	1.3	4.3	8.1	9.3	10.8
		555	-	-	2	-	9	22	31	50	54
	%	1.1	-	-	0.4	-	1.6	4.0	5.6	9.0	9.7
		3317	-	1	2	16	41	143	284	312	366
	%	8.3	-	0.0	0.1	0.5	1.2	4.3	8.6	9.4	11.0
C74		122	20	35	12	-	2	3	1	4	5
	%	0.1	16.4	28.7	9.8	-	1.6	2.5	0.8	3.3	4.1
		75	13	23	6	-	2	2	-	2	3
	%	0.1	17.3	30.7	8.0	-	2.7	2.7	-	2.7	4.0
		47	7	12	6	-	-	1	1	2	2
	%	0.1	14.9	25.5	12.8	-	-	2.1	2.1	4.3	4.3
C75		69	1	1	3	8	10	7	4	5	5
	%	0.1	1.4	1.4	4.3	11.6	14.5	10.1	5.8	7.2	7.2
		48	-	-	2	5	10	7	3	3	4
	%	0.1	-	-	4.2	10.4	20.8	14.6	6.3	6.3	8.3
		21	1	1	1	3	-	-	1	2	1
	%	0.1	4.8	4.8	4.8	14.3	-	-	4.8	9.5	4.8
C76		138	6	4	3	1	3	2	3	4	5
	%	0.2	4.3	2.9	2.2	0.7	2.2	1.4	2.2	2.9	3.6
		70	4	2	2	-	1	-	2	2	-
	%	0.1	5.7	2.9	2.9	-	1.4	-	2.9	2.9	-
		68	2	2	1	1	2	2	1	2	5
	%	0.2	2.9	2.9	1.5	1.5	2.9	2.9	1.5	2.9	7.4
C77		1031	1	18	11	15	33	41	49	66	53
	%	1.1	0.1	1.7	1.1	1.5	3.2	4.0	4.8	6.4	5.1
		655	-	12	7	10	26	22	30	45	34
	%	1.3	-	1.8	1.1	1.5	4.0	3.4	4.6	6.9	5.2
		376	1	6	4	5	7	19	19	21	19
	%	0.9	0.3	1.6	1.1	1.3	1.9	5.1	5.1	5.6	5.1
C80	가	1359	1	1	-	-	4	10	14	24	37
	%	1.5	0.1	0.1	-	-	0.3	0.7	1.0	1.8	2.7
		758	-	-	-	-	4	4	6	7	16
	%	1.5	-	-	-	-	0.5	0.5	0.8	0.9	2.1
		601	1	1	-	-	-	6	8	17	21
	%	1.5	0.2	0.2	-	-	-	1.0	1.3	2.8	3.5

Table 1-1. Marginal Frequency of Malignant Cases by Age, Sex and Topography(T-Code)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
7	4	7	7	9	2	4	-	-	-	-	T	Spinal cord, cranial nerves, and other parts of central nervous system
10.4	6.0	10.4	10.4	13.4	3.0	6.0	-	-	-	-	%	
4	2	3	3	4	1	2	-	-	-	-	M	
11.1	5.6	8.3	8.3	11.1	2.8	5.6	-	-	-	-	%	
3	2	4	4	5	1	2	-	-	-	-	F	
9.7	6.5	12.9	12.9	16.1	3.2	6.5	-	-	-	-	%	
570	498	413	359	306	241	128	53	27	9	-	T	Thyroid and other endocrine glands
14.0	12.3	10.2	8.8	7.5	5.9	3.2	1.3	0.7	0.2	-	%	
80	74	62	62	51	51	30	9	6	-	-	M	
11.8	10.9	9.1	9.1	7.5	7.5	4.4	1.3	0.9	-	-	%	
490	424	351	297	255	190	98	44	21	9	-	F	
14.5	12.5	10.4	8.8	7.5	5.6	2.9	1.3	0.6	0.3	-	%	
560	482	408	346	300	231	123	53	27	9	-	T	Thyroid gland
14.5	12.5	10.5	8.9	7.7	6.0	3.2	1.4	0.7	0.2	-	%	
74	67	61	53	46	44	27	9	6	-	-	M	
13.3	12.1	11.0	9.5	8.3	7.9	4.9	1.6	1.1	-	-	%	
486	415	347	293	254	187	96	44	21	9	-	F	
14.7	12.5	10.5	8.8	7.7	5.6	2.9	1.3	0.6	0.3	-	%	
4	10	3	10	5	6	2	-	-	-	-	T	Adrenal gland
3.3	8.2	2.5	8.2	4.1	4.9	1.6	-	-	-	-	%	
2	6	1	6	4	4	1	-	-	-	-	M	
2.7	8.0	1.3	8.0	5.3	5.3	1.3	-	-	-	-	%	
2	4	2	4	1	2	1	-	-	-	-	F	
4.3	8.5	4.3	8.5	2.1	4.3	2.1	-	-	-	-	%	
6	6	2	3	1	4	3	-	-	-	-	T	Other endocrine glands and related structures
8.7	8.7	2.9	4.3	1.4	5.8	4.3	-	-	-	-	%	
4	1	-	3	1	3	2	-	-	-	-	M	
8.3	2.1	-	6.3	2.1	6.3	4.2	-	-	-	-	%	
2	5	2	-	-	1	1	-	-	-	-	F	
9.5	23.8	9.5	-	-	4.8	4.8	-	-	-	-	%	
8	15	10	13	13	12	15	11	9	1	-	T	Other and ill-defined sites
5.8	10.9	7.2	9.4	9.4	8.7	10.9	8.0	6.5	0.7	-	%	
3	10	5	11	8	4	9	2	5	-	-	M	
4.3	14.3	7.1	15.7	11.4	5.7	12.9	2.9	7.1	-	-	%	
5	5	5	2	5	8	6	9	4	1	-	F	
7.4	7.4	7.4	2.9	7.4	11.8	8.8	13.2	5.9	1.5	-	%	
86	79	87	106	117	105	78	52	25	9	-	T	Lymph nodes
8.3	7.7	8.4	10.3	11.3	10.2	7.6	5.0	2.4	0.9	-	%	
53	61	58	64	75	61	47	33	14	3	-	M	
8.1	9.3	8.9	9.8	11.5	9.3	7.2	5.0	2.1	0.5	-	%	
33	18	29	42	42	44	31	19	11	6	-	F	
8.8	4.8	7.7	11.2	11.2	11.7	8.2	5.1	2.9	1.6	-	%	
74	79	122	144	216	230	171	134	69	31	-	T	Unknown primary site
5.4	5.8	9.0	10.6	15.9	16.9	12.6	9.9	4.9	2.3	-	%	
39	44	68	92	146	137	97	50	34	14	-	M	
5.1	5.8	9.0	12.1	19.3	18.1	12.8	6.6	4.5	1.8	-	%	
35	35	54	52	70	93	74	84	33	17	-	F	
5.8	5.8	9.0	8.7	11.6	15.5	12.3	14.0	5.5	2.8	-	%	

1-2.

(T-Code)

,

	†	0	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
, %	Total	Year								
C00-C80	3598	-	-	-	-	3	41	188	489	645
%	100.0	-	-	-	-	0.1	1.1	5.2	13.6	17.9
	122	-	-	-	-	-	-	2	3	1
%	3.4	-	-	-	-	-	-	1.6	2.5	0.8
	3476	-	-	-	-	3	41	186	486	644
%	96.6	-	-	-	-	0.1	1.2	5.4	14.0	18.5
C53	2898	-	-	-	-	3	36	176	447	576
%	80.5	-	-	-	-	0.1	1.2	6.1	15.4	19.9
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	2898	-	-	-	-	3	36	176	447	576
%	83.4	-	-	-	-	0.1	1.2	6.1	15.4	19.9
C50	474	-	-	-	-	-	4	6	36	62
%	13.2	-	-	-	-	-	0.8	1.3	7.6	13.1
	1	-	-	-	-	-	-	-	-	-
%	0.8	-	-	-	-	-	-	-	-	-
	473	-	-	-	-	-	4	6	36	62
%	13.6	-	-	-	-	-	0.8	1.3	7.6	13.1
C44	48	-	-	-	-	-	-	-	-	-
%	1.3	-	-	-	-	-	-	-	-	-
	21	-	-	-	-	-	-	-	-	-
%	17.2	-	-	-	-	-	-	-	-	-
	27	-	-	-	-	-	-	-	-	-
%	0.8	-	-	-	-	-	-	-	-	-
C18	26	-	-	-	-	-	-	1	1	1
%	0.7	-	-	-	-	-	-	3.8	3.8	3.8
	14	-	-	-	-	-	-	1	-	-
%	11.5	-	-	-	-	-	-	7.1	-	-
	12	-	-	-	-	-	-	-	1	1
%	0.3	-	-	-	-	-	-	-	8.3	8.3
C16	18	-	-	-	-	-	-	-	-	-
%	0.5	-	-	-	-	-	-	-	-	-
	13	-	-	-	-	-	-	-	-	-
%	10.7	-	-	-	-	-	-	-	-	-
	5	-	-	-	-	-	-	-	-	-
%	0.1	-	-	-	-	-	-	-	-	-
C67	16	-	-	-	-	-	-	-	-	-
%	0.4	-	-	-	-	-	-	-	-	-
	14	-	-	-	-	-	-	-	-	-
%	11.5	-	-	-	-	-	-	-	-	-
	2	-	-	-	-	-	-	-	-	-
%	0.1	-	-	-	-	-	-	-	-	-
C52	12	-	-	-	-	-	-	-	-	-
%	0.3	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-
%	-	-	-	-	-	-	-	-	-	-
	12	-	-	-	-	-	-	-	-	-
%	0.3	-	-	-	-	-	-	-	-	-

† Column %,

Row %

Table 1-2. Marginal Frequency of in Situ Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
735	532	298	235	199	121	65	32	11	4	-	T	Total malignant neoplasms
20.4	14.8	8.3	6.5	5.5	3.4	1.8	0.9	0.3	0.1	-	%	
3	12	12	14	29	20	11	11	4	-	-	M	
2.5	9.8	9.8	11.5	23.8	16.4	9.0	9.0	3.3	-	-	%	
732	520	286	221	170	101	54	21	7	4	-	F	Cervix uteri
21.1	15.0	8.2	6.4	4.9	2.9	1.6	0.6	0.2	0.1	-	%	
619	420	210	160	129	75	34	10	2	1	-	T	
21.4	14.5	7.2	5.5	4.5	2.6	1.2	0.3	0.1	0.0	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	Breast
-	-	-	-	-	-	-	-	-	-	-	%	
619	420	210	160	129	75	34	10	2	1	-	F	
21.4	14.5	7.2	5.5	4.5	2.6	1.2	0.3	0.1	0.0	-	%	
103	93	66	48	31	16	8	1	-	-	-	T	Skin
21.7	19.6	13.9	10.1	6.5	3.4	1.7	0.2	-	-	-	%	
-	1	-	-	-	-	-	-	-	-	-	M	
-	100.0	-	-	-	-	-	-	-	-	-	%	
103	92	66	48	31	16	8	1	-	-	-	F	Colon
21.8	19.5	14.0	10.1	6.6	3.4	1.7	0.2	-	-	-	%	
1	2	3	3	10	5	8	11	3	2	-	T	
2.1	4.2	6.3	6.3	20.8	10.4	16.7	22.9	6.3	4.2	-	%	
-	2	1	3	6	3	2	3	1	-	-	M	Stomach
-	9.5	4.8	14.3	28.6	14.3	9.5	14.3	4.8	-	-	%	
1	-	2	-	4	2	6	8	2	2	-	F	
3.7	-	7.4	-	14.8	7.4	22.2	29.6	7.4	7.4	-	%	
1	5	1	5	5	1	3	2	-	-	-	T	Bladder
3.8	19.2	3.8	19.2	19.2	3.8	11.5	7.7	-	-	-	%	
-	3	-	3	4	1	-	2	-	-	-	M	
-	21.4	-	21.4	28.6	7.1	-	14.3	-	-	-	%	
1	2	1	2	1	-	3	-	-	-	-	F	Vagina
8.3	16.7	8.3	16.7	8.3	-	25.0	-	-	-	-	%	
1	1	1	5	1	4	4	1	-	-	-	T	
5.6	5.6	5.6	27.8	5.6	22.2	22.2	5.6	-	-	-	%	
1	1	1	3	1	2	3	1	-	-	-	M	Bladder
7.7	7.7	7.7	23.1	7.7	15.4	23.1	7.7	-	-	-	%	
-	-	-	2	-	2	1	-	-	-	-	F	
-	-	-	40.0	-	40.0	20.0	-	-	-	-	%	
-	-	4	1	4	4	2	1	-	-	-	T	Bladder
-	-	25.0	6.3	25.0	25.0	12.5	6.3	-	-	-	%	
-	-	3	1	4	3	2	1	-	-	-	M	
-	-	21.4	7.1	28.6	21.4	14.3	7.1	-	-	-	%	
-	-	1	-	-	1	-	-	-	-	-	F	Vagina
-	-	50.0	-	-	50.0	-	-	-	-	-	%	
2	3	2	1	2	1	-	1	-	-	-	T	
16.7	25.0	16.7	8.3	16.7	8.3	-	8.3	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	Vagina
-	-	-	-	-	-	-	-	-	-	-	%	
2	3	2	1	2	1	-	1	-	-	-	F	
16.7	25.0	16.7	8.3	16.7	8.3	-	8.3	-	-	-	%	

1-2.

(T-Code)

,

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C20		11	-	-	-	-	-	-	1	1	-
	%	0.3	-	-	-	-	-	-	9.1	9.1	-
		9	-	-	-	-	-	-	-	1	-
	%	7.4	-	-	-	-	-	-	-	11.1	-
		2	-	-	-	-	-	-	1	-	-
	%	0.1	-	-	-	-	-	-	50.0	-	-
C32		11	-	-	-	-	-	-	-	-	-
	%	0.3	-	-	-	-	-	-	-	-	-
		10	-	-	-	-	-	-	-	-	-
	%	8.2	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
C51		9	-	-	-	-	-	-	1	-	1
	%	0.3	-	-	-	-	-	-	11.1	-	11.1
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
		9	-	-	-	-	-	-	1	-	1
	%	0.3	-	-	-	-	-	-	11.1	-	11.1
C23		7	-	-	-	-	-	-	-	1	-
	%	0.2	-	-	-	-	-	-	-	14.3	-
		4	-	-	-	-	-	-	-	1	-
	%	3.3	-	-	-	-	-	-	-	25.0	-
		3	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
C54		7	-	-	-	-	-	-	-	-	2
	%	0.2	-	-	-	-	-	-	-	-	28.6
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
		7	-	-	-	-	-	-	-	-	2
	%	0.2	-	-	-	-	-	-	-	-	28.6
C06		6	-	-	-	-	-	-	1	-	-
	%	0.2	-	-	-	-	-	-	16.7	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
		6	-	-	-	-	-	-	1	-	-
	%	0.2	-	-	-	-	-	-	16.7	-	-
C34		6	-	-	-	-	-	-	-	-	-
	%	0.2	-	-	-	-	-	-	-	-	-
		5	-	-	-	-	-	-	-	-	-
	%	4.1	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
C22		5	-	-	-	-	-	-	-	1	-
	%	0.1	-	-	-	-	-	-	-	20.0	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		4	-	-	-	-	-	-	-	1	-
	%	0.1	-	-	-	-	-	-	-	25.0	-

Table 1-2. Marginal Frequency of in Situ Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
-	1	1	-	3	2	1	1	-	-	-	T	Rectum
-	9.1	9.1	-	27.3	18.2	9.1	9.1	-	-	-	%	
-	1	-	-	3	2	1	1	-	-	-	M	
-	11.1	-	-	33.3	22.2	11.1	11.1	-	-	-	%	
-	-	1	-	-	-	-	-	-	-	-	F	Larynx
-	-	50.0	-	-	-	-	-	-	-	-	%	
1	-	1	3	5	1	-	-	-	-	-	T	
9.1	-	9.1	27.3	45.5	9.1	-	-	-	-	-	%	
1	-	1	2	5	1	-	-	-	-	-	M	Vulva
10.0	-	10.0	20.0	50.0	10.0	-	-	-	-	-	%	
-	-	-	1	-	-	-	-	-	-	-	F	
-	-	-	100.0	-	-	-	-	-	-	-	%	
2	2	-	1	-	1	-	-	1	-	-	T	Gallbladder
22.2	22.2	-	11.1	-	11.1	-	-	11.1	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
2	2	-	1	-	1	-	-	1	-	-	F	Corpus uteri
22.2	22.2	-	11.1	-	11.1	-	-	11.1	-	-	%	
-	-	1	1	2	-	-	-	2	-	-	T	
-	-	14.3	14.3	28.6	-	-	-	28.6	-	-	%	
-	-	1	-	1	-	-	-	1	-	-	M	Other and unspecified parts of mouth
-	-	25.0	-	25.0	-	-	-	25.0	-	-	%	
-	-	-	1	1	-	-	-	1	-	-	F	
-	-	-	33.3	33.3	-	-	-	33.3	-	-	%	
1	-	2	1	-	1	-	-	-	-	-	T	Bronchus and lung
14.3	-	28.6	14.3	-	14.3	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
1	-	2	1	-	1	-	-	-	-	-	F	Liver and intrahepatic bile ducts
14.3	-	28.6	14.3	-	14.3	-	-	-	-	-	%	
2	-	1	1	1	-	-	-	-	-	-	T	
33.3	-	16.7	16.7	16.7	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	Bronchus and lung
-	-	-	-	-	-	-	-	-	-	-	%	
2	-	1	1	1	-	-	-	-	-	-	F	
33.3	-	16.7	16.7	16.7	-	-	-	-	-	-	%	
-	-	1	1	1	1	1	1	-	-	-	T	Liver and intrahepatic bile ducts
-	-	16.7	16.7	16.7	16.7	16.7	16.7	-	-	-	%	
-	-	1	1	1	-	1	1	-	-	-	M	
-	-	20.0	20.0	20.0	-	20.0	20.0	-	-	-	%	
-	-	-	-	-	1	-	-	-	-	-	F	Liver and intrahepatic bile ducts
-	-	-	-	-	100.0	-	-	-	-	-	%	
-	1	-	1	2	-	-	-	-	-	-	T	
-	20.0	-	20.0	40.0	-	-	-	-	-	-	%	
-	-	-	-	1	-	-	-	-	-	-	M	Liver and intrahepatic bile ducts
-	-	-	-	100.0	-	-	-	-	-	-	%	
-	1	-	1	1	-	-	-	-	-	-	F	
-	25.0	-	25.0	25.0	-	-	-	-	-	-	%	

1-2.

(T-Code)

,

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C15		4	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
		4	-	-	-	-	-	-	-	-	-
	%	3.3	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C55		4	-	-	-	-	-	-	1	-	2
	%	0.1	-	-	-	-	-	-	25.0	-	50.0
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
		4	-	-	-	-	-	-	-	-	2
	%	0.1	-	-	-	-	-	-	25.0	-	50.0
C66		4	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
		2	-	-	-	-	-	-	-	-	-
	%	1.6	-	-	-	-	-	-	-	-	-
		2	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
C25		3	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
		3	-	-	-	-	-	-	-	-	-
	%	2.5	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C30		3	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		2	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
C61		3	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
		3	-	-	-	-	-	-	-	-	-
	%	2.5	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C12		2	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
		2	-	-	-	-	-	-	-	-	-
	%	1.6	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C17		2	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-

Table 1-2. Marginal Frequency of in Situ Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
-	1	1	-	1	1	-	-	-	-	-	T	Esophagus
-	25.0	25.0	-	25.0	25.0	-	-	-	-	-	%	
-	1	1	-	1	1	-	-	-	-	-	M	Esophagus
-	25.0	25.0	-	25.0	25.0	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	Esophagus
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	1	-	-	-	T	Uterus NOS
-	-	-	-	-	-	-	25.0	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	Uterus NOS
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	1	-	-	-	F	Uterus NOS
-	-	-	-	-	-	-	25.0	-	-	-	%	
-	-	-	1	-	2	-	-	1	-	-	T	Ureter
-	-	-	25.0	-	50.0	-	-	25.0	-	-	%	
-	-	-	-	-	1	-	-	1	-	-	M	Ureter
-	-	-	-	-	50.0	-	-	50.0	-	-	%	
-	-	-	1	-	1	-	-	-	-	-	F	Ureter
-	-	-	50.0	-	50.0	-	-	-	-	-	%	
-	-	-	-	1	1	1	-	-	-	-	T	Pancreas
-	-	-	-	33.3	33.3	33.3	-	-	-	-	%	
-	-	-	-	1	1	1	-	-	-	-	M	Pancreas
-	-	-	-	33.3	33.3	33.3	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	Pancreas
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	1	-	-	-	1	-	1	-	-	T	Nasal cavity and middle ear
-	-	33.3	-	-	-	33.3	-	33.3	-	-	%	
-	-	1	-	-	-	-	-	-	-	-	M	Nasal cavity and middle ear
-	-	100.0	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	1	-	1	-	-	F	Nasal cavity and middle ear
-	-	-	-	-	-	50.0	-	50.0	-	-	%	
-	-	-	-	-	1	-	1	1	-	-	T	Prostage gland
-	-	-	-	-	33.3	-	33.3	33.3	-	-	%	
-	-	-	-	-	1	-	1	1	-	-	M	Prostage gland
-	-	-	-	-	33.3	-	33.3	33.3	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	Prostage gland
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	1	1	-	-	-	-	-	T	Pyriform sinus
-	-	-	-	50.0	50.0	-	-	-	-	-	%	
-	-	-	-	1	1	-	-	-	-	-	M	Pyriform sinus
-	-	-	-	50.0	50.0	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	Pyriform sinus
-	-	-	-	-	-	-	-	-	-	-	%	
-	1	-	1	-	-	-	-	-	-	-	T	Small intestine
-	50.0	-	50.0	-	-	-	-	-	-	-	%	
-	1	-	-	-	-	-	-	-	-	-	M	Small intestine
-	100.0	-	-	-	-	-	-	-	-	-	%	
-	-	-	1	-	-	-	-	-	-	-	F	Small intestine
-	-	-	100.0	-	-	-	-	-	-	-	%	

1-2.

(T-Code)

,

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C21		2	-	-	-	-	-	-	-	-	1
	%	0.1	-	-	-	-	-	-	-	-	50.0
		2	-	-	-	-	-	-	-	-	1
	%	1.6	-	-	-	-	-	-	-	-	50.0
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C69		2	-	-	-	-	-	-	-	-	-
	%	0.1	-	-	-	-	-	-	-	-	-
		2	-	-	-	-	-	-	-	-	-
	%	1.6	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C02		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
C05		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C07		1	-	-	-	-	-	-	-	1	-
	%	0.0	-	-	-	-	-	-	-	100.0	-
		1	-	-	-	-	-	-	-	1	-
	%	0.8	-	-	-	-	-	-	-	100.0	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C08		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
C13		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C19	S	1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-

Table 1-2. Marginal Frequency of in Situ Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %		
-	-	1	-	-	-	-	-	-	-	-	T	Anus and anal canal	
-	-	50.0	-	-	-	-	-	-	-	-	%		
-	-	1	-	-	-	-	-	-	-	-	M		
-	-	50.0	-	-	-	-	-	-	-	-	%		
-	-	-	-	-	-	-	-	-	-	-	F		
-	-	-	-	-	-	-	-	-	-	-	%		
-	1	-	-	-	1	-	-	-	-	-	T		Eye and adnexa
-	50.0	-	-	-	50.0	-	-	-	-	-	%		
-	1	-	-	-	1	-	-	-	-	-	M		
-	50.0	-	-	-	50.0	-	-	-	-	-	%		
-	-	-	-	-	-	-	-	-	-	-	F		
-	-	-	-	-	-	-	-	-	-	-	%		
-	-	-	-	-	-	-	-	-	1	-	T		Other and unspecified parts of tongue
-	-	-	-	-	-	-	-	-	100.0	-	%		
-	-	-	-	-	-	-	-	-	-	-	M		
-	-	-	-	-	-	-	-	-	-	1	F		
-	-	-	-	-	-	-	-	-	100.0	-	%		
-	1	-	-	-	-	-	-	-	-	-	T		Palate
-	100.0	-	-	-	-	-	-	-	-	-	%		
-	1	-	-	-	-	-	-	-	-	-	M		
-	100.0	-	-	-	-	-	-	-	-	-	%		
-	-	-	-	-	-	-	-	-	-	-	F		
-	-	-	-	-	-	-	-	-	-	-	%		
-	-	-	-	-	-	-	-	-	-	-	T		Parotid gland
-	-	-	-	-	-	-	-	-	-	-	%		
-	-	-	-	-	-	-	-	-	-	-	M		
-	-	-	-	-	-	-	-	-	-	-	%		
1	-	-	-	-	-	-	-	-	-	-	T	Other and unspecified major salivary glands	
100.0	-	-	-	-	-	-	-	-	-	-	%		
-	-	-	-	-	-	-	-	-	-	-	M		
-	-	-	-	-	-	-	-	-	-	-	%		
1	-	-	-	-	-	-	-	-	-	-	F		
100.0	-	-	-	-	-	-	-	-	-	-	%		
-	-	-	-	-	-	-	1	-	-	-	T		Hypopharynx
-	-	-	-	-	-	-	100.0	-	-	-	%		
-	-	-	-	-	-	-	1	-	-	-	M		
-	-	-	-	-	-	-	100.0	-	-	-	%		
-	-	-	-	-	-	-	-	-	-	-	F		
-	-	-	-	-	-	-	-	-	-	-	%		
-	-	-	-	-	1	-	-	-	-	-	T		Rectosigmoid junction
-	-	-	-	-	100.0	-	-	-	-	-	%		
-	-	-	-	-	1	-	-	-	-	-	M		
-	-	-	-	-	100.0	-	-	-	-	-	%		
-	-	-	-	-	-	-	-	-	-	-	F		
-	-	-	-	-	-	-	-	-	-	-	%		

1-2.

(T-Code)

,

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C24		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
C26		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C33		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C57		1	-	-	-	-	-	1	-	-	-
	%	0.0	-	-	-	-	-	100.0	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	1	-	-	-
	%	0.0	-	-	-	-	-	100.0	-	-	-
C60		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C63		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C68		1	-	-	-	-	-	-	1	-	-
	%	0.0	-	-	-	-	-	-	100.0	-	-
		1	-	-	-	-	-	-	1	-	-
	%	0.8	-	-	-	-	-	-	100.0	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
C76		1	-	-	-	-	-	-	-	-	-
	%	0.0	-	-	-	-	-	-	-	-	-
		1	-	-	-	-	-	-	-	-	-
	%	0.8	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-

Table 1-2. Marginal Frequency of in Situ Cases by Age, Sex and Topography(T-Code)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %	
-	-	-	-	-	-	1	-	-	-	-	T	Other and unspecified parts of biliary tract
-	-	-	-	-	-	100.0	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	1	-	-	-	-	F	
-	-	-	-	-	-	100.0	-	-	-	-	%	
-	-	-	-	-	1	-	-	-	-	-	T	Other and ill-defined digestive organs
-	-	-	-	-	100.0	-	-	-	-	-	%	
-	-	-	-	-	1	-	-	-	-	-	M	
-	-	-	-	-	100.0	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	1	-	-	-	-	-	-	-	-	T	Trachea
-	-	100.0	-	-	-	-	-	-	-	-	%	
-	-	1	-	-	-	-	-	-	-	-	M	
-	-	100.0	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	T	Other and unspecified female genital organs
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	1	-	-	-	-	-	-	-	T	Penis
-	-	-	100.0	-	-	-	-	-	-	-	%	
-	-	-	1	-	-	-	-	-	-	-	M	
-	-	-	100.0	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	1	-	-	-	-	T	Other and unspecified male genital organs
-	-	-	-	-	-	100.0	-	-	-	-	%	
-	-	-	-	-	-	1	-	-	-	-	M	
-	-	-	-	-	-	100.0	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	T	Other and unspecified urinary organs
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	M	
-	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	
1	-	-	-	-	-	-	-	-	-	-	T	Other and ill-defined sites
100.0	-	-	-	-	-	-	-	-	-	-	%	
1	-	-	-	-	-	-	-	-	-	-	M	
100.0	-	-	-	-	-	-	-	-	-	-	%	
-	-	-	-	-	-	-	-	-	-	-	F	
-	-	-	-	-	-	-	-	-	-	-	%	

1-2.

(T-Code)

,

	, %	Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C80	가	1	-	-	-	-	-	-	-	1	-
	%	0.0	-	-	-	-	-	-	-	100.0	-
	%	-	-	-	-	-	-	-	-	-	-
	%	-	-	-	-	-	-	-	-	-	-
	%	1	-	-	-	-	-	-	-	1	-
	%	0.0	-	-	-	-	-	-	-	100.0	-

Table 1-2. Marginal Frequency of in Situ Cases by Age, Sex and Topography(T-Code)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Topography, sex, %
-	-	-	-	-	-	-	-	-	-	-	T
-	-	-	-	-	-	-	-	-	-	-	%
-	-	-	-	-	-	-	-	-	-	-	M
-	-	-	-	-	-	-	-	-	-	-	%
-	-	-	-	-	-	-	-	-	-	-	F
-	-	-	-	-	-	-	-	-	-	-	%

2-1.

(/)

	†	0	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
, %	Total	Year								
	91944	128	409	312	287	502	766	1477	2647	4347
%	100.0	0.1	0.4	0.3	0.3	0.5	0.8	1.6	2.9	4.7
	51753	75	237	189	160	256	298	500	869	1546
%	100.0	0.1	0.5	0.4	0.3	0.5	0.6	1.0	1.7	3.0
	40191	53	172	123	127	246	468	977	1778	2801
%	100.0	0.1	0.4	0.3	0.3	0.6	1.2	2.4	4.4	7.0
	21644	26	85	67	68	121	199	413	598	1000
%	23.5	0.1	0.4	0.3	0.3	0.6	0.9	1.9	2.8	4.6
	11561	13	50	40	35	52	70	116	208	375
%	22.3	0.1	0.4	0.3	0.3	0.4	0.6	1.0	1.8	3.2
	10083	13	35	27	33	69	129	297	390	625
%	25.1	0.1	0.3	0.3	0.3	0.7	1.3	2.9	3.9	6.2
	7574	6	19	24	27	41	52	93	201	322
%	8.2	0.1	0.3	0.3	0.4	0.5	0.7	1.2	2.7	4.3
	4256	5	10	15	15	22	17	40	58	111
%	8.2	0.1	0.2	0.4	0.4	0.5	0.4	0.9	1.4	2.6
	3318	1	9	9	12	19	35	53	143	211
%	8.3	0.0	0.3	0.3	0.4	0.6	1.1	1.6	4.3	6.4
	5076	5	17	18	19	27	56	67	131	213
%	5.5	0.1	0.3	0.4	0.4	0.5	1.1	1.3	2.6	4.2
	2826	1	6	15	11	16	23	27	47	69
%	5.5	0.0	0.2	0.5	0.4	0.6	0.8	1.0	1.7	2.4
	2250	4	11	3	8	11	33	40	84	144
%	5.6	0.2	0.5	0.1	0.4	0.5	1.5	1.8	3.7	6.4
	4230	4	25	24	15	23	35	77	121	226
%	4.6	0.1	0.6	0.6	0.4	0.5	0.8	1.8	2.9	5.3
	2312	2	17	10	8	10	9	26	35	80
%	4.5	0.1	0.7	0.4	0.3	0.4	0.4	1.1	1.5	3.5
	1918	2	8	14	7	13	26	51	86	146
%	4.8	0.1	0.4	0.7	0.4	0.7	1.4	2.7	4.5	7.6
	2149	4	15	11	7	19	27	56	73	128
%	2.3	0.2	0.7	0.5	0.3	0.9	1.3	2.6	3.4	6.0
	1193	3	8	6	7	12	9	20	25	48
%	2.3	0.3	0.7	0.5	0.6	1.0	0.8	1.7	2.1	4.0
	956	1	7	5	-	7	18	36	48	80
%	2.4	0.1	0.7	0.5	-	0.7	1.9	3.8	5.0	8.4

† Column %,

Row %

Table 2-1. Distribution of Malignant Cases by Age, Sex and Place of Residence(Province)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Place of residence, sex, %	
6976	8169	9187	11364	13767	12688	9437	6036	2482	963	-	T	General
7.6	8.9	10.0	12.4	15.0	13.8	10.3	6.6	2.7	1.0	-	%	
2825	3962	5233	7101	9071	8167	5774	3583	1438	469	-	M	General
5.5	7.7	10.1	13.7	17.5	15.8	11.2	6.9	2.8	0.9	-	%	
4151	4207	3954	4263	4696	4521	3663	2453	1044	494	-	F	General
10.3	10.5	9.8	10.6	11.7	11.2	9.1	6.1	2.6	1.2	-	%	
1675	2036	2426	2823	3161	2620	2024	1350	661	291	-	T	Seoul
7.7	9.4	11.2	13.0	14.6	12.1	9.4	6.2	3.1	1.3	-	%	
615	905	1289	1696	2007	1619	1199	765	368	139	-	M	Seoul
5.3	7.8	11.1	14.7	17.4	14.0	10.4	6.6	3.2	1.2	-	%	
1060	1131	1137	1127	1154	1001	825	585	293	152	-	F	Seoul
10.5	11.2	11.3	11.2	11.4	9.9	8.2	5.8	2.9	1.5	-	%	
589	748	861	1065	1141	1010	721	406	171	77	-	T	Busan
7.8	9.9	11.4	14.1	15.1	13.3	9.5	5.4	2.3	1.0	-	%	
253	388	505	665	760	607	452	213	93	27	-	M	Busan
5.9	9.1	11.9	15.6	17.9	14.3	10.6	5.0	2.2	0.6	-	%	
336	360	356	400	381	403	269	193	78	50	-	F	Busan
10.1	10.8	10.7	12.1	11.5	12.1	8.1	5.8	2.4	1.5	-	%	
369	510	540	603	702	712	562	330	123	72	-	T	Daegu
7.3	10.0	10.6	11.9	13.8	14.0	11.1	6.5	2.4	1.4	-	%	
171	233	313	387	458	448	315	182	64	40	-	M	Daegu
6.1	8.2	11.1	13.7	16.2	15.9	11.1	6.4	2.3	1.4	-	%	
198	277	227	216	244	264	247	148	59	32	-	F	Daegu
8.8	12.3	10.1	9.6	10.8	11.7	11.0	6.6	2.6	1.4	-	%	
391	414	422	488	565	545	406	270	146	33	-	T	Incheon
9.2	9.8	10.0	11.5	13.4	12.9	9.6	6.4	3.5	0.8	-	%	
162	195	233	302	378	342	247	165	80	11	-	M	Incheon
7.0	8.4	10.1	13.1	16.3	14.8	10.7	7.1	3.5	0.5	-	%	
229	219	189	186	187	203	159	105	66	22	-	F	Incheon
11.9	11.4	9.9	9.7	9.7	10.6	8.3	5.5	3.4	1.1	-	%	
188	180	248	296	310	241	182	112	37	15	-	T	Gwangju
8.7	8.4	11.5	13.8	14.4	11.2	8.5	5.2	1.7	0.7	-	%	
87	86	133	194	197	159	115	64	13	7	-	M	Gwangju
7.3	7.2	11.1	16.3	16.5	13.3	9.6	5.4	1.1	0.6	-	%	
101	94	115	102	113	82	67	48	24	8	-	F	Gwangju
10.6	9.8	12.0	10.7	11.8	8.6	7.0	5.0	2.5	0.8	-	%	

2-1.

, (/)

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
		2348	3	12	8	8	16	25	40	65	136
	%	2.6	0.1	0.5	0.3	0.3	0.7	1.1	1.7	2.8	5.8
		1283	1	5	2	5	8	12	20	19	49
	%	2.5	0.1	0.4	0.2	0.4	0.6	0.9	1.6	1.5	3.8
		1065	2	7	6	3	8	13	20	46	87
	%	2.6	0.2	0.7	0.6	0.3	0.8	1.2	1.9	4.3	8.2
		1299	2	6	2	5	14	10	21	63	94
	%	1.4	0.2	0.5	0.2	0.4	1.1	0.8	1.6	4.8	7.2
		680	2	6	1	-	8	2	9	25	34
	%	1.3	0.3	0.9	0.1	-	1.2	0.3	1.3	3.7	5.0
		619	-	-	1	5	6	8	12	38	60
	%	1.5	-	-	0.2	0.8	1.0	1.3	1.9	6.1	9.7
		16880	38	101	71	51	82	138	304	632	1021
	%	18.4	0.2	0.6	0.4	0.3	0.5	0.8	1.8	3.7	6.0
		9145	21	59	46	31	41	54	104	204	333
	%	17.7	0.2	0.6	0.5	0.3	0.4	0.6	1.1	2.2	3.6
		7735	17	42	25	20	41	84	200	428	688
	%	19.2	0.2	0.5	0.3	0.3	0.5	1.1	2.6	5.5	8.9
		3356	5	9	10	6	14	27	42	70	139
	%	3.7	0.1	0.3	0.3	0.2	0.4	0.8	1.3	2.1	4.1
		1988	4	4	6	2	4	13	9	28	47
	%	3.8	0.2	0.2	0.3	0.1	0.2	0.7	0.5	1.4	2.4
		1368	1	5	4	4	10	14	33	42	92
	%	3.4	0.1	0.4	0.3	0.3	0.7	1.0	2.4	3.1	6.7
		2672	2	15	11	5	11	26	46	73	105
	%	2.9	0.1	0.6	0.4	0.2	0.4	1.0	1.7	2.7	3.9
		1615	2	9	7	5	6	16	13	21	32
	%	3.1	0.1	0.6	0.4	0.3	0.4	1.0	0.8	1.3	2.0
		1057	-	6	4	-	5	10	33	52	73
	%	2.6	-	0.6	0.4	-	0.5	0.9	3.1	4.9	6.9
		3883	7	17	7	10	19	26	44	97	135
	%	4.2	0.2	0.4	0.2	0.3	0.5	0.7	1.1	2.5	3.5
		2374	5	10	4	6	10	14	18	35	55
	%	4.6	0.2	0.4	0.2	0.3	0.4	0.6	0.8	1.5	2.3
		1509	2	7	3	4	9	12	26	62	80
	%	3.8	0.1	0.5	0.2	0.3	0.6	0.8	1.7	4.1	5.3

Table 2-1. Distribution of Malignant Cases by Age, Sex and Place of Residence(Province)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Place of residence, sex, %	
193	243	257	238	311	279	232	182	66	34	-	T	Daejeon
8.2	10.3	10.9	10.1	13.2	11.9	9.9	7.8	2.8	1.4	-	%	
76	113	148	133	212	181	130	117	36	16	-	M	
5.9	8.8	11.5	10.4	16.5	14.1	10.1	9.1	2.8	1.2	-	%	
117	130	109	105	99	98	102	65	30	18	-	F	
11.0	12.2	10.2	9.9	9.3	9.2	9.6	6.1	2.8	1.7	-	%	
141	166	131	147	165	144	99	54	30	5	-	T	Ulsan
10.9	12.8	10.1	11.3	12.7	11.1	7.6	4.2	2.3	0.4	-	%	
44	77	82	93	102	87	57	33	16	2	-	M	
6.5	11.3	12.1	13.7	15.0	12.8	8.4	4.9	2.4	0.3	-	%	
97	89	49	54	63	57	42	21	14	3	-	F	
15.7	14.4	7.9	8.7	10.2	9.2	6.8	3.4	2.3	0.5	-	%	
1506	1486	1486	1917	2417	2298	1647	1058	456	171	-	T	Geonggi-Do
8.9	8.8	8.8	11.4	14.3	13.6	9.8	6.3	2.7	1.0	-	%	
607	733	809	1150	1520	1478	974	623	272	86	-	M	
6.6	8.0	8.8	12.6	16.6	16.2	10.7	6.8	3.0	0.9	-	%	
899	753	677	767	897	820	673	435	184	85	-	F	
11.6	9.7	8.8	9.9	11.6	10.6	8.7	5.6	2.4	1.1	-	%	
235	256	265	441	561	478	389	274	104	31	-	T	Gangweon-Do
7.0	7.6	7.9	13.1	16.7	14.2	11.6	8.2	3.1	0.9	-	%	
90	138	151	284	401	318	242	169	62	16	-	M	
4.5	6.9	7.6	14.3	20.2	16.0	12.2	8.5	3.1	0.8	-	%	
145	118	114	157	160	160	147	105	42	15	-	F	
10.6	8.6	8.3	11.5	11.7	11.7	10.7	7.7	3.1	1.1	-	%	
163	227	244	339	443	402	278	198	60	24	-	T	Chungcheongbug-Do
6.1	8.5	9.1	12.7	16.6	15.0	10.4	7.4	2.2	0.9	-	%	
66	116	156	238	310	267	174	127	35	15	-	M	
4.1	7.2	9.7	14.7	19.2	16.5	10.8	7.9	2.2	0.9	-	%	
97	111	88	101	133	135	104	71	25	9	-	F	
9.2	10.5	8.3	9.6	12.6	12.8	9.8	6.7	2.4	0.9	-	%	
229	298	321	443	581	708	468	303	123	47	-	T	Chungcheongnam-Do
5.9	7.7	8.3	11.4	15.0	18.2	12.1	7.8	3.2	1.2	-	%	
100	147	197	286	389	495	306	191	82	24	-	M	
4.2	6.2	8.3	12.0	16.4	20.9	12.9	8.0	3.5	1.0	-	%	
129	151	124	157	192	213	162	112	41	23	-	F	
8.5	10.0	8.2	10.4	12.7	14.1	10.7	7.4	2.7	1.5	-	%	

2-1.

, (/)

	, %	Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
		3620	6	18	7	12	24	24	45	81	126
%	3.9		0.2	0.5	0.2	0.3	0.7	0.7	1.2	2.2	3.5
		2116	2	9	4	8	16	8	16	16	39
%	4.1		0.1	0.4	0.2	0.4	0.8	0.4	0.8	0.8	1.8
		1504	4	9	3	4	8	16	29	65	87
%	3.7		0.3	0.6	0.2	0.3	0.5	1.1	1.9	4.3	5.8
		4058	6	14	11	19	22	20	49	94	139
%	4.4		0.1	0.3	0.3	0.5	0.5	0.5	1.2	2.3	3.4
		2586	4	7	5	10	13	7	18	31	60
%	5.0		0.2	0.3	0.2	0.4	0.5	0.3	0.7	1.2	2.3
		1472	2	7	6	9	9	13	31	63	79
%	3.7		0.1	0.5	0.4	0.6	0.6	0.9	2.1	4.3	5.4
		6541	5	25	18	14	26	54	83	149	244
%	7.1		0.1	0.4	0.3	0.2	0.4	0.8	1.3	2.3	3.7
		3954	4	21	11	9	17	26	28	49	96
%	7.6		0.1	0.5	0.3	0.2	0.4	0.7	0.7	1.2	2.4
		2587	1	4	7	5	9	28	55	100	148
%	6.4		0.0	0.2	0.3	0.2	0.3	1.1	2.1	3.9	5.7
		5749	7	26	20	15	38	41	80	172	269
%	6.3		0.1	0.5	0.3	0.3	0.7	0.7	1.4	3.0	4.7
		3375	4	12	14	5	20	16	33	60	94
%	6.5		0.1	0.4	0.4	0.1	0.6	0.5	1.0	1.8	2.8
		2374	3	14	6	10	18	25	47	112	175
%	5.9		0.1	0.6	0.3	0.4	0.8	1.1	2.0	4.7	7.4
		810	2	5	3	5	5	6	16	27	46
%	0.9		0.2	0.6	0.4	0.6	0.6	0.7	2.0	3.3	5.7
		457	2	4	3	2	1	2	3	8	21
%	0.9		0.4	0.9	0.7	0.4	0.2	0.4	0.7	1.8	4.6
		353	-	1	-	3	4	4	13	19	25
%	0.9		-	0.3	-	0.8	1.1	1.1	3.7	5.4	7.1

Table 2-1. Distribution of Malignant Cases by Age, Sex and Place of Residence(Province)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Place of residence, sex, %	
210	276	337	448	604	576	460	271	69	26	-	T	Jeonlabug-Do
5.8	7.6	9.3	12.4	16.7	15.9	12.7	7.5	1.9	0.7	-	%	
70	127	182	281	412	384	302	175	48	17	-	M	
3.3	6.0	8.6	13.3	19.5	18.1	14.3	8.3	2.3	0.8	-	%	
140	149	155	167	192	192	158	96	21	9	-	F	
9.3	9.9	10.3	11.1	12.8	12.8	10.5	6.4	1.4	0.6	-	%	
211	304	377	512	722	684	479	258	107	30	-	T	Jeonlanam-Do
5.2	7.5	9.3	12.6	17.8	16.9	11.8	6.4	2.6	0.7	-	%	
101	160	240	343	510	492	325	176	67	17	-	M	
3.9	6.2	9.3	13.3	19.7	19.0	12.6	6.8	2.6	0.7	-	%	
110	144	137	169	212	192	154	82	40	13	-	F	
7.5	9.8	9.3	11.5	14.4	13.0	10.5	5.6	2.7	0.9	-	%	
387	447	577	776	1057	1024	799	579	207	70	-	T	Gyeongsangbug-Do
5.9	6.8	8.8	11.9	16.2	15.7	12.2	8.9	3.2	1.1	-	%	
174	243	360	509	727	655	522	344	126	33	-	M	
4.4	6.1	9.1	12.9	18.4	16.6	13.2	8.7	3.2	0.8	-	%	
213	204	217	267	330	369	277	235	81	37	-	F	
8.2	7.9	8.4	10.3	12.8	14.3	10.7	9.1	3.1	1.4	-	%	
413	507	571	737	909	842	620	346	105	31	-	T	Gyeongsangnam- Do
7.2	8.8	9.9	12.8	15.8	14.6	10.8	6.0	1.8	0.5	-	%	
173	269	358	482	615	544	374	216	68	18	-	M	
5.1	8.0	10.6	14.3	18.2	16.1	11.1	6.4	2.0	0.5	-	%	
240	238	213	255	294	298	246	130	37	13	-	F	
10.1	10.0	9.0	10.7	12.4	12.6	10.4	5.5	1.6	0.5	-	%	
69	67	116	87	113	119	67	41	11	5	-	T	Jeju-Do
8.5	8.3	14.3	10.7	14.0	14.7	8.3	5.1	1.4	0.6	-	%	
31	30	72	54	71	89	37	22	4	1	-	M	
6.8	6.6	15.8	11.8	15.5	19.5	8.1	4.8	0.9	0.2	-	%	
38	37	44	33	42	30	30	19	7	4	-	F	
10.8	10.5	12.5	9.3	11.9	8.5	8.5	5.4	2.0	1.1	-	%	

2-2.

, ()

	, %	† Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
가 *		91889	128	409	312	286	502	766	1476	2647	4343
	%	100.0	0.1	0.4	0.3	0.3	0.5	0.8	1.6	2.9	4.7
		51721	75	237	189	159	256	298	500	869	1543
	%	100.0	0.1	0.5	0.4	0.3	0.5	0.6	1.0	1.7	3.0
		40168	53	172	123	127	246	468	976	1778	2800
	%	100.0	0.1	0.4	0.3	0.3	0.6	1.2	2.4	4.4	7.0
7		44320	50	179	154	149	261	404	767	1252	2119
	%	48.2	0.1	0.4	0.3	0.3	0.6	0.9	1.7	2.8	4.8
		24111	27	102	89	81	128	142	258	417	766
	%	46.6	0.1	0.4	0.4	0.3	0.5	0.6	1.1	1.7	3.2
		20209	23	77	65	68	133	262	509	835	1353
	%	50.3	0.1	0.4	0.3	0.3	0.7	1.3	2.5	4.1	6.7
· ()		34865	68	181	127	110	198	290	581	1175	1846
	%	37.9	0.2	0.5	0.4	0.3	0.6	0.8	1.7	3.4	5.3
		19498	43	110	82	61	110	116	192	360	624
	%	37.7	0.2	0.6	0.4	0.3	0.6	0.6	1.0	1.8	3.2
		15367	25	71	45	49	88	174	389	815	1222
	%	38.3	0.2	0.5	0.3	0.3	0.6	1.1	2.5	5.3	8.0
· ()		12704	10	49	31	27	43	72	128	220	378
	%	13.8	0.1	0.4	0.2	0.2	0.3	0.6	1.0	1.7	3.0
		8112	5	25	18	17	18	40	50	92	153
	%	15.7	0.1	0.3	0.2	0.2	0.2	0.5	0.6	1.1	1.9
		4592	5	24	13	10	25	32	78	128	225
	%	11.4	0.1	0.5	0.3	0.2	0.5	0.7	1.7	2.8	4.9

† Column %, * 55

Row %

Table 2-2. Distribution of Malignant Cases by Age, Sex and Place of Residence(Region)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Region, sex, %	
6969	8165	9179	11360	13762	12682	9433	6032	2476	962	-	T	Classifiable cases by place of residence
7.6	8.9	10.0	12.4	15.0	13.8	10.3	6.6	2.7	1.0	-	%	
2820	3960	5228	7097	9069	8165	5771	3582	1434	469	-	M	
5.5	7.7	10.1	13.7	17.5	15.8	11.2	6.9	2.8	0.9	-	%	
4149	4205	3951	4263	4693	4517	3662	2450	1042	493	-	F	
10.3	10.5	9.8	10.6	11.7	11.2	9.1	6.1	2.6	1.2	-	%	
3546	4297	4885	5660	6355	5551	4226	2704	1234	527	-	T	Metropolitan (7 cities)
8.0	9.7	11.0	12.8	14.3	12.5	9.5	6.1	2.8	1.2	-	%	
1408	1997	2703	3470	4114	3443	2515	1539	670	242	-	M	
5.8	8.3	11.2	14.4	17.1	14.3	10.4	6.4	2.8	1.0	-	%	
2138	2300	2182	2190	2241	2108	1711	1165	564	285	-	F	
10.6	11.4	10.8	10.8	11.1	10.4	8.5	5.8	2.8	1.4	-	%	
2810	3093	3260	4166	5144	4809	3576	2269	840	322	-	T	Small to medium sized cities
8.1	8.9	9.4	11.9	14.8	13.8	10.3	6.5	2.4	0.9	-	%	
1127	1538	1863	2599	3369	3097	2175	1352	510	170	-	M	
5.8	7.9	9.6	13.3	17.3	15.9	11.2	6.9	2.6	0.9	-	%	
1683	1555	1397	1567	1775	1712	1401	917	330	152	-	F	
11.0	10.1	9.1	10.2	11.6	11.1	9.1	6.0	2.1	1.0	-	%	
613	775	1034	1534	2263	2322	1631	1059	402	113	-	T	Country sized
4.8	6.1	8.1	12.1	17.8	18.3	12.8	8.3	3.2	0.9	-	%	
285	425	662	1028	1586	1625	1081	691	254	57	-	M	
3.5	5.2	8.2	12.7	19.6	20.0	13.3	8.5	3.1	0.7	-	%	
328	350	372	506	677	697	550	368	148	56	-	F	
7.1	7.6	8.1	11.0	14.7	15.2	12.0	8.0	3.2	1.2	-	%	

3.

(10)

		†	0	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
		Total	Year								
C16	7	8558	-	-	-	1	6	25	101	217	412
	%	100.0	-	-	-	0.0	0.1	0.3	1.2	2.5	4.8
		5688	-	-	-	-	3	10	48	104	224
	%	66.5	-	-	-	-	0.0	0.1	0.6	1.2	2.6
		2870	-	-	-	1	3	15	53	113	188
	%	33.5	-	-	-	0.0	0.0	0.2	0.6	1.3	2.2
		7161	-	-	-	5	6	12	78	210	351
	%	100.0	-	-	-	0.1	0.1	0.2	1.1	2.9	4.9
		4740	-	-	-	2	2	2	32	111	185
	%	66.2	-	-	-	0.0	0.0	0.0	0.4	1.6	2.6
		2421	-	-	-	3	4	10	46	99	166
	%	33.8	-	-	-	0.0	0.1	0.1	0.6	1.4	2.3
	2918	-	-	-	-	1	8	17	38	67	
%	100.0	-	-	-	-	0.0	0.3	0.6	1.3	2.3	
	2046	-	-	-	-	1	3	8	20	39	
%	70.1	-	-	-	-	0.0	0.1	0.3	0.7	1.3	
	872	-	-	-	-	-	-	5	9	18	
%	29.9	-	-	-	-	-	-	0.2	0.3	0.6	
C34	7	4837	-	-	-	3	8	3	15	31	62
	%	100.0	-	-	-	0.1	0.2	0.1	0.3	0.6	1.3
		3541	-	-	-	3	5	1	6	19	38
	%	73.2	-	-	-	0.1	0.1	0.0	0.1	0.4	0.8
		1296	-	-	-	-	3	2	9	12	24
	%	26.8	-	-	-	-	0.1	0.0	0.2	0.2	0.5
		4156	-	-	-	1	2	7	7	26	57
	%	100.0	-	-	-	0.0	0.0	0.2	0.2	0.6	1.4
		3177	-	-	-	1	1	-	4	14	31
	%	76.4	-	-	-	0.0	0.0	-	0.1	0.3	0.7
		979	-	-	-	-	1	7	3	12	26
	%	23.6	-	-	-	-	0.0	0.2	0.1	0.3	0.6
	1922	-	1	-	-	-	2	1	5	16	
%	100.0	-	0.1	-	-	-	0.1	0.1	0.3	0.8	
	1559	-	-	-	-	-	1	1	4	10	
%	81.1	-	-	-	-	-	0.1	0.1	0.2	0.5	
	363	-	1	-	-	-	1	-	1	6	
%	18.9	-	0.1	-	-	-	0.1	-	0.1	0.3	

† Column %,

Row %

Table 3. Distribution of Malignant Cases by Age, Sex, Place of Residence(Region) and Topography(10 Leading Primary Cancer Site)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Region, Sex, %	Topography	
597	736	936	1210	1377	1202	910	516	227	85	-	T	Metropolitan (7 cities)	Stomach
7.0	8.6	10.9	14.1	16.1	14.0	10.6	6.0	2.7	1.0	-	%		
371	501	664	898	1026	822	566	291	116	44	-	M		
4.3	5.9	7.8	10.5	12.0	9.6	6.6	3.4	1.4	0.5	-	%		
226	235	272	312	351	380	344	225	111	41	-	F		
2.6	2.7	3.2	3.6	4.1	4.4	4.0	2.6	1.3	0.5	-	%		
545	593	684	940	1180	1119	767	473	147	51	-	T	Small to medium sized cities	
7.6	8.3	9.6	13.1	16.5	15.6	10.7	6.6	2.1	0.7	-	%		
346	413	484	670	852	765	470	290	90	26	-	M		
4.8	5.8	6.8	9.4	11.9	10.7	6.6	4.0	1.3	0.4	-	%		
199	180	200	270	328	354	297	183	57	25	-	F		
2.8	2.5	2.8	3.8	4.6	4.9	4.1	2.6	0.8	0.3	-	%		
128	150	241	358	581	596	391	223	91	28	-	T	Country sized	
4.4	5.1	8.3	12.3	19.9	20.4	13.4	7.6	3.1	1.0	-	%		
87	108	179	255	439	429	266	146	51	15	-	M		
3.0	3.7	6.1	8.7	15.0	14.7	9.1	5.0	1.7	0.5	-	%		
41	42	62	103	142	167	125	77	40	13	-	F		
1.4	1.4	2.1	3.5	4.9	5.7	4.3	2.6	1.4	0.4	-	%		
160	221	382	629	887	878	748	514	222	74	-	T	Metropolitan (7 cities)	Lung
3.3	4.6	7.9	13.0	18.3	18.2	15.5	10.6	4.6	1.5	-	%		
89	156	280	470	690	680	550	367	142	45	-	M		
1.8	3.2	5.8	9.7	14.3	14.1	11.4	7.6	2.9	0.9	-	%		
71	65	102	159	197	198	198	147	80	29	-	F		
1.5	1.3	2.1	3.3	4.1	4.1	4.1	3.0	1.7	0.6	-	%		
115	191	286	503	762	866	691	433	159	50	-	T	Small to medium sized cities	
2.8	4.6	6.9	12.1	18.3	20.8	16.6	10.4	3.8	1.2	-	%		
65	132	241	398	595	707	529	325	105	29	-	M		
1.6	3.2	5.8	9.6	14.3	17.0	12.7	7.8	2.5	0.7	-	%		
50	59	45	105	167	159	162	108	54	21	-	F		
1.2	1.4	1.1	2.5	4.0	3.8	3.9	2.6	1.3	0.5	-	%		
23	57	117	218	364	441	362	232	66	17	-	T	Country sized	
1.2	3.0	6.1	11.3	18.9	22.9	18.8	12.1	3.4	0.9	-	%		
11	42	94	186	308	368	291	184	50	9	-	M		
0.6	2.2	4.9	9.7	16.0	19.1	15.1	9.6	2.6	0.5	-	%		
12	15	23	32	56	73	71	48	16	8	-	F		
0.6	0.8	1.2	1.7	2.9	3.8	3.7	2.5	0.8	0.4	-	%		

3.

, (10)

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	
C22	7	5230	4	6	1	1	5	7	29	62	166	
		% 100.0	0.1	0.1	0.0	0.0	0.1	0.1	0.6	1.2	3.2	
		3969	1	5	-	-	5	5	23	55	137	
		% 75.9	0.0	0.1	-	-	0.1	0.1	0.4	1.1	2.6	
		1261	3	1	1	1	-	2	6	7	29	
		% 24.1	0.1	0.0	0.0	0.0	-	0.0	0.1	0.1	0.6	
		• ()	4058	4	5	1	2	2	4	14	46	129
			% 100.0	0.1	0.1	0.0	0.0	0.0	0.1	0.3	1.1	3.2
			3073	1	4	-	2	1	3	10	32	100
			% 75.7	0.0	0.1	-	0.0	0.0	0.1	0.2	0.8	2.5
			985	3	1	1	-	1	1	4	14	29
			% 24.3	0.1	0.0	0.0	-	0.0	0.0	0.1	0.3	0.7
		• ()	1563	-	2	1	2	-	3	8	11	42
			% 100.0	-	0.1	0.1	0.1	-	0.2	0.5	0.7	2.7
			1215	-	2	-	1	-	3	6	11	37
			% 77.7	-	0.1	-	0.1	-	0.2	0.4	0.7	2.4
			348	-	-	1	1	-	-	2	-	5
			% 22.3	-	-	0.1	0.1	-	-	0.1	-	0.3
	C18-C20	7	4841	-	-	1	1	6	13	32	68	143
			% 100.0	-	-	0.0	0.0	0.1	0.3	0.7	1.4	3.0
			2742	-	-	-	1	3	6	15	41	75
			% 56.6	-	-	-	0.0	0.1	0.1	0.3	0.8	1.5
			2099	-	-	1	-	3	7	17	27	68
			% 43.4	-	-	0.0	-	0.1	0.1	0.4	0.6	1.4
		• ()	3665	-	-	1	3	4	10	25	72	124
			% 100.0	-	-	0.0	0.1	0.1	0.3	0.7	2.0	3.4
			2055	-	-	1	1	4	6	14	26	76
			% 56.1	-	-	0.0	0.0	0.1	0.2	0.4	0.7	2.1
			1610	-	-	-	2	-	4	11	46	48
			% 43.9	-	-	-	0.1	-	0.1	0.3	1.3	1.3
		• ()	1188	1	-	1	-	2	2	9	14	28
			% 100.0	0.1	-	0.1	-	0.2	0.2	0.8	1.2	2.4
			677	-	-	-	-	1	2	4	10	16
			% 57.0	-	-	-	-	0.1	0.2	0.3	0.8	1.3
			511	1	-	1	-	1	-	5	4	12
			% 43.0	0.1	-	0.1	-	0.1	-	0.4	0.3	1.0

Table 3. Distribution of Malignant Cases by Age, Sex, Place of Residence(Region) and Topography(10 Leading Primary Cancer Site)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Region, Sex, %	Topography	
373	608	808	872	871	597	418	252	104	46	-	T	Metropolitan (7 cities)	Liver
7.1	11.6	15.4	16.7	16.7	11.4	8.0	4.8	2.0	0.9	-	%		
313	525	664	691	658	406	255	145	67	14	-	M		
6.0	10.0	12.7	13.2	12.6	7.8	4.9	2.8	1.3	0.3	-	%		
60	83	144	181	213	191	163	107	37	32	-	F		
1.1	1.6	2.8	3.5	4.1	3.7	3.1	2.0	0.7	0.6	-	%		
289	462	580	647	714	548	336	192	58	25	-	T	Small to medium sized cities	
7.1	11.4	14.3	15.9	17.6	13.5	8.3	4.7	1.4	0.6	-	%		
239	386	469	524	541	372	215	126	35	13	-	M		
5.9	9.5	11.6	12.9	13.3	9.2	5.3	3.1	0.9	0.3	-	%		
50	76	111	123	173	176	121	66	23	12	-	F		
1.2	1.9	2.7	3.0	4.3	4.3	3.0	1.6	0.6	0.3	-	%		
78	136	171	262	310	272	138	83	36	8	-	T	Country sized	
5.0	8.7	10.9	16.8	19.8	17.4	8.8	5.3	2.3	0.5	-	%		
67	116	150	207	245	190	93	58	26	3	-	M		
4.3	7.4	9.6	13.2	15.7	12.2	6.0	3.7	1.7	0.2	-	%		
11	20	21	55	65	82	45	25	10	5	-	F		
0.7	1.3	1.3	3.5	4.2	5.2	2.9	1.6	0.6	0.3	-	%		
296	409	569	675	738	706	564	371	164	85	-	T	Metropolitan (7 cities)	Colorectum
6.1	8.4	11.8	13.9	15.2	14.6	11.7	7.7	3.4	1.8	-	%		
166	225	357	427	465	371	302	195	67	26	-	M		
3.4	4.6	7.4	8.8	9.6	7.7	6.2	4.0	1.4	0.5	-	%		
130	184	212	248	273	335	262	176	97	59	-	F		
2.7	3.8	4.4	5.1	5.6	6.9	5.4	3.6	2.0	1.2	-	%		
225	274	353	462	608	604	440	302	117	41	-	T	Small to medium sized cities	
6.1	7.5	9.6	12.6	16.6	16.5	12.0	8.2	3.2	1.1	-	%		
119	158	212	279	358	357	210	147	67	20	-	M		
3.2	4.3	5.8	7.6	9.8	9.7	5.7	4.0	1.8	0.5	-	%		
106	116	141	183	250	247	230	155	50	21	-	F		
2.9	3.2	3.8	5.0	6.8	6.7	6.3	4.2	1.4	0.6	-	%		
52	53	84	136	223	230	166	130	46	11	-	T	Country sized	
4.4	4.5	7.1	11.4	18.8	19.4	14.0	10.9	3.9	0.9	-	%		
33	34	49	85	131	135	85	58	30	4	-	M		
2.8	2.9	4.1	7.2	11.0	11.4	7.2	4.9	2.5	0.3	-	%		
19	19	35	51	92	95	81	72	16	7	-	F		
1.6	1.6	2.9	4.3	7.7	8.0	6.8	6.1	1.3	0.6	-	%		

3.

, (10)

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39		
C50	7	3538	-	-	-	-	3	15	75	208	392		
		%	100.0	-	-	-	-	0.1	0.4	2.1	5.9	11.1	
		12	-	-	-	-	-	-	-	-	-	1	
		%	0.3	-	-	-	-	-	-	-	-	0.0	
			3526	-	-	-	-	3	15	75	208	391	
			99.7	-	-	-	-	0.1	0.4	2.1	5.9	11.1	
	• ()	%	2465	-	-	-	-	2	8	68	198	371	
			100.0	-	-	-	-	0.1	0.3	2.8	8.0	15.1	
			15	-	-	-	-	-	-	-	-	-	2
			%	0.6	-	-	-	-	-	-	-	-	0.1
				2450	-	-	-	-	2	8	68	198	369
				99.4	-	-	-	-	0.1	0.3	2.8	8.0	15.0
• ()	%	501	-	-	-	-	-	1	5	28	56		
		100.0	-	-	-	-	-	0.2	1.0	5.6	11.2		
		9	-	-	-	-	-	-	-	-	-	-	
		%	1.8	-	-	-	-	-	-	-	-	-	
			492	-	-	-	-	-	1	5	28	56	
			98.2	-	-	-	-	-	0.2	1.0	5.6	11.2	
C53	7	2059	-	-	-	-	1	4	42	111	224		
		%	100.0	-	-	-	-	0.0	0.2	2.0	5.4	10.9	
		-	-	-	-	-	-	-	-	-	-	-	
		%	-	-	-	-	-	-	-	-	-	-	
			2059	-	-	-	-	1	4	42	111	224	
			100.0	-	-	-	-	0.0	0.2	2.0	5.4	10.9	
	• ()	%	1594	-	-	-	1	2	6	28	111	210	
			100.0	-	-	-	0.1	0.1	0.4	1.8	7.0	13.2	
			-	-	-	-	-	-	-	-	-	-	-
			%	-	-	-	-	-	-	-	-	-	-
				1594	-	-	-	1	2	6	28	111	210
				100.0	-	-	-	0.1	0.1	0.4	1.8	7.0	13.2
• ()	%	402	-	-	-	-	1	-	10	26	39		
		100.0	-	-	-	-	0.2	-	2.5	6.5	9.7		
		-	-	-	-	-	-	-	-	-	-	-	
		%	-	-	-	-	-	-	-	-	-	-	
			402	-	-	-	-	1	-	10	26	39	
			100.0	-	-	-	-	0.2	-	2.5	6.5	9.7	

Table 3. Distribution of Malignant Cases by Age, Sex, Place of Residence(Region) and Topography(10 Leading Primary Cancer Site)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Region, Sex, %	Topography	
662	725	529	377	249	153	90	30	22	8	-	T	Metropolitan (7 cities)	Breast
18.7	20.5	15.0	10.7	7.0	4.3	2.5	0.8	0.6	0.2	-	%		
1	2	1	-	2	3	1	1	-	-	-	M		
0.0	0.1	0.0	-	0.1	0.1	0.0	0.0	-	-	-	%		
661	723	528	377	247	150	89	29	22	8	-	F		
18.7	20.4	14.9	10.7	7.0	4.2	2.5	0.8	0.6	0.2	-	%		
529	455	275	204	154	111	49	31	6	4	-	T	Small to medium sized cities	
21.5	18.5	11.2	8.3	6.2	4.5	2.0	1.3	0.2	0.2	-	%		
2	2	-	-	2	1	3	2	1	-	-	M		
0.1	0.1	-	-	0.1	0.0	0.1	0.1	0.0	-	-	%		
527	453	275	204	152	110	46	29	5	4	-	F		
21.4	18.4	11.2	8.3	6.2	4.5	1.9	1.2	0.2	0.2	-	%		
94	91	65	58	42	29	18	8	5	1	-	T	Country sized	
18.8	18.2	13.0	11.6	8.4	5.8	3.6	1.6	1.0	0.2	-	%		
1	1	-	-	1	2	1	1	1	1	-	M		
0.2	0.2	-	-	0.2	0.4	0.2	0.2	0.2	0.2	-	%		
93	90	65	58	41	27	17	7	4	-	-	F		
18.6	18.0	13.0	11.6	8.2	5.4	3.4	1.4	0.8	-	-	%		
346	314	236	217	219	141	111	57	25	11	-	T	Metropolitan (7 cities)	Cervix uteri
16.8	15.3	11.5	10.5	10.6	6.8	5.4	2.8	1.2	0.5	-	%		
-	-	-	-	-	-	-	-	-	-	-	M		
-	-	-	-	-	-	-	-	-	-	-	%		
346	314	236	217	219	141	111	57	25	11	-	F		
16.8	15.3	11.5	10.5	10.6	6.8	5.4	2.8	1.2	0.5	-	%		
246	215	168	162	148	117	104	51	19	6	-	T	Small to medium sized cities	
15.4	13.5	10.5	10.2	9.3	7.3	6.5	3.2	1.2	0.4	-	%		
-	-	-	-	-	-	-	-	-	-	-	M		
-	-	-	-	-	-	-	-	-	-	-	%		
246	215	168	162	148	117	104	51	19	6	-	F		
15.4	13.5	10.5	10.2	9.3	7.3	6.5	3.2	1.2	0.4	-	%		
54	52	35	47	53	37	27	13	5	3	-	T	Country sized	
13.4	12.9	8.7	11.7	13.2	9.2	6.7	3.2	1.2	0.7	-	%		
-	-	-	-	-	-	-	-	-	-	-	M		
-	-	-	-	-	-	-	-	-	-	-	%		
54	52	35	47	53	37	27	13	5	3	-	F		
13.4	12.9	8.7	11.7	13.2	9.2	6.7	3.2	1.2	0.7	-	%		

3.

(10)

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	
C73	7	1975	-	1	4	7	35	94	152	159	194	
		%	100.0	-	0.1	0.2	0.4	1.8	4.8	7.7	8.1	9.8
		272	-	-	2	-	5	12	13	23	22	
		%	13.8	-	-	0.1	-	0.3	0.6	0.7	1.2	1.1
		1703	-	1	2	7	30	82	139	136	172	
		%	86.2	-	0.1	0.1	0.4	1.5	4.2	7.0	6.9	8.7
		• ()	1528	-	-	-	7	14	65	138	172	183
			%	100.0	-	-	-	0.5	0.9	4.3	9.0	11.3
			221	-	-	-	-	4	8	15	19	27
			%	14.5	-	-	-	-	0.3	0.5	1.0	1.2
			1307	-	-	-	7	10	57	123	153	156
			%	85.5	-	-	-	0.5	0.7	3.7	8.0	10.0
		• ()	368	-	-	-	2	1	6	25	31	43
			%	100.0	-	-	-	0.5	0.3	1.6	6.8	8.4
			62	-	-	-	-	-	2	3	8	5
			%	16.8	-	-	-	-	-	0.5	0.8	2.2
			306	-	-	-	2	1	4	22	23	38
			%	83.2	-	-	-	0.5	0.3	1.1	6.0	6.3
	C42	7	1171	10	60	59	50	55	43	57	72	70
			%	100.0	0.9	5.1	5.0	4.3	4.7	3.7	4.9	6.1
			666	4	32	36	31	35	23	31	37	36
			%	56.9	0.3	2.7	3.1	2.6	3.0	2.0	2.6	3.2
			505	6	28	23	19	20	20	26	35	34
			%	43.1	0.5	2.4	2.0	1.6	1.7	1.7	2.2	3.0
		• ()	1010	17	63	64	32	45	46	51	58	59
			%	100.0	1.7	6.2	6.3	3.2	4.5	4.6	5.0	5.7
			565	12	34	43	18	30	25	33	29	33
			%	55.9	1.2	3.4	4.3	1.8	3.0	2.5	3.3	2.9
			445	5	29	21	14	15	21	18	29	26
			%	44.1	0.5	2.9	2.1	1.4	1.5	2.1	1.8	2.9
		• ()	322	2	18	17	9	11	11	10	10	9
			%	100.0	0.6	5.6	5.3	2.8	3.4	3.4	3.1	3.1
			179	1	11	11	6	3	9	6	5	5
			%	55.6	0.3	3.4	3.4	1.9	0.9	2.8	1.9	1.6
			143	1	7	6	3	8	2	4	5	4
			%	44.4	0.3	2.2	1.9	0.9	2.5	0.6	1.2	1.6

Table 3. Distribution of Malignant Cases by Age, Sex, Place of Residence(Region) and Topography(10 Leading Primary Cancer Site)

- Continued -

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Region, Sex, %	Topography	
296	271	233	167	150	112	53	31	10	6	-	T	Metropolitan (7 cities)	Thyroid gland
15.0	13.7	11.8	8.5	7.6	5.7	2.7	1.6	0.5	0.3	-	%		
42	35	33	29	19	19	11	6	1	-	-	M		
2.1	1.8	1.7	1.5	1.0	1.0	0.6	0.3	0.1	-	-	%		
254	236	200	138	131	93	42	25	9	6	-	F		
12.9	11.9	10.1	7.0	6.6	4.7	2.1	1.3	0.5	0.3	-	%		
219	183	132	135	114	94	43	16	12	1	-	T	Small to medium sized cities	
14.3	12.0	8.6	8.8	7.5	6.2	2.8	1.0	0.8	0.1	-	%		
24	31	19	16	25	17	9	3	4	-	-	M		
1.6	2.0	1.2	1.0	1.6	1.1	0.6	0.2	0.3	-	-	%		
195	152	113	119	89	77	34	13	8	1	-	F		
12.8	9.9	7.4	7.8	5.8	5.0	2.2	0.9	0.5	0.1	-	%		
45	28	43	44	35	25	27	6	5	2	-	T	Country sized	
12.2	7.6	11.7	12.0	9.5	6.8	7.3	1.6	1.4	0.5	-	%		
8	1	9	8	2	8	7	-	1	-	-	M		
2.2	0.3	2.4	2.2	0.5	2.2	1.9	-	0.3	-	-	%		
37	27	34	36	33	17	20	6	4	2	-	F		
10.1	7.3	9.2	9.8	9.0	4.6	5.4	1.6	1.1	0.5	-	%		
83	78	86	102	102	106	80	37	18	3	-	T	Metropolitan (7 cities)	Hemato- poietic systems
7.1	6.7	7.3	8.7	8.7	9.1	6.8	3.2	1.5	0.3	-	%		
44	51	50	67	62	51	44	21	9	2	-	M		
3.8	4.4	4.3	5.7	5.3	4.4	3.8	1.8	0.8	0.2	-	%		
39	27	36	35	40	55	36	16	9	1	-	F		
3.3	2.3	3.1	3.0	3.4	4.7	3.1	1.4	0.8	0.1	-	%		
77	61	63	75	95	89	67	32	12	4	-	T	Small to medium sized cities	
7.6	6.0	6.2	7.4	9.4	8.8	6.6	3.2	1.2	0.4	-	%		
43	36	31	40	58	46	30	15	7	2	-	M		
4.3	3.6	3.1	4.0	5.7	4.6	3.0	1.5	0.7	0.2	-	%		
34	25	32	35	37	43	37	17	5	2	-	F		
3.3	2.5	3.2	3.5	3.7	4.3	3.7	1.7	0.5	0.2	-	%		
18	25	15	22	41	50	35	13	3	3	-	T	Country sized	
5.6	7.8	4.7	6.8	12.7	15.5	10.9	4.0	0.9	0.9	-	%		
10	15	7	15	19	30	19	3	3	1	-	M		
3.1	4.7	2.2	4.7	5.9	9.3	5.9	0.9	0.9	0.3	-	%		
8	10	8	7	22	20	16	10	-	2	-	F		
2.5	3.1	2.5	2.2	6.8	6.2	5.0	3.1	-	0.6	-	%		

3.

, (10)

		Total	0 Year	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
C67	7	1081	-	-	1	-	1	3	6	7	20
	%	100.0	-	-	0.1	-	0.1	0.3	0.6	0.6	1.9
		861	-	-	1	-	-	1	5	7	18
	%	79.6	-	-	0.1	-	-	0.1	0.5	0.6	1.7
		220	-	-	-	-	1	2	1	-	2
	%	20.4	-	-	-	-	0.1	0.2	0.1	-	0.2
		747	1	2	-	-	-	-	4	10	13
	()	%	100.0	0.1	0.3	-	-	-	0.5	1.3	1.7
		605	1	2	-	-	-	-	3	8	11
	%	81.0	0.1	0.3	-	-	-	-	0.4	1.1	1.5
		142	-	-	-	-	-	-	1	2	2
	%	19.0	-	-	-	-	-	-	0.1	0.3	0.3
	319	-	-	-	-	-	2	1	2	4	
()	%	100.0	-	-	-	-	0.6	0.3	0.6	1.3	
	266	-	-	-	-	-	2	1	2	4	
%	83.4	-	-	-	-	-	0.6	0.3	0.6	1.3	
	53	-	-	-	-	-	-	-	-	-	
%	16.6	-	-	-	-	-	-	-	-	-	
C25	7	965	1	-	-	-	1	1	2	8	19
	%	100.0	0.1	-	-	-	0.1	0.1	0.2	0.8	2.0
		554	1	-	-	-	-	-	2	2	13
	%	57.4	0.1	-	-	-	-	-	0.2	0.2	1.3
		411	-	-	-	-	1	1	-	6	6
	%	42.6	-	-	-	-	0.1	0.1	-	0.6	0.6
		757	-	1	-	-	-	-	2	6	13
	()	%	100.0	-	0.1	-	-	-	0.3	0.8	1.7
		446	-	1	-	-	-	-	-	5	7
	%	58.9	-	0.1	-	-	-	-	-	0.7	0.9
		311	-	-	-	-	-	-	2	1	6
	%	41.1	-	-	-	-	-	-	0.3	0.1	0.8
	319	-	-	-	-	-	-	1	2	1	
()	%	100.0	-	-	-	-	-	0.3	0.6	0.3	
	187	-	-	-	-	-	-	1	2	1	
%	58.6	-	-	-	-	-	-	0.3	0.6	0.3	
	132	-	-	-	-	-	-	-	-	-	
%	41.4	-	-	-	-	-	-	-	-	-	

Table 3. Distribution of Malignant Cases by Age, Sex, Place of Residence(Region) and Topography(10 Leading Primary Cancer Site)

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Region, Sex, % Topography		
40	71	89	123	199	180	136	111	64	30	-	T	Metropolitan (7 cities)	Urinary bladder
3.7	6.6	8.2	11.4	18.4	16.7	12.6	10.3	5.9	2.8	-	%		
35	59	75	99	166	145	106	76	45	23	-	M		
3.2	5.5	6.9	9.2	15.4	13.4	9.8	7.0	4.2	2.1	-	%		
5	12	14	24	33	35	30	35	19	7	-	F		
0.5	1.1	1.3	2.2	3.1	3.2	2.8	3.2	1.8	0.6	-	%		
39	46	48	83	112	106	126	106	38	13	-	T	Small to medium sized cities	
5.2	6.2	6.4	11.1	15.0	14.2	16.9	14.2	5.1	1.7	-	%		
31	40	40	71	98	83	100	78	28	11	-	M		
4.1	5.4	5.4	9.5	13.1	11.1	13.4	10.4	3.7	1.5	-	%		
8	6	8	12	14	23	26	28	10	2	-	F		
1.1	0.8	1.1	1.6	1.9	3.1	3.5	3.7	1.3	0.3	-	%		
4	8	23	25	51	61	57	57	18	6	-	T	Country sized	
1.3	2.5	7.2	7.8	16.0	19.1	17.9	17.9	5.6	1.9	-	%		
3	7	21	20	44	54	48	47	9	4	-	M		
0.9	2.2	6.6	6.3	13.8	16.9	15.0	14.7	2.8	1.3	-	%		
1	1	2	5	7	7	9	10	9	2	-	F		
0.3	0.3	0.6	1.6	2.2	2.2	2.8	3.1	2.8	0.6	-	%		
42	50	95	123	156	169	139	101	37	21	-	T	Metropolitan (7 cities)	Pancreas
4.4	5.2	9.8	12.7	16.2	17.5	14.4	10.5	3.8	2.2	-	%		
27	38	64	80	103	86	74	41	15	8	-	M		
2.8	3.9	6.6	8.3	10.7	8.9	7.7	4.2	1.6	0.8	-	%		
15	12	31	43	53	83	65	60	22	13	-	F		
1.6	1.2	3.2	4.5	5.5	8.6	6.7	6.2	2.3	1.3	-	%		
32	44	50	90	140	136	133	70	28	12	-	T	Small to medium sized cities	
4.2	5.8	6.6	11.9	18.5	18.0	17.6	9.2	3.7	1.6	-	%		
17	33	35	58	94	74	72	29	14	7	-	M		
2.2	4.4	4.6	7.7	12.4	9.8	9.5	3.8	1.8	0.9	-	%		
15	11	15	32	46	62	61	41	14	5	-	F		
2.0	1.5	2.0	4.2	6.1	8.2	8.1	5.4	1.8	0.7	-	%		
11	8	15	40	60	67	55	39	14	6	-	T	Country sized	
3.4	2.5	4.7	12.5	18.8	21.0	17.2	12.2	4.4	1.9	-	%		
8	2	7	31	38	40	29	19	6	3	-	M		
2.5	0.6	2.2	9.7	11.9	12.5	9.1	6.0	1.9	0.9	-	%		
3	6	8	9	22	27	26	20	8	3	-	F		
0.9	1.9	2.5	2.8	6.9	8.5	8.2	6.3	2.5	0.9	-	%		

4.

	†	0	1-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
, %	Total	Year								
	91944	128	409	312	287	502	766	1477	2647	4347
%	100.0	0.1	0.4	0.3	0.3	0.5	0.8	1.6	2.9	4.7
	51753	75	237	189	160	256	298	500	869	1546
%	100.0	0.1	0.5	0.4	0.3	0.5	0.6	1.0	1.7	3.0
	40191	53	172	123	127	246	468	977	1778	2801
%	100.0	0.1	0.4	0.3	0.3	0.6	1.2	2.4	4.4	7.0
(1342	-	4	2	3	7	5	20	23	37
)	1.5	-	0.3	0.1	0.2	0.5	0.4	1.5	1.7	2.8
	764	-	2	-	2	3	-	6	6	19
%	1.5	-	0.3	-	0.3	0.4	-	0.8	0.8	2.5
	578	-	2	2	1	4	5	14	17	18
%	1.4	-	0.3	0.3	0.2	0.7	0.9	2.4	2.9	3.1
	13246	8	44	16	13	27	24	66	142	323
%	14.4	0.1	0.3	0.1	0.1	0.2	0.2	0.5	1.1	2.4
	8891	6	29	10	8	20	18	40	92	225
%	17.2	0.1	0.3	0.1	0.1	0.2	0.2	0.4	1.0	2.5
	4355	2	15	6	5	7	6	26	50	98
%	10.8	0.0	0.3	0.1	0.1	0.2	0.1	0.6	1.1	2.3
	108	-	-	1	-	1	-	-	7	4
%	0.1	-	-	0.9	-	0.9	-	-	6.5	3.7
	57	-	-	-	-	-	-	-	3	-
%	0.1	-	-	-	-	-	-	-	5.3	-
	51	-	-	1	-	1	-	-	4	4
%	0.1	-	-	2.0	-	2.0	-	-	7.8	7.8
,	373	-	-	1	4	3	2	9	4	11
%	0.4	-	-	0.3	1.1	0.8	0.5	2.4	1.1	2.9
	231	-	-	1	2	2	2	5	2	9
%	0.4	-	-	0.4	0.9	0.9	0.9	2.2	0.9	3.9
	142	-	-	-	2	1	-	4	2	2
%	0.4	-	-	-	1.4	0.7	-	2.8	1.4	1.4
(76875	120	361	292	267	464	735	1382	2471	3972
, %	83.6	0.2	0.5	0.4	0.3	0.6	1.0	1.8	3.2	5.2
,	41810	69	206	178	148	231	278	449	766	1293
%	80.8	0.2	0.5	0.4	0.4	0.6	0.7	1.1	1.8	3.1
)	35065	51	155	114	119	233	457	933	1705	2679
%	87.2	0.1	0.4	0.3	0.3	0.7	1.3	2.7	4.9	7.6

† Column %,

Row %

Table 4. Distribution of Malignant Cases by age, sex and Basis of Diagnosis

40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+		Basis of diagnosis, sex, %	
6976	8169	9187	11364	13767	12688	9437	6036	2482	963	-	T	Total malignant neoplasms
7.6	8.9	10.0	12.4	15.0	13.8	10.3	6.6	2.7	1.0	-	%	
2825	3962	5233	7101	9071	8167	5774	3583	1438	469	-	M	
5.5	7.7	10.1	13.7	17.5	15.8	11.2	6.9	2.8	0.9	-	%	
4151	4207	3954	4263	4696	4521	3663	2453	1044	494	-	F	
10.3	10.5	9.8	10.6	11.7	11.2	9.1	6.1	2.6	1.2	-	%	
80	76	110	121	173	185	187	178	85	46	-	T	Clinical only
6.0	5.7	8.2	9.0	12.9	13.8	13.9	13.3	6.3	3.4	-	%	
31	38	72	80	116	117	112	98	45	17	-	M	
4.1	5.0	9.4	10.5	15.2	15.3	14.7	12.8	5.9	2.2	-	%	
49	38	38	41	57	68	75	80	40	29	-	F	
8.5	6.6	6.6	7.1	9.9	11.8	13.0	13.8	6.9	5.0	-	%	
712	1022	1386	1717	2051	1825	1589	1319	652	310	-	T	Clinical investigation (Sono, CT, MRI etc)
5.4	7.7	10.5	13.0	15.5	13.8	12.0	10.0	4.9	2.3	-	%	
537	811	1089	1281	1481	1161	906	709	335	133	-	M	
6.0	9.1	12.2	14.4	16.7	13.1	10.2	8.0	3.8	1.5	-	%	
175	211	297	436	570	664	683	610	317	177	-	F	
4.0	4.8	6.8	10.0	13.1	15.2	15.7	14.0	7.3	4.1	-	%	
6	5	15	15	19	15	7	10	2	1	-	T	Exploratory surgery
5.6	4.6	13.9	13.9	17.6	13.9	6.5	9.3	1.9	0.9	-	%	
4	2	10	10	11	9	3	5	-	-	-	M	
7.0	3.5	17.5	17.5	19.3	15.8	5.3	8.8	-	-	-	%	
2	3	5	5	8	6	4	5	2	1	-	F	
3.9	5.9	9.8	9.8	15.7	11.8	7.8	9.8	3.9	2.0	-	%	
15	27	47	61	47	48	36	35	15	8	-	T	Specific biochemical and/or immunological tests
4.0	7.2	12.6	16.4	12.6	12.9	9.7	9.4	4.0	2.1	-	%	
9	19	36	38	29	31	17	17	8	4	-	M	
3.9	8.2	15.6	16.5	12.6	13.4	7.4	7.4	3.5	1.7	-	%	
6	8	11	23	18	17	19	18	7	4	-	F	
4.2	5.6	7.7	16.2	12.7	12.0	13.4	12.7	4.9	2.8	-	%	
6163	7039	7629	9450	11477	10615	7618	4494	1728	598	-	T	Microscopic (cytology, hematology, histology, exploratory surgery, autopsy)
8.0	9.2	9.9	12.3	14.9	13.8	9.9	5.8	2.2	0.8	-	%	
2244	3092	4026	5692	7434	6849	4736	2754	1050	315	-	M	
5.4	7.4	9.6	13.6	17.8	16.4	11.3	6.6	2.5	0.8	-	%	
3919	3947	3603	3758	4043	3766	2882	1740	678	283	-	F	
11.2	11.3	10.3	10.7	11.5	10.7	8.2	5.0	1.9	0.8	-	%	

5.

Table 5. Distribution of Malignant Cases by Sex, Place of Residence(Region) and Basis of Diagnosis

, %	† Total	(Clinical only)	(Clinical investigations)	(Explo-ratory surgery)	(Specific biochemical immunolo-gical test)	(Micro-scopic)	Basis of Diagnosis	
							region, Sex, %	
가 * %	91889	1341	13236	108	373	76831	T	Classifiable cases by place of residence
	100.0	1.5	14.4	0.1	0.4	83.6	%	
	51721	764	8884	57	231	41785	M	
	56.3	1.5	17.2	0.1	0.4	80.8	%	
	40168	577	4352	51	142	35046	F	
	43.7	1.4	10.8	0.1	0.4	87.2	%	
7 %	44320	533	6551	55	227	36954	T	Metropolitan (7 cities)
	48.2	1.2	14.8	0.1	0.5	83.4	%	
	24111	280	4340	29	141	19321	M	
	46.6	1.2	18.0	0.1	0.6	80.1	%	
	20209	253	2211	26	86	17633	F	
	50.3	1.3	10.9	0.1	0.4	87.3	%	
() %	34865	590	4731	38	108	29398	T	Small to Medium sized cities
	37.9	1.7	13.6	0.1	0.3	84.3	%	
	19498	338	3193	19	68	15880	M	
	37.7	1.7	16.4	0.1	0.3	81.4	%	
	15367	252	1538	19	40	13518	F	
	38.3	1.6	10.0	0.1	0.3	88.0	%	
() %	12704	218	1954	15	38	10479	T	Country sized
	13.8	1.7	15.4	0.1	0.3	82.5	%	
	8112	146	1351	9	22	6584	M	
	15.7	1.8	16.7	0.1	0.3	81.2	%	
	4592	72	603	6	16	3895	F	
	11.4	1.6	13.1	0.1	0.3	84.8	%	

† Column %, * 55

Row %

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C16) : 18648			
Stomach			
T-Code	%	Topography	
C16.3	6273	33.6	Gastric antrum
C16.2	4523	24.3	Body of stomach
C16.8	2536	13.6	Overlapping lesion of stomach
C16.0	653	3.5	Cardia, NOS
C16.5	558	3.0	Lesser curvature of stomach, NOS
C16.4	242	1.3	Pylorus
C16.1	132	0.7	Fundus of stomach
C16.6	57	0.3	Greater curvature of stomach, NOS
C16.9	3674	19.7	Stomach, NOS
M-code	%	Morphology	
814	9559	51.3	Adenocarcinoma
821	4120	22.1	Tubular adenocarcinoma
849	2914	15.6	Signet ring cell carcinoma
848	285	1.5	Mucinous adenocarcinoma
889	151	0.8	Leiomyosarcoma
826	130	0.7	Papillary adenocarcinoma
:	:	:	:
801	93	0.5	Epithelial neoplasms, NOS
800	916	4.9	Neoplasms, NOS
(C34) : 10922			
Lung			
T-Code	%	Topography	
C34.1	3310	30.3	Upper lobe, lung
C34.3	2365	21.7	Lower lobe, lung
C34.2	449	4.1	Middle lobe, lung
C34.0	448	4.1	Main bronchus
C34.8	312	2.9	Overlapping lesion of lung
C34.9	4038	37.0	Lung, NOS
M-code	%	Morphology	
807	3615	33.1	Squamous cell carcinoma
814	2894	26.5	Adenocarcinoma
804	1446	13.2	Small cell carcinoma
825	172	1.6	Bronchiolo-alveolar adenocarcinoma
855	88	0.8	Acinar cell carcinoma
824	84	0.8	Carcinoid tumor
:	:	:	:
801	696	6.4	Epithelial neoplasms, NOS
800	1537	14.1	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C22) : 10856			
Liver			
T-Code	%	Topography	
C22.0	8967	82.6	Liver
C22.1	1889	17.4	Intrahepatic bile ducts
M-code	%	Morphology	
817	7947	73.2	Hepatocellular carcinoma
816	631	5.8	Cholangiocarcinoma
814	265	2.4	Adenocarcinoma
818	35	0.3	Combined hepatocellular carcinoma and cholangiocarcinoma.
897	20	0.2	Hepatoblastoma
821	18	0.2	Tubular adenocarcinoma
:	:	:	:
801	44	0.4	Epithelial neoplasms, NOS
800	1817	16.7	Neoplasms, NOS
(C50) : 6505			
Breast			
T-Code	%	Topography	
C50.4	2301	35.4	Upper-outer quadrant of breast
C50.8	843	13.0	Overlapping lesion of breast
C50.2	753	11.6	Upper-inner quadrant of breast
C50.5	374	5.7	Lower-outer quadrant of breast
C50.1	333	5.1	Central portion of breast
C50.3	214	3.3	Lower-inner quadrant of breast
C50.0	168	2.6	Nipple
C50.6	9	0.1	A xillary tail of breast
C50.9	1510	23.2	Breast, NOS
M-code	%	Morphology	
850	5369	82.5	Infiltrating duct carcinoma
852	223	3.4	Lobular carcinoma
848	146	2.2	Mucinous adenocarcinoma
851	116	1.8	Medullary carcinoma
805	81	1.2	Papillary carcinoma
854	68	1.0	Paget's disease, mammary
:	:	:	:
801	89	1.4	Epithelial neoplasms, NOS
800	215	3.3	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C19-C20) : 4899					
Rectum					
T-Code			%		Topography
C20.9		4351	88.8		Rectum, NOS
C19.9	S	548	11.2		Rectosigmoid junction
M-code			%		Morphology
814		3023	61.7		Adenocarcinoma
821		1155	23.6		Tubular adenocarcinoma
848		139	2.8		Mucinous adenocarcinoma
826		96	2.0		Papillary adenocarcinoma
824		76	1.6		Carcinoid tumor
849		38	0.8		Signet ring cell carcinoma
:	:	:	:	:	:
801		33	0.7		Epithelial neoplasms, NOS
800		265	5.4		Neoplasms, NOS
(C18) : 4796					
Colon					
T-Code			%		Topography
C18.7	S	1820	37.9		Sigmoid colon
C18.2		1011	21.1		Ascending colon
C18.4		368	7.7		Transverse colon
C18.0		262	5.5		Cecum
C18.6		253	5.3		Descending colon
C18.3		212	4.4		Hepatic flexure of colon
C18.8		90	1.9		Overlapping lesion of colon
C18.5		62	1.3		Splenic flexure of colon
C18.1		56	1.2		Appendix
C18.9		662	13.8		Colon, NOS
M-code			%		Morphology
814		2879	60.0		Adenocarcinoma
821		990	20.6		Tubular adenocarcinoma
848		312	6.5		Mucinous adenocarcinoma
826		107	2.2		Papillary adenocarcinoma
968		41	0.9		Malignant lymphoma, large cell, diffuse, specified type
849		25	0.5		Signet ring cell carcinoma
:	:	:	:	:	:
801		33	0.7		Epithelial neoplasms, NOS
800		316	6.6		Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C53) : 4061			
Cervix uteri			
T-Code		%	Topography
C53.9	3860	95.1	Cervix uteri
C53.0	95	2.3	Endocervix
C53.1	93	2.3	Exocervix
C53.8	13	0.3	Overlapping lesion of cervix uteri
M-code		%	Morphology
807	3162	77.9	Squamous cell carcinoma
814	351	8.6	Adenocarcinoma
856	100	2.5	Adenosquamous carcinoma
848	28	0.7	Mucinous adenocarcinoma
805	20	0.5	Papillary carcinoma
821	19	0.5	Tubular adenocarcinoma
:	:	:	:
801	28	0.7	Epithelial neoplasms, NOS
800	255	6.3	Neoplasms, NOS
(C73) : 3872			
Thyroid gland			
T-Code		%	Topography
C73.9	3872	100.0	Thyroid gland
M-code		%	Morphology
805	2979	76.9	Papillary carcinoma
833	254	6.6	Follicular adenocarcinoma
834	167	4.3	Papillary carcinoma, follicular variant
826	160	4.1	Papillary adenocarcinoma
851	52	1.3	Medullary carcinoma
802	31	0.8	Carcinoma, undifferentiated
:	:	:	:
801	22	0.6	Epithelial neoplasms, NOS
800	129	3.3	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C42) : 2507			
Hematopoietic & reticuloendothelial systems			
T-Code	%	Topography	
C42.1	2450	97.7	Bone marrow
C42.0	32	1.3	Blood
C42.2	24	1.0	Spleen
C42.3	1	0.0	Reticuloendothelial system, NOS
M-code	%	Morphology	
986	1129	45.0	Myeloid leukemia
982	479	19.1	Lymphoid leukemia
973	441	17.6	Plasmacytoma
980	78	3.1	Leukemia
959	42	1.7	Malignant lymphomas
968	41	1.6	Malignant lymphoma, large cell, diffuse, specified type
:	:	:	:
800	153	6.1	Neoplasms, NOS
(C67) : 2150			
Urinary bladder			
T-Code	%	Topography	
C67.2	243	11.3	Lateral wall of bladder
C67.8	223	10.4	Overlapping lesion of bladder
C67.6	91	4.2	Ureteric orifice
C67.4	76	3.5	Posterior wall of bladder
C67.5	52	2.4	Bladder neck
C67.3	34	1.6	Anterior wall of bladder
C67.0	28	1.3	Trigone of bladder
C67.1	27	1.3	Dome of bladder
C67.7	11	0.5	Urachus
C67.9	1365	63.5	Bladder, NOS
M-code	%	Morphology	
812	1236	57.5	Transitional cell carcinoma
813	656	30.5	Papillary transitional cell carcinoma
814	28	1.3	Adenocarcinoma
807	12	0.6	Squamous cell carcinoma
805	10	0.5	Papillary carcinoma
821	10	0.5	Tubular adenocarcinoma
848	6	0.3	Mucinous adenocarcinoma
:	:	:	:
801	18	0.8	Epithelial neoplasms, NOS
800	138	6.4	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C25) : 2041					
Pancreas					
T-Code			%	Topography	
C25.0	942	46.2		Head of pancreas	
C25.2	269	13.2		Tail of pancreas	
C25.1	176	8.6		Body of pancreas	
C25.8	88	4.3		Overlapping lesion of pancreas	
C25.7	21	1.0		Other specified parts of pancreas	
C25.3	13	0.6		Pancreatic duct	
C25.4	10	0.5		Islets of Langerhans	
C25.9	522	25.6		Pancreas, NOS	
M-code			%	Morphology	
814	584	28.6		Adenocarcinoma	
850	68	3.3		Infiltrating duct carcinoma	
821	43	2.1		Tubular adenocarcinoma	
848	19	0.9		Mucinous adenocarcinoma	
847	17	0.8		Mucinous cystadenocarcinoma	
815	12	0.6		Islet cell carcinoma	
:	:	:	:	:	
801	39	1.9		Epithelial neoplasms, NOS	
800	1205	59.0		Neoplasms, NOS	
(C15) : 1540					
Esophagus					
T-Code			%	Topography	
C15.4	3	1	363	23.6	Middle third of esophagus
C15.5	3	1	307	19.9	Lower third of esophagus
C15.3	3	1	111	7.2	Upper third of esophagus
C15.1			73	4.7	Thoracic esophagus
C15.8			56	3.6	Overlapping lesion of esophagus
C15.0			32	2.1	Cervical esophagus
C15.2			1	0.1	Abdominal esophagus
C15.9			597	38.8	Esophagus, NOS
M-code			%	Morphology	
807			1310	85.1	Squamous cell carcinoma
814			44	2.9	Adenocarcinoma
804			10	0.6	Small cell carcinoma
821			9	0.6	Tubular adenocarcinoma
856			8	0.5	Adenosquamous cell carcinoma
812			5	0.3	Basaloid carcinoma
:	:	:	:	:	:
801			23	1.5	Epithelial neoplasms, NOS
800			118	7.7	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C56) : 1517			
Ovary			
T-Code	%	Topography	
C56.9	1517	100.0	Ovary
M-code	%	Morphology	
847	379	25.0	Mucinous cystadenocarcinoma
844	221	14.6	Cystadenocarcinoma
846	219	14.4	Papillary serous cystadenocarcinoma
814	103	6.8	Adenocarcinoma
838	92	6.1	Endometrioid carcinoma
831	63	4.2	Clear cell adenocarcinoma
:	:	:	:
801	22	1.5	Epithelial neoplasms, NOS
800	135	8.9	Neoplasms, NOS

(C64) : 1478			
Kidney			
T-Code	%	Topography	
C64.9	1478	100.0	Kidney, NOS
M-code	%	Morphology	
831	1162	78.6	Renal cell carcinoma
896	50	3.4	Nephroblastoma
812	31	2.1	Transitional cell carcinoma
813	10	0.7	Papillary transitional cell carcinoma
968	5	0.3	Malignant lymphoma, large cell, diffuse, specified type
807	3	0.2	Squamous cell carcinoma
814	3	0.2	Adenocarcinoma
889	3	0.2	Leiomyosarcoma
:	:	:	:
801	11	0.7	Epithelial neoplasms, NOS
800	185	12.5	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C61) : 1467			
Prostate gland			
T-Code	%	Topography	
C61.9	1467	100.0	Prostate gland
M-code	%	Morphology	
814	1215	82.8	Adenocarcinoma
855	74	5.0	Acinar cell carcinoma
812	13	0.9	Transitional cell carcinoma
850	4	0.3	Infiltrating duct carcinoma
804	3	0.2	Small cell carcinoma
848	3	0.2	Mucinous adenocarcinoma
849	3	0.2	Signet ring cell carcinoma
880	3	0.2	Sarcoma
805	2	0.1	Papillary carcinoma
813	2	0.1	Papillary transitional cell carcinoma
838	2	0.1	Endometrioid carcinoma
:	:	:	:
801	23	1.6	Epithelial neoplasms, NOS
800	113	7.7	Neoplasms, NOS

(C24) : 1397			
Biliary tract			
T-Code	%	Topography	
C24.0	978	70.0	Extrahepatic bile duct
C24.1	397	28.4	Ampulla of Vater
C24.8	6	0.4	Overlapping lesion of biliary tract
C24.9	16	1.1	Biliary tract, NOS
M-code	%	Morphology	
814	609	43.6	Adenocarcinoma
821	114	8.2	Tubular adenocarcinoma
826	28	2.0	Papillary adenocarcinoma
816	27	1.9	Cholangiocarcinoma
848	9	0.6	Mucinous adenocarcinoma
802	5	0.4	Carcinoma, undifferentiated
824	5	0.4	Carcinoid tumor
856	5	0.4	Adenosquamous carcinoma
:	:	:	:
801	11	0.8	Epithelial neoplasms, NOS
800	572	40.9	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C44) : 1261			
Skin			
T-Code	425	33.7	Skin of other and unspecified parts of face
C44.3	185	14.7	Skin of lower limb and hip
C44.7	156	12.4	Skin of trunk
C44.5	135	10.7	Eyelid
C44.1	108	8.6	Skin of upper limb and shoulder
C44.6	101	8.0	Skin of scalp and neck
C44.4	67	5.3	External ear
C44.2	31	2.5	Skin of lip, NOS
C44.0	9	0.7	Overlapping lesion of skin
C44.8	44	3.5	Skin, NOS
C44.9			
M-code	471	37.4	Basal cell carcinoma
809	317	25.1	Squamous cell carcinoma
807	179	14.2	Malignant melanoma
872	69	5.5	Fibrous histiocytoma, malignant
883	30	2.4	Malignant melanoma in precancerous melanosis
874	23	1.8	Sebaceous adenocarcinoma
841	:	:	:
:	6	0.5	Epithelial neoplasms, NOS
801	36	2.9	Neoplasms, NOS
800			

(C23) : 1208			
Gallbladder			
T-Code	1208	100.0	Gallbladder
C23.9			
M-code	476	39.4	Adenocarcinoma
814	82	6.8	Tubular adenocarcinoma
821	27	2.2	Papillary adenocarcinoma
826	18	1.5	Adenosquamous carcinoma
856	6	0.5	Squamous cell carcinoma
807	3	0.2	Carcinoma, undifferentiated
802	:	:	:
:	30	2.5	Epithelial neoplasms, NOS
801	543	45.0	Neoplasms, NOS
800			

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C77) : 1031				
Lymph node				
T-Code		%	Topography	
C77.0	,	543	52.7	Lymph nodes of head, face and neck
C77.2		157	15.2	Intra-abdominal lymph nodes
C77.4		84	8.1	Lymph nodes of inguinal region or leg
C77.3		50	4.8	Lymph nodes of axilla or arm
C77.1		36	3.5	Intrathoracic lymph nodes
C77.8		15	1.5	Lymph nodes of multiple regions
C77.5		13	1.3	Pelvic lymph nodes
C77.9		133	12.9	Lymph nodes, NOS
M-code		%	Morphology	
968		447	43.4	Malignant lymphoma, large cell, diffuse, specified type
959		194	18.8	Malignant lymphomas
965		84	8.1	Hodgkin's disease
970	T-	77	7.5	Cutaneous and peripheral T-cell lymphoma
967		63	6.1	Malignant lymphoma, diffuse specified type
969		46	4.5	Malignant lymphoma, follicular or nodular
:	:	:	:	:
801		2	0.2	Epithelial neoplasms, NOS
800		55	5.3	Neoplasms, NOS
(C71) : 1028				
Brain				
T-Code		%	Topography	
C71.1		165	16.1	Frontal lobe
C71.2		123	12.0	Temporal lobe
C71.6		115	11.2	Cerebellum, NOS
C71.0		93	9.0	Cerebrum
C71.8		91	8.9	Overlapping lesion of brain
C71.7		49	4.8	Brain stem
C71.3		48	4.7	Parietal lobe
C71.5		31	3.0	Ventricles, NOS
C71.4		18	1.8	Occipital lobe
C71.9		295	28.7	Brain, NOS
M-code		%	Morphology	
944		243	23.6	Glioblastoma
940		168	16.3	Astrocytoma
945		98	9.5	Oligodendroglioma
947		63	6.1	Medulloblastoma
942		62	6.0	Fibrillary astrocytoma
938		57	5.5	Glioma, malignant
:	:	:	:	:
801		5	0.5	Epithelial neoplasms, NOS
800		193	18.8	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C32) : 997			
Larynx			
T-Code		%	Topography
C32.0		481	48.2 Glottis
C32.1		332	33.3 Supraglottis
C32.2		23	2.3 Subglottis
C32.8		15	1.5 Overlapping lesion of larynx
C32.3		7	0.7 Laryngeal cartilage
C32.9		139	13.9 Larynx, NOS
M-code		%	Morphology
807		878	88.1 Squamous cell carcinoma
805		9	0.9 Papillary carcinoma
814		7	0.7 Adenocarcinoma
971		3	0.3 Non-Hodgkin's lymphomas
804		2	0.2 Small cell carcinoma
824		2	0.2 Carcinoid tumor
889		2	0.2 Leiomyosarcoma
803		1	0.1 Giant cell carcinoma
812		1	0.1 Transitional cell carcinoma
820		1	0.1 Adenoid cystic carcinoma
843		1	0.1 Mucoepidermoid neoplasms
856		1	0.1 Adenosquamous carcinoma
871		1	0.1 Glomangiosarcoma
880		1	0.1 Sarcoma
908		1	0.1 Teratoma, malignant
922		1	0.1 Chondrosarcoma
968		1	0.1 Malignant lymphoma, large cell, diffuse
970	T-	1	0.1 Cutaneous and peripheral T-cell lymphoma
973		1	0.1 Plasmacytoma
801		5	0.5 Epithelial neoplasms, NOS
800		78	7.8 Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C54) : 719			
Corpus uteri			
T-Code		%	Topography
C54.1	653	90.8	Endometrium
C54.2	18	2.5	Myometrium
C54.8	6	0.8	Overlapping lesion of corpus uteri
C54.3	5	0.7	Fundus uteri
C54.0	2	0.3	Isthmus uteri
C54.9	35	4.9	Corpus uteri
M-code		%	Morphology
838	314	43.7	Endometrioid carcinoma
814	186	25.9	Adenocarcinoma
893	40	5.6	Endometrioid stromal sarcoma
889	19	2.6	Leiomyosarcoma
895	18	2.5	Mullerian mixed tumor
846	15	2.1	Papillary serous cystadenocarcinoma
:	:	:	:
801	21	2.9	Epithelial neoplasms, NOS
800	21	2.9	Neoplasms, NOS
(C49) : 507			
Connective, subcutaneous and other soft tissues			
T-Code		%	Topography
C49.2	176	34.7	Lower limb and hip
C49.0	70	13.8	Head, face and neck
C49.5	64	12.6	Pelvis
C49.1	63	12.4	Upper limb and shoulder
C49.3	45	8.9	Thorax
C49.4	41	8.1	Abdomen
C49.6	22	4.3	Trunk, NOS
C49.8	4	0.8	Overlapping lesion
C49.9	22	4.3	Connective, subcutaneous and other soft tissue, NOS
M-code		%	Morphology
885	83	16.4	Liposarcoma
883	76	15.0	Fibrous histiocytoma, malignant
880	64	12.6	Sarcoma
904	40	7.9	Synovial sarcoma
889	36	7.1	Leiomyosarcoma
968	16	3.2	Malignant lymphoma, large cell, diffuse, specified type
:	:	:	:
801	3	0.6	Epithelial neoplasms, NOS
800	45	8.9	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C40-C41) : 425			
Bone, joint & articular cartilage			
T-Code		%	Topography
C40.2		175	41.2 Long bones of lower limb
C41.4		66	15.5 Pelvic bones, sacrum, coccyx
C40.0		38	8.9 Long bones of upper limb, scapular
C41.2		35	8.2 Vertebral column
C41.0		29	6.8 Bones of skull and face
C41.3		27	6.4 Rib, sternum, clavicle
C41.1		25	5.9 Mandible
C40.3		12	2.8 Short bones of lower limb
C40.1		6	1.4 Short bones of upper limb
C41.8		1	0.2 Overlapping lesion of bones, joints
C40.9		1	0.2 Bones of limb, NOS
C41.9		10	2.4 Bone, NOS
M-code		%	Morphology
918		172	40.5 Osteosarcoma
922		60	14.1 Chondrosarcoma
926		36	8.5 Ewing's sarcoma
968		14	3.3 Malignant lymphoma, large cell, diffuse, specified type
937		13	3.1 Chordoma
973		8	1.9 Plasmacytoma
:	:	:	:
800		54	12.7 Neoplasms, NOS
(C17) : 415			
Small intestine			
T-Code		%	Topography
C17.0		223	53.7 Duodenum
C17.1		61	14.7 Jejunum
C17.2		53	12.8 Ileum
C17.8		5	1.2 Overlapping lesion of small intestine
C17.9		73	17.6 Small intestine, NOS
M-code		%	Morphology
814		121	29.2 Adenocarcinoma
889		96	23.1 Leiomyosarcoma
968		36	8.7 Malignant lymphoma, large cell, diffuse, specified type
821		34	8.2 Tubular adenocarcinoma
824		18	4.3 Carcinoid tumor
959		18	4.3 Malignant lymphomas
893		12	2.9 Gastrointestinal stromal tumor, malignant
:	:	:	:
801		4	1.0 Epithelial neoplasms, NOS
800		41	9.9 Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C11) : 325			
Nasopharynx			
T-Code		%	Topography
C11.1	13	4.0	Posterior wall of nasopharynx
C11.2	7	2.2	Lateral wall of nasopharynx
C11.3	4	1.2	Anterior wall of nasopharynx
C11.8	4	1.2	Overlapping lesion of nasopharynx
C11.0	1	0.3	Superior wall of nasopharynx
C11.9	296	91.1	Nasopharynx, NOS
M-code		%	Morphology
807	123	37.8	Squamous cell carcinoma
802	77	23.7	Carcinoma, undifferentiated
968	17	5.2	Malignant lymphoma, large cell, diffuse, specified type
808	5	1.5	Lymphoepithelial carcinoma
820	3	0.9	Adenoid cystic carcinoma
959	3	0.9	Malignant lymphomas
812	2	0.6	Transitional cell carcinoma
814	2	0.6	Acenocarcinoma
824	2	0.6	Carcinoid tumor
880	2	0.6	Sarcoma
967	2	0.6	Malignant lymphoma, diffuse specified type
970	2	0.6	Cutaneous and peripheral T-cell lymphoma
:	:	:	:
801	38	11.7	Epithelial neoplasms, NOS
800	40	12.3	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C01-C02) : 298					
Tongue					
T-Code			%	Topography	
C01.9			70	23.5	Base of tongue
C02.1			58	19.5	Border of tongue
C02.2			10	3.4	Ventral surface of tongue
C02.0			6	2.0	Dorsal surface of tongue
C02.3	3	2	6	2.0	Anterior 2/3 of tongue
C02.4			4	1.3	Lingual tonsil
C02.8			3	1.0	Overlapping lesion of tongue
C02.9			141	47.3	Tongue, NOS
M-code			%		Morphology
807			253	84.9	Squamous cell carcinoma
843			6	2.0	Mucoepidermoid neoplasms
968			6	2.0	Malignant lymphoma, large cell, diffuse, specified type
805			3	1.0	Papillary carcinoma
820			2	0.7	Adenoid cystic carcinoma
856			2	0.7	Adenosquamous carcinoma
880			2	0.7	Sarcoma
802			1	0.3	Carcinoma, undifferentiated
809			1	0.3	Basal cell carcinoma
812			1	0.3	Transitional cell carcinoma
814			1	0.3	Acenocarcinoma
848			1	0.3	Mucinous adenocarcinoma
889			1	0.3	Leiomyosarcoma
914			1	0.3	Kaposi's sarcoma
965			1	0.3	Hodgkin's disease
969			1	0.3	Malignant lymphoma, follicular or nodular
801			3	1.0	Epithelial neoplasms, NOS
800			12	4.0	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C09) : 202				
Tonsil				
T-Code		%		Topography
C09.0		10	5.0	Tonsillar fossa
C09.1		7	3.5	Tonsillar pillar
C09.8		1	0.5	Overlapping lesion of tonsil
C09.9		184	91.1	Tonsil, NOS
M-code		%		Morphology
807		104	51.5	Squamous cell carcinoma
968		49	24.3	Malignant lymphoma, large cell, diffuse, specified type
959		10	5.0	Malignant lymphomas
969		7	3.5	Malignant lymphoma, follicular or nodular
967		5	2.5	Malignant lymphoma, diffuse specified type
970	T-	5	2.5	Cutaneous and peripheral T-cell lymphoma
802		3	1.5	Carcinoma, undifferentiated
805		3	1.5	Papillary carcinoma
:	:	:	:	:
801		2	1.0	Epithelial neoplasms, NOS
800		10	5.0	Neoplasms, NOS
(C07) : 185				
Parotid gland				
T-Code		%		Topography
C07.9		185	100.0	Parotid gland
M-code		%		Morphology
843		49	26.5	Mucoepidermoid neoplasms
820		21	11.4	Adenoid cystic carcinoma
807		20	10.8	Squamous cell carcinoma
855		18	9.7	Acinar cell carcinoma
814		15	8.1	Adenocarcinoma
856		9	4.9	Adenosquamous carcinoma
894		9	4.9	Mixed tumor, malignant
:	:	:	:	:
801		16	8.6	Epithelial neoplasms, NOS
800		8	4.3	Neoplasms, NOS

6.

Table 6. Marginal Frequency of Topography and Morphology in Primary Cancer Sites

(C66) : 179			
Ureter			
T-Code	%	Topography	
C66.9	179	100.0	Posterior wall of hypopharynx
M-code	%	Morphology	
812	114	63.7	Transitional cell carcinoma
813	44	24.6	Papillary transitional cell carcinoma
807	4	2.2	Squamous cell carcinoma
821	1	0.6	Tubular adenocarcinoma
824	1	0.6	Carcinoid tumor
856	1	0.6	Adenosquamous carcinoma
889	1	0.6	Leiomyosarcoma
800	13	7.3	Neoplasms, NOS

7.

Table 7. Marginal Frequency of Morphology(M-Code) in Malignant Cases

			Morphology
	91,944	100.0	Total malignant neoplasms
800	9,992	10.9	Neoplasms, NOS
801-804	3,338	3.6	Epithelial neoplasms, NOS
805-808	14,182	15.4	Squamous cell neoplasms
809-811	496	0.5	Basal cell neoplasms
812-813	2,317	2.5	Transitional cell carcinomas
814-838	41,984	45.7	Adenocarcinomas
839-842	54	0.1	Adnexal & skin appendage neoplasms
843	117	0.1	Mucoepidermoid neoplasms
844-849	5,074	5.5	Cystic, mucinous & serous neoplasms
850-854	5,964	6.5	Ductal, lobular & medullary neoplasms
855	194	0.2	Acinar cell neoplasms
856-858	385	0.4	Complex epithelial neoplasms
859-867	32	0.0	Specialized gonadal neoplasms
868-871	17	0.0	Paragangliomas & glomus tumors
872-879	288	0.3	Melanomas
880	166	0.2	Soft tissue tumors & sarcomas, NOS
881-883	196	0.2	Fibromatous neoplasms
884	-	-	Myxomatous neoplasms
885-888	123	0.1	Lipomatous neoplasms
889-892	506	0.6	Myomatous neoplasms
893-899	248	0.3	Complex mixed & stromal neoplasms
900-903	53	0.1	Fibroepithelial neoplasms
904	55	0.1	Synovial-like neoplasms
905	38	0.0	Mesothelial neoplasms
906-909	310	0.3	Germ cell neoplasms
910	48	0.1	Trophoblastic neoplasms
911	-	-	Mesonephromas
912-916	64	0.1	Blood vessel tumors
917	-	-	Lymphatic vessel tumors
918-924	263	0.3	Osteous & chondromatous neoplasms
925	8	0.0	Giant cell tumors
926	39	0.0	Miscellaneous bone tumors
927-934	3	0.0	Odontogenic tumors
935-937	39	0.0	Miscellaneous tumors

7.

Table 7. Marginal Frequency of Morphology(M-Code) in Malignant Cases

			Morphology
938-948		790	0.9 Gliomas
949-952		126	0.1 Neuroepitheliomatous neoplasms
953		38	0.0 Meningiomas
954-957		32	0.0 Nerve sheath tumors
958		14	0.0 Granular cell tumors, malignant & alveolar soft part sarcoma
959-970		1,969	2.1 Hodgkin's & non-Hodgkin's lymphoma
959		519	0.6 Malignant lymphomas, NOS or diffuse
965-966		134	0.1 Hodgkin's disease
967-968		1,105	1.2 Malignant lymphoma specified type, diffuse or NOS
969		63	0.1 Malignant lymphoma, follicular or nodular
970	T-	148	0.2 Specified cutaneous and peripheral T-cell Lymphomas
971		124	0.1 Other specified non-Hodgkin's lymphomas
972		18	0.0 Other lymphoreticular neoplasms
973		458	0.5 Plasma cell tumors
974		-	- Mast cell tumors
976		9	0.0 Immunoproliferative diseases
980-994		1,773	1.9 Leukemias
980	NOS	78	0.1 Leukemias, NOS
982		480	0.5 Lymphoid leukemias
983		11	0.0 Plasma cell leukemia
984		13	0.0 Erythroleukemias
985		-	- Lymphosarcoma cell leukemia
986	()	1,129	1.2 Myeloid(granulocytic) leukemias
987		1	0.0 Basophilic leukemia
988		2	0.0 Eosinophilic leukemia
989		38	0.0 Monocytic leukemias
990-994		21	0.0 Other leukemias
995-997		-	- Miscellaneous myeloproliferative & lymphoproliferative disorders
998		-	- Myelodysplastic syndrome

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	† Total	0-4 Year	5-9	10-14	Diagnostic group
	1136	537	312	287	TOTAL MALIGNANT NEOPLASMS
%	100.0	100.0	100.0	100.0	
	661	312	189	160	
%	100.0	100.0	100.0	100.0	
	475	225	123	127	
%	100.0	100.0	100.0	100.0	
	384	164	134	86	LEUKEMIAS
%	33.8	30.5	42.9	30.0	
	230	90	87	53	
%	34.8	28.8	46.0	33.1	
	154	74	47	33	
%	32.4	32.9	38.2	26.0	
	239	110	85	44	Lymphoid leukemia
%	21.0	20.5	27.2	15.3	
	153	68	56	29	
%	23.1	21.8	29.6	18.1	
	86	42	29	15	
%	18.1	18.7	23.6	11.8	
	109	40	37	32	Acute non-lymphocytic leukemia
%	9.6	7.4	11.9	11.1	
	56	17	21	18	
%	8.5	5.4	11.1	11.3	
	53	23	16	14	
%	11.2	10.2	13.0	11.0	
	19	8	6	5	Chronic myeloid leukemia
%	1.7	1.5	1.9	1.7	
	11	3	4	4	
%	1.7	1.0	2.1	2.5	
	8	5	2	1	
%	1.7	2.2	1.6	0.8	
	2	-	1	1	Other specified leukemias
%	0.2	-	0.3	0.3	
	2	-	1	1	
%	0.3	-	0.5	0.6	
	-	-	-	-	
%	-	-	-	-	

† Column %

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group
	15	6	5	4	Unspecified leukemias
%	1.3	1.1	1.6	1.4	
	8	2	5	1	
%	1.2	0.6	2.6	0.6	
	7	4	-	3	LYMPHOMAS
%	1.5	1.8	-	2.4	
	89	29	25	35	
%	7.8	5.4	8.0	12.2	
	57	19	15	23	Hodgkin's disease
%	8.6	6.1	7.9	14.4	
	32	10	10	12	
%	6.7	4.4	8.1	9.4	
	13	3	2	8	Non-Hodgkin's lymphoma
%	1.1	0.6	0.6	2.8	
	9	3	1	5	
%	1.4	1.0	0.5	3.1	
	4	-	1	3	Burkitt's lymphoma
%	0.8	-	0.8	2.4	
	45	11	19	15	
%	4.0	2.0	6.1	5.2	
	32	8	14	10	Miscellaneous lymphoreticular neoplasms
%	4.8	2.6	7.4	6.3	
	13	3	5	5	
%	2.7	1.3	4.1	3.9	
	14	7	2	5	
%	1.2	1.3	0.6	1.7	
	8	4	-	4	
%	1.2	1.3	-	2.5	
	6	3	2	1	
%	1.3	1.3	1.6	0.8	
	6	4	1	1	
%	0.5	0.7	0.3	0.3	
	3	2	-	1	
%	0.5	0.6	-	0.6	
	3	2	1	-	
%	0.6	0.9	0.8	-	

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group
	11	4	1	6	Unspecified lymphomas
%	1.0	0.7	0.3	2.1	
	5	2	-	3	
%	0.8	0.6	-	1.9	
	6	2	1	3	CENTRAL NERVOUS SYSTEM
%	1.3	0.9	0.8	2.4	
	172	76	54	42	
%	15.1	14.2	17.3	14.6	
	100	43	29	28	Ependymoma
%	15.1	13.8	15.3	17.5	
	72	33	25	14	
%	15.2	14.7	20.3	11.0	
	17	16	1	-	Astrocytoma
%	1.5	3.0	0.3	-	
	8	8	-	-	
%	1.2	2.6	-	-	
	9	8	1	-	Primitive neuroectodermal tumors
%	1.9	3.6	0.8	-	
	59	23	19	17	
%	5.2	4.3	6.1	5.9	
	36	15	10	11	Other gliomas
%	5.4	4.8	5.3	6.9	
	23	8	9	6	
%	4.8	3.6	7.3	4.7	
	51	21	19	11	
%	4.5	3.9	6.1	3.8	
	32	13	12	7	
%	4.8	4.2	6.3	4.4	
	19	8	7	4	
%	4.0	3.6	5.7	3.1	
	12	5	3	4	
%	1.1	0.9	1.0	1.4	
	5	1	2	2	
%	0.8	0.3	1.1	1.3	
	7	4	1	2	
%	1.5	1.8	0.8	1.6	

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group
	1	-	-	1	Other specified intracranial and intraspinal neoplasms
%	0.1	-	-	0.3	
	1	-	-	1	
%	0.2	-	-	0.6	
	-	-	-	-	
%	-	-	-	-	
	32	11	12	9	Unspecified intracranial and intraspinal neoplasms
%	2.8	2.0	3.8	3.1	
	18	6	5	7	
%	2.7	1.9	2.6	4.4	
	14	5	7	2	
%	2.9	2.2	5.7	1.6	
	84	72	12	-	SYMPATHETIC NERVOUS SYSTEM TUMORS
%	7.4	13.4	3.8	-	
	53	44	9	-	
%	8.0	14.1	4.8	-	
	31	28	3	-	
%	6.5	12.4	2.4	-	
	83	71	12	-	Neuroblastoma and ganglioneuroblastoma
%	7.3	13.2	3.8	-	
	53	44	9	-	
%	8.0	14.1	4.8	-	
	30	27	3	-	
%	6.3	12.0	2.4	-	
	1	1	-	-	Other sympathetic nervous system tumors
%	0.1	0.2	-	-	
	-	-	-	-	
%	-	-	-	-	
	1	1	-	-	
%	0.2	0.4	-	-	
	21	21	-	-	RETINOBLASTOMA
%	1.8	3.9	-	-	
	10	10	-	-	
%	1.5	3.2	-	-	
	11	11	-	-	
%	2.3	4.9	-	-	

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group	
	42	33	8	1	RENAL TUMORS	
%	3.7	6.1	2.6	0.3		
	23	20	3	-		
%	3.5	6.4	1.6	-		
	19	13	5	1		
%	4.0	5.8	4.1	0.8		
	39	31	7	1		Wilms' tumor
%	3.4	5.8	2.2	0.3		
	21	19	2	-		
%	3.2	6.1	1.1	-		
	18	12	5	1		
%	3.8	5.3	4.1	0.8		
	1	-	1	-	Renal carcinoma	
%	0.1	-	0.3	-		
	1	-	1	-		
%	0.2	-	0.5	-		
	-	-	-	-		
%	-	-	-	-		
	2	2	-	-	Unspecified malignant renal tumors	
%	0.2	0.4	-	-		
	1	1	-	-		
%	0.2	0.3	-	-		
	1	1	-	-		
%	0.2	0.4	-	-		
	26	20	2	4	HEPATIC TUMORS	
%	2.3	3.7	0.6	1.4		
	14	12	-	2		
%	2.1	3.8	-	1.3		
	12	8	2	2		
%	2.5	3.6	1.6	1.6		
	19	16	1	2		Hepatoblastoma
%	1.7	3.0	0.3	0.7		
	9	8	-	1		
%	1.4	2.6	-	0.6		
	10	8	1	1		
%	2.1	3.6	0.8	0.8		

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group
	6	3	1	2	Hepatic carcinoma
%	0.5	0.6	0.3	0.7	
	4	3	-	1	
%	0.6	1.0	-	0.6	
	2	-	1	1	Unspecified malignant hepatic tumors
%	0.4	-	0.8	0.8	
	1	1	-	-	
%	0.1	0.2	-	-	
	1	1	-	-	MALIGNANT BONE TUMORS
%	0.2	0.3	-	-	
	-	-	-	-	
%	-	-	-	-	
	60	6	17	37	Osteosarcoma
%	5.3	1.1	5.4	12.9	
	34	2	13	19	
%	5.1	0.6	6.9	11.9	
	26	4	4	18	Chondrosarcoma
%	5.5	1.8	3.3	14.2	
	37	1	12	24	
%	3.3	0.2	3.8	8.4	
	20	1	9	10	Ewing's sarcoma
%	3.0	0.3	4.8	6.3	
	17	-	3	14	
%	3.6	-	2.4	11.0	
	-	-	-	-	
%	-	-	-	-	
	-	-	-	-	
%	-	-	-	-	
	14	4	3	7	
%	1.2	0.7	1.0	2.4	
	8	-	2	6	
%	1.2	-	1.1	3.8	
	6	4	1	1	
%	1.3	1.8	0.8	0.8	

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group
	1	-	-	1	Other specified malignant bone tumors
%	0.1	-	-	0.3	
	1	-	-	1	
%	0.2	-	-	0.6	Unspecified malignant bone tumors
	-	-	-	-	
%	-	-	-	-	
	8	1	2	5	Unspecified malignant bone tumors
%	0.7	0.2	0.6	1.7	
	5	1	2	2	
%	0.8	0.3	1.1	1.3	Unspecified malignant bone tumors
	3	-	-	3	
%	0.6	-	-	2.4	
	66	27	20	19	SOFT TISSUE SARCOMAS
%	5.8	5.0	6.4	6.6	
	44	15	17	12	
%	6.7	4.8	9.0	7.5	
	22	12	3	7	
%	4.6	5.3	2.4	5.5	
	35	18	11	6	Rhabdomyosarcoma and embryonal sarcoma
%	3.1	3.4	3.5	2.1	
	23	11	8	4	
%	3.5	3.5	4.2	2.5	
	12	7	3	2	Rhabdomyosarcoma and embryonal sarcoma
%	2.5	3.1	2.4	1.6	
	8	1	1	6	
%	0.7	0.2	0.3	2.1	
	6	1	1	4	Fibrosarcoma, neurofibrosarcoma
%	0.9	0.3	0.5	2.5	
	2	-	-	2	
%	0.4	-	-	1.6	Fibrosarcoma, neurofibrosarcoma
	-	-	-	-	
%	-	-	-	-	
	-	-	-	-	
%	-	-	-	-	
	-	-	-	-	Kaposi's sarcoma
%	-	-	-	-	
	-	-	-	-	
%	-	-	-	-	Kaposi's sarcoma

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group
	16	6	4	6	Other specified soft tissue sarcomas
%	1.4	1.1	1.3	2.1	
	10	2	4	4	
%	1.5	0.6	2.1	2.5	
	6	4	-	2	Unspecified soft tissue sarcoma
%	1.3	1.8	-	1.6	
	7	2	4	1	
%	0.6	0.4	1.3	0.3	
	5	1	4	-	GONADAL AND GERM CELL TUMOR
%	0.8	0.3	2.1	-	
	2	1	-	1	
%	0.4	0.4	-	0.8	
	83	40	17	26	Intracranial and intraspinal germ cell tumor
%	7.3	7.4	5.4	9.1	
	39	27	3	9	
%	5.9	8.7	1.6	5.6	
	44	13	14	17	Other and unspecified non-gonadal germ cell tumors
%	9.3	5.8	11.4	13.4	
	20	2	8	10	
%	1.8	0.4	2.6	3.5	
	10	1	3	6	Gonadal germ cell tumor
%	1.5	0.3	1.6	3.8	
	10	1	5	4	
%	2.1	0.4	4.1	3.1	
	12	12	-	-	
%	1.1	2.2	-	-	
	3	3	-	-	
%	0.5	1.0	-	-	
	9	9	-	-	
%	1.9	4.0	-	-	
	43	20	9	14	
%	3.8	3.7	2.9	4.9	
	21	18	-	3	
%	3.2	5.8	-	1.9	
	22	2	9	11	
%	4.6	0.9	7.3	8.7	

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group
	6	4	-	2	Gonadal carcinomas
%	0.5	0.7	-	0.7	
	3	3	-	-	
%	0.5	1.0	-	-	
	3	1	-	2	
%	0.6	0.4	-	1.6	
	2	2	-	-	Other and unspecified malignant gonadal tumors
%	0.2	0.4	-	-	
	2	2	-	-	
%	0.3	0.6	-	-	
	-	-	-	-	
%	-	-	-	-	
	50	8	11	31	CARCINOMAS AND EPITHELIAL NEOPLASMS
%	4.4	1.5	3.5	10.8	
	20	4	5	11	
%	3.0	1.3	2.6	6.9	
	30	4	6	20	
%	6.3	1.8	4.9	15.7	
	3	1	2	-	Adrenocortical carcinoma
%	0.3	0.2	0.6	-	
	-	-	-	-	
%	-	-	-	-	
	3	1	2	-	
%	0.6	0.4	1.6	-	
	21	1	4	16	Thyroid carcinoma
%	1.8	0.2	1.3	5.6	
	2	-	2	-	
%	0.3	-	1.1	-	
	19	1	2	16	
%	4.0	0.4	1.6	12.6	
	1	-	-	1	Nasopharyngeal carcinoma
%	0.1	-	-	0.3	
	1	-	-	1	
%	0.2	-	-	0.6	
	-	-	-	-	
%	-	-	-	-	

8.
Table 8. Distribution of Childhood Malignancies by Age, Sex and Diagnostic Groups

	Total	0-4 Year	5-9	10-14	Diagnostic group
	1	-	-	1	Malignant melanoma
%	0.1	-	-	0.3	
	1	-	-	1	
%	0.2	-	-	0.6	
	-	-	-	-	Skin carcinoma
%	-	-	-	-	
	2	1	1	-	
%	0.2	0.2	0.3	-	
	2	1	1	-	Other and unspecified carcinomas
%	0.3	0.3	0.5	-	
	-	-	-	-	
%	-	-	-	-	
	22	5	4	13	OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS
%	1.9	0.9	1.3	4.5	
	14	3	2	9	
%	2.1	1.0	1.1	5.6	
	8	2	2	4	Other specified malignant tumors
%	1.7	0.9	1.6	3.1	
	59	41	12	6	
%	5.2	7.6	3.8	2.1	
	37	26	8	3	Other unspecified malignant tumors
%	5.6	8.3	4.2	1.9	
	22	15	4	3	
%	4.6	6.7	3.3	2.4	
	2	2	-	-	Other unspecified malignant tumors
%	0.2	0.4	-	-	
	1	1	-	-	
%	0.2	0.3	-	-	
	1	1	-	-	Other unspecified malignant tumors
%	0.2	0.4	-	-	
	57	39	12	6	
%	5.0	7.3	3.8	2.1	
	36	25	8	3	Other unspecified malignant tumors
%	5.4	8.0	4.2	1.9	
	21	14	4	3	
%	4.4	6.2	3.3	2.4	

9.

Table 9. Marginal Frequency of the 'Microscopically Unconfirmed' and the 'Clinical Investigation only' by Topography

		(Microscopically unconfirmed)		(Clinical Investigation only)		
		91944	9963	10.8	13246	14.4
C00		31	1	3.2	-	-
C01		70	4	5.7	3	4.3
C02		228	8	3.5	3	1.3
C03		55	1	1.8	1	1.8
C04		65	4	6.2	2	3.1
C05		103	4	3.9	3	2.9
C06		134	4	3.0	-	-
C07		185	8	4.3	7	3.8
C08		75	2	2.7	1	1.3
C09		202	10	5.0	8	4.0
C10		61	8	13.1	5	8.2
C11		325	40	12.3	24	7.4
C12		80	4	5.0	2	2.5
C13		178	23	12.9	14	7.9
C14	,	37	4	10.8	2	5.4
C15		1540	118	7.7	96	6.2
C16		18648	916	4.9	565	3.0
C17		415	39	9.4	31	7.5
C18		4796	316	6.6	205	4.3
C19	S	548	19	3.5	13	2.4
C20		4351	246	5.7	135	3.1
C21		122	4	3.3	4	3.3
C22		10856	1817	16.7	7351**	67.7
C23		1208	543	45.0	477	39.5
C24		1397	572	40.9	495	35.4
C25		2041	1205	59.0	1038	50.9
C26		79	12	15.2	8	10.1
C30		164	6	3.7	3	1.8
C31		145	8	5.5	7	4.8
C32		997	78	7.8	48	4.8
C33		24	-	-	-	-
C34		10922	1532	14.0	1180	10.8
C37		120	13	10.8	12	10.0
C38	,	175	14	8.0	9	5.1

*

** (CT, MRI, Sono)

9.

Table 9. Marginal Frequency of the 'Microscopically Unconfirmed' and the 'Clinical Investigation only' by Topography

		(Microscopically unconfirmed)		(Clinical Investigation only)		
C39		2	-	-	-	
C40	,	232	23	9.9	15	6.5
C41		193	26	13.5	20	10.4
C42		2507	153	6.1	76	3.0
C44		1261	35	2.8	8	0.6
C47		40	10	25.0	2	5.0
C48		165	32	19.4	21	12.7
C49	,	507	41	8.1	18	3.6
C50		6505	215	3.3	121	1.9
C51		68	2	2.9	1	1.5
C52		49	3	6.1	-	-
C53		4061	254	6.3	129	3.2
C54		719	20	2.8	7	1.0
C55		62	9	14.5	2	3.2
C56		1517	133	8.8	88	5.8
C57		34	1	2.9	1	2.9
C58		69	37	53.6	18	26.1
C60		44	2	4.5	1	2.3
C61		1467	113	7.7	67	4.6
C62		147	7	4.8	5	3.4
C63		34	-	-	-	-
C64		1478	185	12.5	155	10.5
C65		158	11	7.0	7	4.4
C66		179	13	7.3	9	5.0
C67		2150	138	6.4	88	4.1
C68		47	2	4.3	-	-
C69		143	30	21.0	28	19.6
C70		43	8	18.6	6	14.0
C71		1028	192	18.7	165	16.1
C72	,	67	12	17.9	9	13.4
C73		3872	129	3.3	52	1.3
C74		122	16	13.1	13	10.7
C75		69	14	20.3	12	17.4
C76		138	21	15.2	8	5.8
C77		1031	55	5.3	30	2.9
C80	가	1359	438	32.2	312	23.0

Appendix

1.

001			4968	4.4	320	294	<1>8	4347	4.5
002			5294	4.7	221	253	14	4806	5.0
003			1432	1.3	68	69	2	1293	1.4
004			425	0.4	30	21	-	374	0.4
005	가		2067	1.9	158	(1)126	1	1783	1.9
006			1264	1.1	115	31	(1)9	1110	1.2
007			1160	1.0	83	36	2	1039	1.1
008			291	0.3	35	8	-	248	0.3
009			1018	0.9	84	(2)56	(1)6	875	0.9
010			740	0.7	46	19	-	675	0.7
011			1637	1.5	100	(2)69	-	1470	1.5
012			1864	1.7	95	37	-	1732	1.8
013			1186	1.1	62	70	-	1054	1.1
014			851	0.8	61	6	1	783	0.8
015			2218	2.0	139	74	-	2005	2.1
016			286	0.3	19	3	-	264	0.3
017			3862	3.5	301	142	2	3417	3.6
018			419	0.4	33	15	1	370	0.4
019			64	0.1	18	10	-	36	0.0
020			463	0.4	46	19	-	398	0.4
021			393	0.4	49	(1)64	-	281	0.3
023			219	0.2	17	3	-	199	0.2
024			216	0.2	27	16	-	173	0.2
025			108	0.1	6	5	-	97	0.1
026			329	0.3	33	8	-	288	0.3
027			401	0.4	40	7	1	353	0.4
028			169	0.2	22	10	<1>16	122	0.1
029			1094	1.0	129	35	1	929	1.0
030			258	0.2	52	24	-	182	0.2
032	가		421	0.4	53	22	2	344	0.4
033			188	0.2	10	5	-	173	0.2
034	가	가	882	0.8	105	(1)81	-	697	0.7
036			337	0.3	14	-	-	323	0.3
037			574	0.5	66	33	-	475	0.5
038			193	0.2	20	5	-	168	0.2
039			3839	3.4	315	(1)153	1	3371	3.5
040			140	0.1	25	6	-	109	0.1
041	가		1166	1.0	55	6	5	1100	1.2
042	가		508	0.5	34	-	-	474	0.5
043	가		1197	1.1	68	44	2	1083	1.1
044			1376	1.2	113	57	3	1203	1.3
045	가		565	0.5	46	26	-	493	0.5
046			755	0.7	85	(1)28	-	643	0.7
047			669	0.6	82	23	1	563	0.6

1.

048		2189	2.0	146	49	7	1987	2.1
049		699	0.6	51	(1) 27	-	622	0.7
050		141	0.1	26	-	-	115	0.1
052		5521	4.9	1021	(5)561	3	3941	4.1
053		39	0.0	8	1	-	30	0.0
054		983	0.9	122	9	(1)1	852	0.9
055	가	1792	1.5	143	(1)111	4	1535	1.6
056		2257	2.0	164	58	1	2034	2.1
057		1364	1.2	74	58	-	1232	1.3
059	가	244	0.2	13	(1)6	-	226	0.2
060		1346	1.2	78	(1)38	-	1231	1.3
061		79	0.1	11	2	1	65	0.1
062		766	0.7	49	14	-	703	0.7
063	가	153	0.1	15	13	-	125	0.1
064		434	0.4	17	11	-	406	0.4
065		162	0.1	19	-	-	143	0.1
066		124	0.1	26	12	-	86	0.1
068		900	0.8	46	3	-	851	0.9
069		1134	1.0	110	(1)47	-	978	1.0
070	가	871	0.8	61	25	-	785	0.8
071		63	0.1	4	1	-	58	0.1
072		522	0.5	68	18	-	436	0.5
073		686	0.6	64	(2)35	-	589	0.6
074		242	0.2	31	3	-	208	0.2
075		327	0.3	79	62	-	186	0.2
076		340	0.3	60	12	-	268	0.3
077		8746	7.8	614	(7)464	(7)25	7657	8.0
078		881	0.8	57	23	-	801	0.8
079		929	0.8	168	(3)68	-	696	0.7
080		67	0.1	15	11	-	41	0.0
081		138	0.4	60	20	-	58	0.1
082		768	0.7	75	32	-	661	0.7
083		96	0.1	13	1	-	82	0.1
084		578	0.5	96	56	-	426	0.4
086		122	0.1	36	25	-	61	0.1
088		127	0.1	47	3	(1)1	77	0.1
089		117	0.1	15	1	-	101	0.1
094		68	0.1	33	2	-	33	0.0
095		111	0.1	27	8	-	76	0.1
096		125	0.1	22	10	-	93	0.1
097		54	0.1	4	-	-	50	0.1
098		2065	1.9	164	(1)117	<1>3	1783	1.9
099		18	0.0	3	1	-	14	0.0
100		111	0.1	24	26	-	61	0.1

1.

103		72	0.1	6	3	-	63	0.1
107		14	0.0	-	-	-	14	0.0
108		42	0.0	13	10	-	19	0.0
111		35	0.0	7	11	-	17	0.0
112		119	0.1	21	43	-	55	0.1
114		86	0.1	26	8	-	52	0.1
115		191	0.2	20	39	-	132	0.1
118		466	0.4	91	(1)70	-	306	0.3
122		585	0.5	77	(1)49	-	460	0.5
124		116	0.1	15	12	-	89	0.1
126		128	0.1	29	8	-	91	0.1
127		20	0.0	5	6	-	9	0.0
129		100	0.1	43	25	-	32	0.0
132		87	0.1	15	22	-	50	0.1
135		45	0.0	10	1	-	34	0.0
137	가	65	0.1	14	18	-	33	0.0
139		33	0.0	15	7	-	11	0.0
141		723	0.2	82	59	-	582	0.6
142		122	0.1	30	9	-	83	0.1
144		224	0.2	26	2	-	196	0.2
145		1012	0.9	73	(1)61	-	879	0.9
147		839	0.8	99	(1)37	1	703	0.7
148		7168	6.4	467	(4)387	15	6303	6.6
150		719	0.6	48	31	-	640	0.7
151		184	0.2	14	7	1	162	0.2
152		2225	2.0	162	98	3	1962	2.1
153		106	0.1	35	18	-	53	0.1
154		1064	1.0	164	(1)63	1	837	0.9
155		120	0.1	34	6	-	80	0.1
157		1502	1.3	73	23	4	1402	1.5
158		30	0.0	9	-	-	21	0.0
160		481	0.4	64	(6)59	1	363	0.4
161	가	299	0.3	52	63	-	184	0.2
162		198	0.2	21	36	2	139	0.1
164		152	0.1	40	23	-	89	0.1
169		1018	0.9	106	57	2	853	0.9
170		99	0.1	19	29	-	51	0.1
171		697	0.6	77	79	-	541	0.6
172		1196	1.1	119	141	1	935	1.0
173		233	0.2	30	34	-	169	0.2
175		718	0.6	68	49	1	600	0.6
176		331	0.3	85	50	<1>1	196	0.2
177		2027	1.8	211	(2)254	3	1561	1.6
178		1	0.0	-	-	-	1	0.0

1.

180	47	0.0	9	1	<1>2	36	0.0
181	72	0.0	3	-	-	69	0.1
	111816	100.0	10106	6071 *(49)	162 *(11) #<5>	95542	100.0

* ()

< >

2.

- -

	(C16)			(C34)		
		18648	100.0		10922	100.0
1		9040	48.5		4472	40.9
2		4744	25.4		2712	24.8
3	+	2930	15.7		1523	13.9
4		1308	7.0		926	8.5
5	+ +	177	0.9	+	695	6.4
6	+ +	156	0.8	+	327	3.0
7	+	110	0.6	+	141	1.3
8		63	0.3	+ +	88	0.8
9	+	47	0.3		30	0.3
10	+	36	0.2	+	3	0.0

	(C22)			(C50)		
		10856	100.0		6505	100.0
1		5764	53.1		3143	48.3
2		3209	29.6	+	2189	33.7
3		1034	9.5		357	5.5
4		331	3.0		287	4.4
5	+	223	2.1	+ +	271	4.2
6	+	200	1.8	+	118	1.8
7		39	0.4	+	36	0.6
8	+	26	0.2		30	0.5
9	+ +	18	0.2	+ +	25	0.4
10	+	8	0.1	+ +	18	0.3

	(C19-C20)			(C18)		
		4899	100.0		4796	100.0
1		2380	48.6		2470	51.5
2	+	991	20.2	+	1261	26.3
3		699	14.3		762	15.9
4	+ +	326	6.7		206	4.3
5		173	3.5	+ +	29	0.6
6	+	168	3.4	+	18	0.4
7	+	78	1.6		17	0.4
8		58	1.2	+	16	0.3
9	+	10	0.2	+	9	0.2
10	+ +	8	0.2		5	0.1


2.

	(C53)			(C73)		
	4061	100.0		3872	100.0	
1	1649	40.6		3004	77.6	
2	683	16.8	+	479	12.4	
3	444	10.9		218	5.6	
4	387	9.5	+	55	1.4	
5	348	8.6		53	1.4	
6	244	6.0		49	1.3	
7	155	3.8	+	9	0.2	
8	150	3.7	+	3	0.1	+
9	1	0.0	+	2	0.1	
10	-	-	+	-	-	+

	(C42)			(C67)		
	2507	100.0		2150	100.0	
1	1347	53.7		1596	74.2	
2	782	31.2		231	10.7	
3	122	4.9	+	203	9.4	
4	83	3.3		37	1.7	
5	58	2.3	+	32	1.5	
6	53	2.1	+	19	0.9	
7	32	1.3	+	18	0.8	+
8	14	0.6	+	9	0.4	+
9	12	0.5		3	0.1	
10	4	0.2	+	2	0.1	

	(C25)			(C15)		
	2041	100.0		1540	100.0	
1	1192	58.4		538	34.9	
2	338	16.6		360	23.4	
3	274	13.4		191	12.4	
4	91	4.5	+	183	11.9	
5	63	3.1		120	7.8	
6	41	2.0	+	77	5.0	
7	16	0.8	+	40	2.6	+
8	14	0.7	+	25	1.6	
9	10	0.5		6	0.4	
10	2	0.1	+	-	-	

3.



1998 (Carcinoma in situ)

2001 '95 ~ 2000

1.

암등록 [?] [X]

병원

입력일 입력자 환자번호

입원일 퇴원일

레코드 수 : 0

주민번호 성명

성별 남 여 모름

직업 전화번호

1. 전문, 기술직 2. 행정직 3. 사무직 4. 판매종사자 5. 서비스직
 6. 농업, 축산업, 임업, 수산업 및 수렵업 7. 생산직 8. 운수장비운전자
 9. 단순노무자 10. 분류불능자 11. 학생 12. 군인 13. 주부
 14. 기타 15. 불명확한 구분

출생지

주소

초진년월일 나이 (만 세) 나이 자동입력

원발장기명 C

조직학적 M- /

진단명

최종진단방법 병기분류

<임상적 방법> <현미경적 방법>
 1) 검사없이 임상만으로 5) 세포학적 또는 혈액학적 검사
 2) 임상검사 Sono CT MRI 기타 6) 전이부위의 조직학적 검사
 3) 조직검사 없는 진단적 수술 또는 부검 7) 원발부위의 조직학적 생검
 4) 특수 생화학적 또는 면역학적 검사 8) 조직검사를 시행한 진단적 수술 또는 부검

진단후 첫 4개월간의 치료 (해당사항 모두 기재 : 모름-빨간색체크)
 1. 수술 2. 화학요법 3. 방사선요법 4. 면역요법
 기타

자료 년도 : 01 년도 사망년월일 생존기간 년 개월

()

가

(가)

()

www.ncc.re.kr -- /

2001 (:2003)